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Abstract 
There are numerous benefits to treating patients in the upright position such as 
better patient comfort and increased total lung volume with reduced lung motion. The 
purpose of this study was to investigate the feasibility of implementing upright 
treatments for lung and H&N cancers. Several clinical aspects were examined, 
including radiation shielding for various fixed beams, collision avoidance, retrospective 
treatment planning, and an end-to-end test with an anthropomorphic lung phantom. 
 Results from the shielding study indicated that the primary barrier required an 
additional 10-26 cm of shielding while the secondary barrier in the beam path required 
an additional 2-12 cm for the fixed-beam scenarios. Due to the conservative 
assumptions in the workloads and the NCRP computational methods, it was determined 
that additional shielding for a pre-existing treatment vault was not likely. However, 
physical measurements are required to ensure that regulatory limits are not exceeded. 
The collision software safely predicted all collisions for three tested cases. The 
differences between the computed results and the actual measurements were between 
0.2-4.1 cm, which was compensated by the uncertainties incorporated into the results. 
The actual measured collisions were never in the area of the maps that was designated 
v 
 
as safe. The treatment planning study resulted in clinically acceptable upright plans for 
five lung and five H&N patient cases. The upright lung plans produced acceptable and 
comparable results to those in the original plans. The dose coverage and normal tissue 
doses were less optimal in the upright H&N plans. However, with proper planning 
techniques, similar quality as the original plans is likely achievable. For the end-to-end 
test, the treatment plan passed the IMRT QA criteria of 0.95-1.05 for point dose and 
obtained a gamma index of 89.25%. Dosimetry verification demonstrated good 
agreement between the treatment plan doses and the delivered doses and obtained a 
point-dose dose difference of 2% and gamma analysis index of 100%, which were 
within the acceptability of IROC Houston criteria. The results of this research 
confirmed the feasibility of upright treatments for lung and H&N cancers and can aid 
the institution in future clinical studies with actual subjects. 
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Chapter 1 
INTRODUCTION AND BACKGROUND 
1.1 Statement of Problem 
 Radiation therapy has been widely adopted as the standard of care for lung and 
head and neck cancers.
1-3
 Advanced techniques such as intensity-modulated radiation 
therapy (IMRT) improve dose conformity to the target volume while sparing the normal 
tissue structures.
4-7
 Currently, patients who are receiving radiation treatments are 
positioned supine or prone on the treatment couch with immobilization devices for 
computed tomography (CT) simulation and radiation treatment. The treatment positions 
are confined to these two postures due to the horizontal design of the imaging devices 
(e.g. CT, MRI). Although radiation therapy has been a promising treatment modality for 
various cancers, many patients experience discomfort and difficulties in maintaining the 
treatment position for the entire duration of delivery due to dyspnea, dysphagia, or 
excess saliva and may require frequent rests throughout treatment. This not only 
prolongs the treatment time to reposition the patient but also introduces additional 
patient setup errors and uncertainties. An alternative treatment technique is needed to 
provide comfortable positioning for these patients while maintaining the standard 
quality of radiation therapy. The aim of this research is to investigate the feasibility of 
upright treatments for lung and head and neck cancers on a pre-existing linear 
accelerator. As a preparatory step for clinical implementation, several practical aspects 
of radiation therapy were examined, including radiation shielding, collision avoidance, 
treatment planning, and end-to-end tests. 
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 In addition to the above considerations, upright treatments may allow the design 
of a low-cost, fixed-beam linac. The number of newly reported cancer cases in low- and 
middle-income countries have increased significantly, making cancer the leading cause 
of death in those regions.
8
 Approximately two-thirds of cancer deaths every year 
worldwide came from developing countries.
8
 These countries have limited access to 
radiation treatments due to the unfavorable economic situation and the large cost of 
assembling a radiation therapy center. International Atomic Energy Agency estimated 
that currently, there is a shortage of at least 5,000 radiotherapy machines in developing 
countries.
9
 As a result, there is a high demand for affordable radiation treatment options 
for implementation in developing countries. One possible option could be a fixed-beam 
linac. In this research, a transportable shipping container equipped with a fixed-beam 
linear accelerator that may be a less expensive alternative to a conventional treatment 
vault was proposed. The fixed-beam linac may require less machine maintenance, 
reducing the total cost of building a radiation treatment room. 
 
1.2 Background 
1.2.1 Upright Treatments 
Treating patients in an upright position has numerous benefits. It has been 
shown that upright position can achieve lung motion similar to abdominal compression 
and lung volume comparable to deep-inspiration breath hold, a technique that is 
extensively used to reduce tumor motion.
10, 11
 Diaphragmatic excursion is significantly 
reduced by 3 mm on average and the lung volume is increased by 27% on average when 
in a sitting position.
12, 13
 As there is less tumor motion, there may be a corresponding 
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reduction in the volume of normal tissues irradiated. These advantages may allow a 
dose increase to the target volume for the same normal tissue complication probability 
and a reduction in the margins that are applied to the target volume to account for tumor 
motion in treatment planning. 
Radiation treatments for Hodgkin’s disease often involve irradiations of the 
mantle and the mediastinum, and many patients who received treatments for Hodgkin’s 
disease are at an increased risk of stroke due to radiation exposure to the heart.
14
 These 
patients may benefit from upright irradiations because the apparent width of the tumor 
and the heart volume are smaller in an upright position, reducing the risk of heart 
disease and secondary cancer.
15
 Additionally, this technique may keep the breast tissues 
out of the treatment fields, minimizing the risk of radiation-induced breast cancer.
16
 
Thoracic cancer patients undergoing treatments experience a variety of 
symptoms, such as fatigue, dyspnea, insomnia, and pain.
17
 Dyspnea is the most 
prevalent symptom and affects patients’ social and physical well-being. Approximately 
60% of patients suffer from dyspnea or difficulty in breathing.
18, 19
 For patients with 
dyspnea, the upright position is the most comfortable due to the increase in lung volume 
as mentioned previously. The total lung capacity and the vital capacity are also 
enhanced with an upright position.
20, 21
 Patients’ comfort may be further improved by 
leaning forward and placing the arms on a stabilized support.
22
 This position allows the 
chest and neck muscles to facilitate breathing.
22
 
Radiation treatment for H&N cancers is particularly challenging due to the close 
proximity of the tumors to critical structures (i.e. the spinal cord, brainstem, and 
parotids). Side effects of surgery and radiation often arise from the normal tissues that 
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were in the treatment fields. Excessive saliva is the most common due to dysphagia and 
local oral irradiation.
23
 Excess secretions may also result due to limited or difficulty in 
swallowing. When patients are immobilized in a supine position with a head mask that 
is locked to the treatment couch, accumulated fluid could be a choking hazard. 
Elevation of patients’ head can reduce saliva pooling in the pharyngeal and assist in 
fluid clearance.
23
 
 
1.2.2 Radiation Therapy in Developing Countries 
While cancer incidence and mortality rates have declined in developed 
countries, the newly reported cancer cases increased from 15% in 1970 to 56% in 2008 
in low- and middle-income countries.
24
 It is estimated that approximately more than 
half of the cancer cases in the world will occur in low- and middle-income regions, and 
the proportion will increase to 70% by 2020.
25
 Currently 75% of cancer patients in 
those regions do not have access to radiation therapy and 22 countries in Asia and 
Africa do not have any radiation therapy unit.
25
 The scarcity of radiation facilities in 
developing countries is partly due to the high costs of acquiring and maintaining the 
necessary equipment. To implement radiation therapy services, it requires capitals for 
several elements, such as machine maintenance and buildings designed for radiation 
treatments. The cost of maintenance on average is about $41,000 for linear accelerators, 
and the building cost is dependent on location, ranging between forty thousand and one 
million dollars.
26
 Low-cost and effective treatment options are needed to increase the 
availability of radiation therapy to people in the developing countries. 
 
 5 
 
1.3 Hypothesis and Specific Aims 
 Upright treatments using the TrueBeam
TM
 linear accelerator can be a feasible 
treatment alternative for lung and head and neck cancer patients who cannot tolerate 
the conventional treatment positions. Upright treatments can be safely planned and 
delivered while achieving tolerable normal tissue doses and target coverage within 
10% of the original treatments. 
 
The following specific aims and working hypotheses will assess the overall hypothesis: 
1. To evaluate the impact of upright treatments on the room shielding of a 
conventional linear accelerator treatment vault 
Working hypothesis: Upright treatments can be performed in a pre-existing 
conventional treatment vault without additional shielding. 
2. To develop a robust collision predictor that assists in patient setup and collision 
avoidance 
Working hypothesis: Custom-developed software can safely predict collisions 
during upright imaging and treatment processes. 
3. To retrospectively generate IMRT treatment plans in the upright position for 
lung and head and neck cancer patients 
Working hypothesis: IMRT treatment plans created for the upright position can 
be clinically acceptable and deliver tolerable normal tissue doses and target 
coverage within 10% of the original plans. 
4. To perform a complete end-to-end using an anthropomorphic lung phantom 
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Working hypothesis: Complete upright treatments can deliver doses to the target 
and normal tissues within IROC Houston limits. 
 
Thesis Format 
Chapter 2: Specific aim #1 Impact of Upright Treatments on LINAC Room 
Shielding 
Chapter 3: Specific aim #2 Development of Collision Software 
Chapter 4: Specific aim #3 Feasibility of Upright IMRT Treatment Planning 
Chapter 5: Specific aim #4 End-to-End Tests 
Chapter 6: Overall Conclusions 
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Chapter 2 
IMPACT OF UPRIGHT TREATMENTS ON LINAC ROOM SHIELDING 
2.1 Introduction 
 In order to ensure public’s and employees’ safety from therapeutic radiation, 
treatment rooms are required to have adequate shielding that are designed to limit the 
radiation dose received by any individual outside the treatment room to a regulatory 
level, set by state and national standards.
27, 28
 These protective barriers are the walls, the 
ceiling and the floor that are made of lead or concrete, enclosing the treatment unit. 
They need to have enough thicknesses to effectively attenuate the high-energy x-rays 
and electrons coming from the linear accelerators. Several publications over the years 
have provided guidelines and methods for the design and installation of structural 
shielding for radiation therapy facilities.
29-31
 These reports allow institutions to evaluate 
required shielding tailored to their needs and practices. 
Most modern radiation treatments are delivered using the conventional beam 
orientation, which rotates 360° around the patient while the treatment couch is 
stationary. Upright treatments differ from conventional treatments because of their 
distinct approach of beam delivery. The linac is fixed at one angle, pointing the beam in 
one direction, and the treatment couch that the patient is positioned on is rotated to 
multiple positions. This technique produces beams that incident on the patient from 
different angles. With the beam fixed in one direction instead of rotating 360⁰ like a 
conventional beam, the amount of radiation impeding on each barrier may be much 
different than that with a conventional beam. In turn, the shielding barriers for 
conventional treatments may not be appropriate for upright treatments. Therefore, it 
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must be investigated if additional shielding was required to operate a fixed-beam linac 
in a pre-existing conventional linac vault. 
 National Council on Radiation Protection and Measurements (NCRP) Report 
No. 151 is the most recent and extensively used reference for radiotherapy facility 
shielding. Computational methods in this report were adopted for this study. In this 
study we compared the shielding thicknesses at four barriers and the photon dose 
equivalent at the maze door between a conventional beam used in conventional 
treatments and a fixed beam used in upright treatments. We hypothesized that upright 
treatments can be performed in a pre-existing conventional treatment vault without 
additional shielding. 
As mentioned previously in Chapter 1, the cost of building a linear accelerator 
vault ranges between forty thousand and one million dollars and is burdensome for low- 
and middle-income countries.
26
 A transportable shipping container with a fixed-beam 
linac can be a less expensive alternative for third world countries where there are 
limited financial resources. In this study we also evaluated the shielding thicknesses for 
the side walls of a shipping container. 
 
2.2 Materials and Methods 
2.2.1 Conventional Treatment Room Layout and Scenarios 
 The same room layout was used to compare shielding requirements between a 
conventional and a fixed beam. A treatment room layout from NCRP Report No. 151 
was adopted for this study. Figures 2.1 and 2.2 show an overhead and a cross-sectional 
view of the conventional treatment room.  The areas surrounding the room included a 
 9 
 
parking lot (wall C), a control room (wall D), and a film reading room (wall E). The 
rooftop area was assumed to be an unoccupied space. Distances and dimensions were 
kept the same as those in the NCRP Report. Shielding thicknesses were evaluated for 
walls C, D, and E and the ceiling. 
 
Figure 2.1 Layout of the conventional treatment room used for shielding calculations. This figure was adopted 
from NCRP Report No. 151 and reprinted with permission of the National Council on Radiation Protection 
and Measurements. 
 
 
Figure 2.2 Sectional view of a conventional treatment room used for shielding calculations. This figure was 
adopted from NCRP Report No. 151 and reprinted with permission of the National Council on Radiation 
Protection and Measurements 
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Three fixed-beam scenarios were examined and compared to the conventional 
scenario: beam direction exclusively at (1) wall C, (2) wall D, and (3) both wall C and 
wall D. The conventional scenario consisted of a conventional linac that rotates 360°. 
The split beam in scenario (3) resembles the type of beams that would be used if upright 
treatments were performed in the current vault setting. The treatment couch rotation is 
limited to 180⁰, which means that a fixed beam that points in one direction can only 
deliver radiation beams to one side of the patient. To compensate for that, the gantry 
needs to rotate 180⁰ to the opposite side to be able to administer radiation to the other 
part of the patient. Scenarios (1) and (2) represent situations where the treatment couch 
was replaced with a rotating chair which rotates the patient 360⁰. Thus, radiation can be 
administered around the patient without having to move the linac. 
In addition to beam direction, beam energies were also varied. Beams of single 
energy (6 MV) and dual energies (6 & 18 MV) were considered. A dual-energy beam is 
more representative of the therapy units used in most institutions while a single-energy 
beam was proposed because the treatment technique for upright treatments is IMRT, 
which was recommended by studies to utilize 6-MV beams.
32, 33
 Figure 2.3 provides a 
visual breakdown of the scenarios. Results for each fixed-beam scenario were compared 
to those for the conventional scenario. 
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Figure 2.3 Visual representation of the fixed-beam and the conventional scenarios 
 
2.2.2 Shipping Container 
 Figure 2.4 depicts the layout of a shipping container with a fixed 6-MV beam 
that was directed at wall A. The dimension of the treatment area was 6 m by 2.4 m by 
2.4 m while the rest of the space was occupied by the control area. The surrounding 
areas beyond walls A, B, and D were considered to have low occupancies because the 
shipping container is to be transported to rural areas where radiation therapy is not 
available. The occupancies were assumed to be equivalent to an unattended waiting 
room. Wall C is the barrier between the treatment area and the control room. Shielding 
calculations were performed for all side walls. 
 
 
Beam 
direction/Scenarios 
Beam type 
Beam energy Single/Dual 
Fixed 
Wall C Wall D Walls C & D 
Conventional 
Uniform 
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Figure 2.4 Layout of the shipping container that has a fixed-beam linac pointing at wall A. 
 
2.2.3 NCRP Report No. 151 Formalism 
The calculation methods and formulas in NCRP Report No. 151 are presented in 
this section. Shielding calculations were performed for each type of radiation: primary 
radiation, patient-scatter secondary radiation, head-leakage secondary radiation, and 
photon dose equivalent at the maze door.  
 
Primary Barrier 
Primary radiation is originated from the treatment head and emitted directly 
from the target to the barriers, which could be the side walls, the ceiling, and the floor. 
The primary barrier attenuates the primary beam to the appropriate dose equivalent. For 
a conventional beam, primary barriers include the side walls, the ceiling, and the floor 
because the gantry rotates 360⁰. Primary barrier for a fixed beam depends on the beam’s 
direction. For example, a fixed beam that is directed only at wall C has wall C as the 
primary barrier. For a split beam, primary barriers are wall C and wall D. 
The transmission factor of the primary barrier that will decrease the amount of 
radiation to an acceptable level is given by Equation 2.1. 
C 
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 Equation 2.1 
P is the shielding design goal in Sv per week and is determined by the type of area that 
the barrier is protecting. If the area beyond the barrier is a controlled area, in which 
exposures to individuals are under the supervision of a person in charge of radiation 
protection, the recommended shielding design goal in the NCRP Report is 0.1 
mSv/week. If the area is an uncontrolled area, which are all other areas in the hospital or 
the clinic, the shielding design goal is 0.02 mSv/week. d is the distance between the 
target and the point of interest in meters. The distance is measured from the target to 0.3 
m beyond the barrier. W is the workload or the absorbed dose delivered to the isocenter 
from the target in a week (Gy per week). T is the occupancy factor or fraction of the 
week that a person is present beyond the barrier and U is the use factor or fraction of the 
week that the primary beam is directed at the barrier. The primary barriers in a 
conventional scenario each have a use factor of 0.25 because the beam angles are 
assumed to be evenly distributed, and thus, each barrier intercepts the primary beam 
25% of the time that the beam is on. If the radiation beam points in one direction, the 
wall in the beam direction is the only primary barrier with a use factor of 1. With a split 
beam, the use factor becomes 0.5 for each primary barrier. 
After the transmission factor is calculated, the required barrier thickness can be 
determined using the tenth-value layer (TVL), which varies with beam energy and 
shielding material. The number of tenth-value layer required is given by Equation 2.2. 
       ( ) Equation 2.2 
The final barrier thickness can be calculated by Equation 2.3. 
           (   )     Equation 2.3 
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TVL1 and TVLe are the first and the equilibrium tenth-value thickness, respectively. 
The different TVL values account for the changes in radiation characteristics as it 
penetrates the barrier. 
 
Secondary Barriers 
Secondary barriers protect individuals from secondary radiation, which emerges 
from leakage of radiation from the gantry of the linear accelerator and scatter of the 
primary beam in the patient. While the primary radiation is limited by the beam 
direction, secondary scatter is emitted in all directions. Therefore, all surfaces inside the 
treatment room are considered secondary barriers. The energies of the two components 
of secondary radiation are very different, so independent shielding calculations are 
performed for each. 
The transmission factor of patient scattered radiation is given by Equation 2.4. 
     
 
    
    
     
    
 
 Equation 2.4 
dsca is the distance between the x-ray target and the patient in meters; dsec is the distance 
from the patient to the point of interest beyond the barrier in meters; F is the field area 
at the mid plane of the patient and is assumed to be 40 by 40 cm
2
 in this study, which is 
the largest available field size. α is the fraction of the primary beam that is scattered by 
the patient at a particular angle, which is the angle between the scattered radiation and 
the path of the primary beam. Scattered radiation is forward scattering, meaning that the 
amount of scattered radiation is at the greatest at the 0° scatter angle and decreases as 
the scatter angle increases. When calculating radiation shielding, to make the results 
conservatively safe, any distance in the equation is always measured as the shortest 
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distance possible between the radiation source and the barrier. The scatter angle to a 
wall is assumed to be 30° when a primary barrier is present because the width of the 
primary barrier intercepts the scattered radiation at less than 30°. When a wall has only 
a secondary barrier, shielding is calculated with a scatter angle of 90⁰because that gives 
the shortest distance between the patient and the barrier. 
The transmission factor needed for leakage radiation is shown as follows: 
    
   
 
       
 Equation 2.5 
WL is the workload from leakage radiation (Gy per week). dL is the distance (meters) 
from the isocenter to the point of interest and the use factor is considered to be 1 in the 
equation if it can be assumed that the beam angles are distributed symmetrically, as in a 
conventional scenario. If that is not the case, the distance should be measured between 
the treatment unit head and the point of interest and the appropriate use factor should be 
placed in the denominator. The 10
-3
 factor in Equation 2.5 comes from the assumption 
that leakage radiation is 0.1% of the primary beam. 
 Similar to the primary barrier, the individual shielding thickness for patient-
scatter and head-leakage radiation can be determined using Equations 2.2 and 2.3. The 
total secondary barrier thickness is computed using the two-source rule: if one 
secondary thickness is greater than the other by one TVL or more, the larger thickness 
is sufficient; if the two thicknesses differ by less than one TVL, an additional HVL is 
added to the larger of the two. 
 
Dose Equivalent at the Maze Door 
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 The treatment door should provide equivalent radiation protection as the walls 
around it. To avoid using an extremely heavy door, a maze is usually incorporated into 
the room design if space is allowed since it removes direct exposure of the primary 
beam to the door and, therefore, lessens the amount of shielding the door requires. With 
the presence of a maze, the photon dose equivalent at the door is primarily originating 
from scatter radiation of the primary beam and is ultimately used to determine the 
thickness of shielding required for the door. For the shipping container, a maze cannot 
be included in the design due to the space constraint. Thus, in this study the door was 
calculated to have the same shielding as the adjacent barrier, which is wall C. A direct 
shielded door is shielded with lead contained in a steel frame.
31
 To reduce the door 
thickness, a short stub can be added at the door entrance. It was found that this method 
can reduce the door thickness by approximately 50%.
34
 
The photon dose equivalent at the maze door is composed of scatter of the 
primary beam from the room surface and the patient, head-leakage scatter from the 
walls, and direct penetration of head-leakage radiation through the maze barrier. Figure 
2.5 illustrates the distances and areas used in the following calculations when the beam 
is pointing at wall G in the figure. 
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Figure 2.5 Calculation parameters for determining the photon dose equivalent at the maze door, adopted from 
NCRP Report No. 151. This figure was reprinted with permission of the National Council of Radiation 
Protection and Measurements. 
 
The first component of photon dose equivalent is wall-scattered radiation of the 
primary beam (Hs) and can be calculated as follows: 
    
           
(      ) 
 Equation 2.6 
where 
UG = use factor for wall G 
W = workload delivered at 1 m from the target per week (Gy per week) 
α0 = reflection coefficient at the first scattering surface 
A0 = beam area at the first scattering surface (m
2
) 
αz = reflection coefficient at the second scattering surface 
Az = area of maze inner entry projected onto the maze wall from the first 
scattering surface (m
2
) 
dh = perpendicular distance from the target to the first scattering surface (m) 
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dr = distance from the beam center at the first reflection surface to a point on the 
mid-line of the maze (point b in Figure 2.4) (m) 
dz = centerline distance along the maze from point b to the maze door (m) 
 
The second component is described as the dose equivalent due to scatter of 
head-leakage radiation (HLS), given by Equation 2.7. 
     
          
(       ) 
 Equation 2.7 
In Equation 2.7: 
Lf = head-leakage radiation ratio at 1 m from the target. It is assumed to be 
0.001 or 0.1% of the primary beam. 
 WL= workload for leakage radiation (Gy per week) 
UG = use factor for wall G 
 α1 = reflection coefficient for wall G 
 A1 = area of wall G that can be seen from the maze door (m
2
) 
 dsec = distance from the target to the maze centerline at wall G (m) 
 dzz = centerline distance along the maze (m) 
 
The third component, patient-scattered radiation (Hps), can be assessed as 
follows: 
     
 ( )   (
 
   
)    
(           ) 
 Equation 2.8 
α(θ) = fraction of the primary beam that scatters from the patient at angle θ 
W = workload delivered at 1 m from the target per week (Gy per week) 
UG = use factor for wall G 
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F = field area at mid plane of the patient, assumed to be the largest available 
field size (40 by 40 cm
2
) 
α1 = reflection coefficient for wall G 
 A1 = area of wall G that can be seen from the maze door (m
2
) 
dsca = distance from the target to the patient (m). 
dsec = distance from the target to the maze centerline at wall G (m) 
dzz = centerline distance along the maze (m) 
 
The last component is the leakage radiation that is transmitted through the maze 
barrier to the maze door (HLT), shown in Equation 2.9. 
     
       
  
  Equation 2.9 
B = transmission factor for the maze barrier 
dL = distance from the target to the center of the maze door through the maze 
wall in meters 
UG = use factor for wall G 
WL = workload for leakage radiation in Gy per week 
Lf = fraction of the primary beam that is leaking through the head of the gantry 
and assumed to be 0.001 in this study 
 
The total dose equivalent (HG) at the maze door when the beam is directed at 
wall G can be assessed by summing the components: 
                    Equation 2.10 
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The f factor is the fraction of the primary beam that is transmitted through the patient 
and is approximately 0.34 for 18 MV and 0.25 for 6 to 10 MV photon beams. 
Equation 2.11 shows the equation for the final total dose equivalent (HTot):  
             Equation 2.11 
The 2.64 factor accounts for the contributions of dose equivalent from the other beam 
angles and may not be valid if the beam angles are not symmetrical. For the fixed-beam 
scenarios, the 2.64 factor was removed because the total photon dose equivalent at the 
maze door came from only one beam direction. When the beam is split between two 
angles, contribution from each beam angle is added together to get the final value. 
The impact of photoneutrons on room shielding was not considered. The 
production of neutrons becomes significant above photon energy of 10 MV and 
originates mainly from the linac head through interactions between the photons 
produced in the target and the high Z materials in the linac head.
35, 36
 The possibility of 
neutron production is greatly decreased with low-energy beam, and therefore, 
photoneutrons were not evaluated for the single-energy beam of 6 MV. For beam 
energy above 10 MV where photoneutron production is significant, the primary barrier 
will provide adequate protection for photoneutrons and no additional barrier is required 
due to the high hydrogen content of concrete. On the other hand, secondary barriers do 
not experience as much photoneutron production because patient scattered radiation 
beyond the primary barrier does not have enough energy to produce photoneutrons and 
leakage radiation does not produce a significant number of neutrons in secondary 
barriers. 
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Neutron dose equivalent was not included in the calculation of the dose 
equivalent at the maze door. The neutron dose equivalent at the maze door can be 
assessed using the followings: 
           
     √
  
  
[        (
  
   
)     (
  
   
)]Equation 2.12 
φA is the neutron fluence per absorbed dose of photons at the isocenter in neutrons per 
m
2
; S0/S1 is the ratio of the inner maze entrance cross-sectional area to the maze 
entrance cross-sectional area close to the door; d2 is the distance from the centerline of 
the maze to the maze door in meters, and TVD is the tenth value distance that reduces 
the neutron dose equivalent by a factor of 10 in meters. The weekly neutron dose 
equivalent at the maze door can be computed by: 
          Equation 2.13 
 Since the workloads and the room layout were constant between the 
conventional and the fixed-beam scenarios, parameters in Equations 2.12 and 2.13 
would be equivalent between the scenarios and the neutron dose equivalent at the maze 
door would not differ substantially for the fixed-beam scenarios from that for the 
conventional scenario. 
 
IMRT Modification 
 Over the past two decades, IMRT has become a standard radiation treatment 
technique. IMRT uses multileaf collimators to modulate the beams, offering high dose 
conformity to tumor volume and reducing normal tissue toxicities.
37, 38
 During treatment 
delivery, only a small fraction of each field size is being irradiated. To deliver the 
prescribed dose, a large number of small beamlets must be used. As a result, IMRT is 
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relatively insufficient in terms of the use of the monitor units (MU) and requires about 
two to five times more MUs than conventional therapy techniques, increasing the 
amount of leakage radiation.
39
 The IMRT factor CI, shown in Equation 2.14, accounts 
for the increase in MUs and leakage radiation when IMRT is performed. 
    
      
      
 Equation 2.14 
 MUIMRT and MUconv are the total monitor units required to deliver the same 
amount of absorbed dose with IMRT and conventional techniques. Primary radiation, 
patient-scattered and wall-scattered radiation are not affected by the use of IMRT 
because the absorbed dose to the patient from those radiation is similar between IMRT 
and conventional techniques. However, when computing leakage-related shielding 
requirements (i.e. leakage-scatter secondary radiation, HLT, and HLS), a separate 
workload needs to be employed: 
           (   )        Equation 2.15 
where Wconv and WIMRT are workloads for conventional and IMRT procedures, and a is 
the fraction of patients that are treated with conventional techniques. 
The weekly workload is obtained by multiplying the number of patients treated 
in a week and the average absorbed dose delivered to the patient at the isocenter and 
expressed in gray per week. Table 2.1 below summaries the parameters for workload 
calculation for different beam energies. Parameter values for the dual-energy beam were 
the same as those in the NCRP report, and values for the single-energy beam were 
recommended by the author’s group. 
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Table 2.1 Weekly workload parameters and workloads for two beam energies. The dual-energy beam 
parameters were from NCRP Report No. 151, and the single-energy beam parameters were recommended by 
the author’s group. 
 Single-energy Dual-energy 
Energy (MV) 6 6 & 18 
18 MV (patients/week) 0 150 
6 MV (patients/week) 200 75 
Dose at isocenter (Gy/patient) 2 3 
Fraction of 18 MV treated with IMRT 0 0.4 
Fraction of 6 MV treated with IMRT 0.6 0.8 
IMRT factor 5 5 
Workload for 18 MV (Gy/week) 0 450 
Workload for 6 MV (Gy/week) 400 225 
Leakage workload for 18 MV (Gy/week) 0 1170 
Leakage workload for 6 MV (Gy/week) 1360 945 
 
2.3 Results 
 Shielding comparison focuses on thicknesses of the primary barriers and the 
secondary barriers. The shielding thickness for primary radiation is presented in terms 
of two shielding materials: concrete and lead. Concrete is the least expensive material 
and is used extensively in radiation therapy. However, it occupies more space than other 
materials. To reduce the space constraints, concrete may be substituted by lead if 
additional shielding is needed. Secondary radiation barriers are displayed in thicknesses 
of concrete because the TVLs for patient scatter and leakage radiation are not as well-
documented as those for primary radiation.
31
 
 
2.3.1 Conventional Treatment Room 
Primary and Secondary Radiation 
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Tables 2.2 and 2.3 summarize all the barrier thicknesses and the photon dose 
equivalent at the maze door for both energy beams according to the scenarios for 
clarification. 
 
Table 2.2 Primary and secondary barrier thicknesses and the photon dose equivalent at the maze door for a 
single-energy beam in a conventional treatment room according to the beam direction 
Single-energy beam 
Thickness (cm)/wall C D E Ceiling 
Beam direction Conventional 
Primary (concrete) 115.6 145.4  126.1 
(lead) 19.3 24.4  21.1 
Total secondary (concrete) 59.2 85.4 82.4 74.6 
Photon dose equivalent 86.5 µSv/week 
Beam direction Wall C 
Primary (concrete) 135.5    
(lead) 22.7    
Total secondary (concrete) 62.9 83.3 82.4 68.0 
Photon dose equivalent 131.1 µSv/week 
Beam direction wall D 
Primary (concrete)  165.3   
(lead)  27.9   
Total secondary (concrete) 57.2 86.4 82.4 68.0 
Photon dose equivalent 51.9 µSv/week 
Beam direction wall C and wall D 
Primary (concrete) 125.5 155.4   
(lead) 21.0 26.1   
Total secondary (concrete) 55.1 78.6 73.7 59.3 
Photon dose equivalent 89.5 µSv/week 
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Table 2.3 Primary and secondary barrier thicknesses and the photon dose equivalent at the maze door for a 
dual-energy beam in a conventional treatment room according to the beam direction 
Dual-energy beam 
Thickness (cm)/wall C D E Ceiling 
Beam direction Conventional 
Primary (concrete) 149.6 188.5  163.2 
(lead) 19.6 24.7  21.4 
Total secondary (concrete) 72.8 102.4 101.2 91.0 
Photon dose equivalent 113 µSv/week 
Beam direction Wall C 
Primary (concrete) 175.5    
(lead) 23.0    
Total secondary (concrete) 85.7 102.5 101.4 84.5 
Photon dose equivalent 171.3 µSv/week 
Beam direction wall D 
Primary (concrete)  214.4   
(lead)  28.1   
Total secondary (concrete) 71.8 114.2 101.4 84.5 
Photon dose equivalent 64.8 µSv/week 
Beam direction wall C and wall D 
Primary (concrete) 162.6 201.4   
(lead) 21.3 26.4   
Total secondary (concrete) 75.5 104.4 91.1 94.2 
Photon dose equivalent 116.9 µSv/week 
 
Results shown in this section compare shielding requirements between the 
conventional scenario and each fixed-beam scenario and are expressed as the change in 
thicknesses from a conventional to a fixed beam. 
 
Beam Direction: Wall C 
Figure 2.6 shows the amount of additional primary shielding required when the 
photon beam was directed at wall C. Blue bars represent thicknesses of concrete and red 
bars represent thicknesses of lead. As shown in the figure, the primary barrier needed an 
additional 0.6 TVL of shielding materials, which equals to 19.8 cm and 25.8 cm of 
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concrete for single- and dual-energy linacs, respectively, or 3.4 cm of lead. The increase 
was due to the change in the use factor from 0.25 to 1 for wall C when a fixed beam 
was employed. 
TVL of concrete increases with photon beam energy. Thus, although both 
energy beams had the same amount of increase in TVL, a dual-energy beam required 
more added concrete. In contrast, lead has a constant TVL across the energy spectrum
31
 
and therefore, both single and dual energies had the same amount of additional lead.  
 
Figure 2.6 Change in the thicknesses of the primary barrier when the beam direction is fixed at wall C, 
compared to those for a conventional beam 
 
 Figure 2.7 shows the change in the total secondary thickness at each barrier. 
Overall shielding at wall C was increased by 3.7 cm for single energy and 13 cm for 
dual energies due to the increase in the use factor. Patient scattered radiation at wall C 
was greater than that for a conventional beam because the use factor was increased to 
account for the fact that the beam was facing in the wall C direction. On the other hand, 
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leakage radiation decreased slightly. As mentioned previously, dL in Equation 2.5 was 
measured from the linac head to the barrier for an unsymmetrical beam, instead of from 
the isocenter. This caused an increase in dL for the fixed beam and thus a decrease in the 
amount of leakage radiation at wall C. However, the reduction was outweighed by the 
increase in patient scatter. 
Wall E had the same shielding thickness as that for a conventional beam since 
the scatter fraction and the use factor were not affected by the fixed beam. Leakage 
radiation at wall D increased slightly because the distance between the linac head and 
the wall (dL) was shortened when the beam was directed at wall C. Patient scattered 
radiation, on the other hand, was reduced substantially due to the large scatter angle, 
decreasing the fraction of scattered primary beam at wall D. With the slight increase in 
leakage radiation, this resulted in a modest change in shielding for secondary radiation 
at wall D. 
With a conventional beam, the ceiling was considered a primary barrier because 
it was in the path of the primary beam when the linac was pointing up towards the 
ceiling. The scatter angle in that case was 30°. However, when a fixed beam was in 
place, the ceiling no longer intercepted the primary beam and was required to shield for 
only secondary radiation, increasing the scatter angle to 90°. This change had a notable 
impact on shielding at the ceiling and the secondary shielding thickness was reduced by 
6.5 cm. 
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Figure 2.7 Change in the shielding thicknesses for secondary radiation at each barrier for a fixed beam that 
pointed at wall C compared to those for a conventional beam  
 
 Figures 2.10 and 2.11 illustrate the secondary shielding requirements at various 
scatter angles along wall C, wall E, and the ceiling. Thicknesses for head-leakage and 
patient-scatter radiation were evaluated for wall E and the ceiling, while only shielding 
for patient-scatter radiation was calculated for wall C. Figures 2.8 and 2.9 show the 
scatter positions along each wall. As described by the figures, patient-scatter radiation 
decreased as the scatter angle increased. The reduction was more substantial at smaller 
angles as shown in the situation at wall C. The decreasing trend was because that at 
greater scatter angle, there was less scattering of the primary beam. In contrast, 
shielding for leakage radiation increased with the scatter angle due to the decrease in 
distance between the linac head and the barriers. Patient scattered radiation was more 
dominant than leakage radiation at the 30° scatter angle. After that, leakage radiation 
became greater than patient scatter. 
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Figure 2.8 Illustration of the positions of different scatter angles along wall C and wall E of the conventional 
treatment room 
 
 
Figure 2.9 Illustration of the different scatter angle positions along the ceiling of the conventional treatment 
room 
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Figure 2.10 Shielding thicknesses for head leakage and patient scattered radiation at various scatter angles for 
a single-energy beam when the beam was directed at wall C 
 
Figure 2.11 Shielding thicknesses for head leakage and patient scattered radiation at various scatter angles for 
a dual-energy beam when the beam was directed at wall C 
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 Table 2.4 shows the total thicknesses for secondary radiation at each scatter 
angle for wall E and the ceiling. Despite the fact that the two radiation components 
exhibited different trends in shielding thickness as a function of scatter angle, the total 
required shielding was similar among various scatter angles. The variation in 
thicknesses was between 6 and 12 cm. 
 
Table 2.4 Total thickness for secondary radiation at various scatter angles for wall E and the ceiling when the 
beam was directed at wall C 
 Wall E Ceiling 
Scatter angle (θ) Single Dual Single Dual 
30 77.3 103.4 64.4 87.5 
45 83.9 101.9 69.5 85.0 
60 89.0 107.9 74.6 91.1 
90 82.4 101.4 68 84.5 
 
Beam Direction: Wall D 
 Figure 2.12 shows the effect of a fixed beam that was directed at wall D on 
primary shielding thickness. The primary shielding at wall D required an additional 19.9 
cm and 25.9 cm of concrete (0.6 TVL) for single- and dual-energy fixed beams, 
respectively. This was equivalent to 3.4 cm of lead. These results were consistent with 
those in the previous scenario. The only shielding parameter that differed between the 
fixed beam and a conventional beam was the use factor, which increased from 0.25 to 1 
for wall D because the beam was facing solely in the wall D direction. 
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Figure 2.12 Change in the thicknesses of the primary barrier when the beam direction is fixed at wall D, 
compared to those for a conventional beam 
 
 Figure 2.13 depicts the change in total secondary barrier thickness when the 
beam was pointed at wall D according to the barrier. Analogous to the previous 
scenario, the photon beam was facing in only one direction, increasing the use factor for 
wall D from 0.25 to 1. However, leakage radiation was reduced due to the greater 
distance between the linac head and wall D. As a result, secondary shielding for wall D 
increased by a negligible amount for single energy and 11.8 cm for dual energies. 
Wall E and the ceiling obtained the same results as the previous scenario. Wall 
E was not affected by the fixed beam and had the same shielding as that for a 
conventional beam. The scatter angle at the ceiling increased from 30° to 90° because it 
was no longer a primary barrier as in a conventional scenario. This reduced the fraction 
of the scattered primary beam at the ceiling, decreasing the overall secondary shielding 
thickness. 
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Wall C was in the backward-scattering direction of patient scattered radiation in 
this scenario, increasing the scatter angle substantially from 30° with a conventional 
beam to 135° with the fixed beam. Leakage radiation, however, was increased because 
the distance between the linac head and the barrier was reduced when the beam 
direction was at wall D. Changes in the two radiation components offset each other, 
resulting in a negligible amount of decrease in the total shielding for secondary 
radiation at wall C. 
 
 
Figure 2.13 Change in the shielding thicknesses for secondary radiation at each barrier for a fixed beam that 
pointed at wall D compared to those for a conventional beam 
 
 Figures 2.14 and 2.15 show the shielding requirements for head-leakage 
radiation and patient-scatter radiation at wall D, wall E, and the ceiling as a function of 
scatter angle. Figures 2.16 and 2.17 depict the location of each scatter angle along the 
walls. Wall E and the ceiling had the same exact values and trends as the previous 
scenario. As the scatter angle increased, shielding for patient-scatter radiation decreased 
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while that for head-leakage radiation increased. Patient scatter is greatly affected by the 
scatter fraction, which decreases as the scatter angle gets larger because scattered 
radiation is forward scattering and becomes less significant at large angles. This 
characteristic was especially evident at small scatter angles, as shown at wall D. 
Leakage radiation is dependent on dL, which is the distance between the linac head and 
the barrier. This distance is the shortest when the scatter angle is 90⁰, which results in 
the greatest shielding for leakage radiation.  
 
 
Figure 2.14 Shielding thicknesses for head leakage and patient scattered radiation at various scatter angles for 
a single-energy beam when the beam was directed at wall D 
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Figure 2.15 Shielding thicknesses for head leakage and patient scattered radiation at various scatter angles for 
a dual-energy beam when the beam was directed at wall D 
 
 
Figure 2.16 Illustration of the scatter angle positions along wall D and wall E of the conventional treatment 
room 
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Figure 2.17 Depiction of the positions of different scatter angles along the ceiling of the conventional treatment 
room 
 
  Table 2.5 lists the total shielding thickness for secondary radiation at various 
scatter angles for wall E and the ceiling when the beam was directed at wall D. The 
values are the same as those when the beam direction was at wall C. The thicknesses 
were mostly comparable at different angles and were within 6 to 12 cm of each other. 
 
Table 2.5 Total thickness for secondary radiation at various scatter angles for wall E and the ceiling when the 
beam was directed at wall D 
 Wall E Ceiling 
Scatter angle (θ) Single Dual Single Dual 
30 77.3 103.4 64.4 87.5 
45 83.9 101.9 69.5 85.0 
60 89.0 107.9 74.6 91.1 
90 82.4 101.4 68 84.5 
 
Beam Direction: Walls C and D 
 Figure 2.18 shows the change in shielding thickness for primary radiation 
compared to a conventional beam when the beam direction was split between walls C 
and D. Both primary barriers (i.e. wall C and wall D) had the same results and are 
plotted in the same figure. For a single-energy linac, the split beam added an additional 
90°       60°       45°       30° 
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10 cm of concrete or 1.7 cm of lead to each barrier. For a dual-energy linac, that amount 
became 13 cm of concrete or 1.7 cm of lead. The increases were approximately half of 
those in the previous fixed-beam scenarios. Different from the one-directional fixed 
beams, a split beam only increased the use factor from 0.25 to 0.5 for each primary 
barrier because the beam was divided evenly between two walls. As a result, the change 
in thicknesses was not as substantial. 
 
Figure 2.18 Increase in shielding thicknesses for primary radiation at wall C and wall D when the beam was 
directed at both walls C and D, compared to those for a conventional beam. Wall C and wall D obtained the 
same amount of increases and are plotted in the same figure. 
 
 Figure 2.19 illustrates the impact of a split beam on shielding for secondary 
radiation compared to that for a conventional beam. Different from the previous two 
scenarios, wall E had a use factor of 0.5 and obtained a decrease in secondary shielding 
of 9 cm with a split beam. The use factor was 0.5 because contribution to the total 
secondary radiation at a certain scatter angle along wall E was half from each beam 
0
2
4
6
8
10
12
14
Single-energy Dual-energy
C
h
an
ge
 in
 s
h
ie
ld
in
g 
th
ic
kn
e
ss
 (
cm
) 
Increase in primary shielding when beam at 
walls C and D 
Concrete
Lead
 38 
 
direction. In other fixed beam scenarios, one beam direction was responsible for the 
total secondary radiation and thus, had a use factor of 1. The reduction in shielding 
thicknesses at the ceiling with a split beam was much greater than that in other 
scenarios. Similar to wall E, the use factor was the cause of this decrease. 
 Shielding at wall C and wall D was reduced by 4 and 7 cm when the beam 
energy was only 6 MV. It was increased when the beam energy was 6 and 18 MV but 
by a negligible amount. The use factor for both walls changed from 0.25 for a 
conventional beam to 0.5 for a split beam because the beam direction was separated into 
two. 
 
Figure 2.19 Change in shielding thicknesses for secondary radiation at each barrier compared to those for a 
conventional beam when the beam is pointing at walls C and D 
 
 Figures 2.20 and 2.21 show the required shielding for each component of 
secondary radiation at multiple scatter angles along wall C, wall D, wall E, and the 
ceiling. The scatter positions along the walls are illustrated in Figures 2.8, 2.9 and 2.16. 
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For leakage radiation, the shielding thicknesses increased with the scatter angle due to 
the reduced distance between the linac head and the barriers. For patient-scatter 
radiation, scatter fraction decreased as the scatter angle increased because scattered 
radiation is more significant in the forward direction (smaller scatter angle). Therefore, 
shielding for patient scatter was reduced with larger scatter angles. 
 
Figure 2.20 Shielding thicknesses for head leakage and patient scattered radiation at various scatter angles for 
a single-energy beam when the beam was directed at walls C and D 
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Figure 2.21 Shielding thicknesses for head leakage and patient scattered radiation at various scatter angles for 
a dual-energy beam when the beam was directed at walls C and D 
 
 Table 2.6 shows that total shielding thicknesses for secondary radiation for wall 
E and the ceiling at different scatter angles. These values were less than those in the 
other fixed-beam scenarios. The differences among the thicknesses ranged between 6 
and 11 cm. 
 
Table 2.6 Total thickness for secondary radiation at various scatter angles for wall E and the ceiling when the 
beam was directed at wall C and wall D 
 Wall E Ceiling 
Scatter angle (θ) Single Dual Single Dual 
30 69.4 93.7 56.6 77.9 
45 75.1 91.7 60.8 74.8 
60 80.2 97.7 65.9 80.8 
90 73.7 91.1 59.3 74.2 
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 The change in the total photon dose equivalents at the maze door is presented in 
Figure 2.22 according to the beam direction. Beam direction at wall D resulted in a 
notable reduction in dose equivalent. The reduction was 34.6 µSv/week and 48.2 
µSv/week for single- and dual-energy linacs, respectively. Split beam direction 
produced a minor increase in dose equivalent (3 µSv/week and 3.9 µSv/week). Dose 
equivalent at the maze door was found to be greater when the beam was pointing 
towards wall C, which increased substantially by 44.6 µSv/week and 58.3 µSv/week. 
 
Figure 2.22 Change in the photon dose equivalent at the maze door for each fixed-beam scenario compared to 
that for a conventional scenario 
 
 The total photon dose equivalent at the maze door includes several components: 
photon scatter (Hs), leakage scatter (HLS), patient scatter (Hps), and transmitted leakage 
radiation (HLT). To further examine the effect of fixed beams on the photon dose 
equivalent, Figures 2.23 and 2.24 illustrate the change in dose equivalent of each 
component according to the beam direction. As described by Figures 2.23 and 2.24, 
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patient scatter of the photon beam had the largest influence on the total dose equivalent. 
When the beam was pointing at wall C, Hps increased by 38 µSv/week for single energy 
and 47 µSv/week for dual energies. When the beam direction was at wall D, Hps was the 
only component with a decrease in value and obtained a 44 and 66 µSv/week reduction 
for single and dual energies. Hps had the largest magnitude of change in dose equivalent 
among the components and was the dominant factor in determining the overall results. 
With a split beam, Hps did not take up as a large fraction as other beam 
directions. Decrease in Hps was offset by increases in other components, resulting in a 
modest increase in the total photon dose equivalent. Wall scatter of the photon beam 
(Hs) and leakage transmitted radiation (HLT) had inconsiderable contribution to the 
change in the total dose equivalent. Increase in either component was less than 3 
µSv/week. 
 
Figure 2.23 Change in the dose equivalent for each component of the total photon dose equivalent at the maze 
door for single-energy beam scenarios compared to those for a conventional beam 
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Figure 2.24 Change in the dose equivalent for each component of the total photon dose equivalent at the maze 
door for dual-energy scenarios compared to those for a conventional scenario 
 
2.3.2 Shipping Container 
Primary Radiation 
The primary barrier for the shipping container was wall A since the beam 
direction was pointed at wall A only. The required shielding thickness was 168 cm of 
concrete. The distance between the fixed linac and wall A was limited by the small 
dimension of the shipping container. Therefore, the shielding thickness was greater than 
that if the beam was placed in a conventional treatment room. The total amount of 
shielding material needed for the primary barrier was 9.3 m
3
 of concrete. 
Land soil has a density of approximately 1.5 g/cm
-3
 and is not too different from 
concrete elementally. Study has shown that soil is an excellent substitute shielding 
material for photons in the energy range of 5 to 15 MeV.
40
 If additional shielding is 
needed for the shipping container, soil can be a low-cost and abundant alternative to 
concrete. 
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Secondary Radiation 
 Table 2.7 lists the amount of concrete required to have adequate protection from 
secondary radiation. Walls B and D obtained the same thickness because they were at 
the same distance from the linac head and had the same use factor and occupancy 
factor. Radiation at walls B and D was dominated by leakage radiation due to the short 
distance between the barriers and the fixed linac. Wall C required the least amount of 
shielding because it was in the backward-scattering direction of patient scattered 
radiation. The scatter angle was 150°, which greatly reduced the amount of patient-
scatter radiation at the barrier. Similar to walls B and D, radiation at wall C was mostly 
originated from leakage radiation. 
The secondary shielding thickness at wall A was 93 cm. However, the primary 
barrier at wall A may be wide and thick enough to cover the whole barrier. As a general 
rule, the primary barrier width is the size of the diagonal of the largest field size with at 
least an additional 30 cm to each side.
31
 Assuming that the largest field size that the 
fixed beam had was 40 by 40 cm
2
 at the isocenter, the diagonal of the field size at wall 
A would be 1.7 m. By adding 30 cm to each side, the primary barrier width would be at 
least 2.3 m, which is almost equivalent to the width of the shipping container. 
Therefore, wall A would only consist of primary barrier. 
 The amount of concrete required to shield the secondary radiation at walls B, C, 
and D was 33.2 m
3
. Including the primary barrier, the shipping container needed a total 
of 43 m
3
 of concrete for all the side walls to properly shield the treatment area. A 
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conventional treatment room with a 6-MV conventional beam would require at least 
155 m
3
 of concrete. 
 
Table 2.7 Total shielding thicknesses required for secondary radiation at each barrier for the shipping 
container 
 Wall A Wall B Wall C Wall D 
Secondary thickness (cm) 93 97 91 97 
 
Scatter Angle 
 Figure 2.25 shows the shielding thickness for the two components of secondary 
radiation at different scatter angles along wall A and wall D. Patient-scatter radiation 
was evaluated at 10°, 20°, and 30° at wall A and at 30°, 50°, 90°, 135° and 150° at wall 
D. Figure 2.26 shows the positions of each scatter angle. Patient-scatter radiation 
decreased quickly as the scatter angle increased. On the other hand, leakage radiation 
first increased because dL (distance between the barrier and the linac head) decreased 
from the 30° to the 90° scatter angle, then decreased because dL was increased again. 
 As the scatter angle increased, the difference in shielding requirements between 
head-leakage and patient-scatter radiation at wall D was broadened. At 90° and greater, 
leakage radiation became the major radiation source at wall D and shielding for leakage 
was enough to shield patient scatter that no HVL needed to be added to obtain the final 
secondary thickness. 
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Figure 2.25 Shielding thicknesses for head-leakage and patient scattered radiation at multiple scatter angles 
along wall A and wall D with a fixed beam that was directed at wall A in a shipping container 
 
 
Figure 2.26 Illustration of the scatter angle positions along wall A and wall D of the shipping container 
 
 Table 2.8 lists the total shielding thickness for secondary radiation at multiple 
scatter angles along wall D of the shipping container. The thicknesses ranged from 80 
cm to 101 cm. Shielding at scatter angles of 135° and 150° was much less than that at 
30°, 50°, and 90°. This indicates that shielding for secondary radiation should be 
calculated at the 90° scatter angle or less for the shipping container. 
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Table 2.8 The total thickness of shielding for secondary radiation at wall D at multiple scatter angles when a 
fixed beam was directed at wall A in a shipping container 
Scatter angle (θ) Thickness at wall D (cm) 
30 90 
50 101 
90 97 
135 88 
150 80 
 
2.4 Discussion 
 Different from conventional treatments, upright treatments utilize photon beams 
that are fixed in the horizontal directions during irradiations. As the result of the 
differences, there may be discrepancies in required shielding between a conventional 
beam and fixed beams. The aim of this study was to investigate the impact of fixed 
beams on conventional vault shielding and the efficacy of operating a fixed-beam linac 
in a pre-existing conventional vault. We proposed three fixed-beam scenarios, evaluated 
and compared their shielding requirements to that for a conventional beam. When the 
photon beam was pointing horizontally in one direction, an additional 0.6 TVL was 
needed for primary shielding. This translates to 3.4 cm of lead or 20 cm and 26 cm of 
concrete for single and dual energies, respectively, due to an increase of the use factor 
from 0.25 to 1. The wall in the beam direction required more secondary shielding by 
approximately 2 cm for single energy and 12 cm for dual energies, which was also 
caused by the use factor. Leakage radiation at the wall opposite from the beam direction 
was increased because the leakage distance was shortened, but the increase was 
outweighed by the considerable reduction in patient-scatter radiation at the barrier. This 
resulted in a 2-cm reduction in total secondary shielding. The ceiling also had a 
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decrease of 7 cm in secondary shielding because the barrier was not considered a 
primary barrier in a fixed-beam scenario and, therefore, the scatter angle increased from 
30⁰ to 90⁰. Shielding requirement for wall E was not affected by the beam direction. 
When the beam direction was split between two horizontal walls, required 
shielding thicknesses were between those for a conventional and a one-directional fixed 
beam. The primary barrier needed 10 cm (single) and 13 cm (dual) more concrete or 1.7 
cm of lead than with a conventional beam. All secondary barriers experienced a 
reduction in shielding thicknesses with a single-energy linac, especially wall E and the 
ceiling. The photon dose equivalent at the maze door reduced substantially by 42 
µSv/week on average when the photon beam was facing wall D. Patient scatter of the 
photon beam played a dominant role in determining the overall change in the total dose 
equivalent. Patient scatter in this scenario was limited by the large scatter angle.  In 
contrast, dose equivalent increased by 48 µSv/week when the beam was directed at wall 
C due to greater Hps. With a split beam, dose equivalent increased slightly by 3.5 
µSv/week. 
A shipping container was shown to be a feasible alternative to a conventional 
treatment room for low- and middle-income regions. The primary barrier was 168-cm 
thick. The width of the primary barrier was large enough to also shield for secondary 
radiation at the barrier. The secondary thicknesses at other side walls were 97 cm, 97 
cm, and 91 cm. The total amount of concrete required was 43 m
3
, which was much less 
than that for a conventional room. Unlike a conventional linac, a fixed-beam linac could 
acquire additional lead shielding to the unit head since the linac will not be rotating and 
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more weight can be withstand. This may reduce the amount of leakage radiation and 
secondary shielding at the barriers. 
In this study the primary barriers and some secondary barriers for a fixed beam 
were found to require more shielding than those for a conventional beam. However, 
their clinical appropriateness may be questionable because the shielding calculations 
assumed that the workloads were consisted of only upright treatments. The actual 
shielding thicknesses will be less than predicted from this study. Furthermore, the 
methodology in NCRP Report No. 151 applies several assumptions that could result in 
conservative estimation of shielding requirements. For examples, patient attenuation of 
the primary beam was neglected in the calculations and it could reduce the primary 
beam by 30%; leakage radiation was assumed to be at the maximum value under 
regulation (0.1%)
41, 42
, but in practice it is lower than that. Such conservatisms applied 
to a conventional vault may result in adequate shielding for fixed beams. One study 
found that the computational methods in NCRP 151 overestimated the photon dose 
equivalent at the maze door when compared to that computed using Monte Carlo.
43
 
Results with NCRP 151 could be as large as twice the values with Monte Carlo. This 
indicates that a conventional vault shielded by using methods in NCRP 151 may 
potentially have sufficient protection for upright treatments. Given the outcome of this 
data, in order to validate the hypothesis, physical measurements of transmitted dose 
equivalent beyond the barriers should be measured and compared to regulations. 
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2.5 Conclusion 
 The goal of this study was to determine if radiation shielding for a conventional 
treatment vault could provide adequate protection when upright treatments were 
performed. Three fixed-beam scenarios were created and the results were compared to 
those for a conventional beam. When the photon beam was pointing in one horizontal, 
fixed direction, the primary barrier required an additional 0.6 TVL and the secondary 
barrier in the beam direction needed about 2-12 cm more concrete, depending on the 
beam energy. Other secondary barriers either had no change in shielding requirements 
or obtained a reduction in shielding thickness. When the beam was split into two 
directions, the increase in primary shielding was 0.3 TVL. Shielding for secondary 
radiation decreased with a single-energy beam and increased by a negligible amount 
with a dual-energy beam. Despite the fact that our results demonstrated increases in 
several barriers when a fixed beam was implemented, it is unlikely that additional 
shielding is needed unless all patients are treated using the upright technique. However, 
physical measurements of the dose equivalent beyond the barriers are necessary to 
confirm this claim.  
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Chapter 3 
DEVELOPMENT OF COLLISION SOFTWARE 
3.1 Introduction 
The direction and orientation of beams in radiation therapy are specified by 
complex configurations of the gantry, treatment couch, and collimator. During delivery 
of treatments, the linear accelerator can collide with the patient or the treatment couch 
as a result of gantry and couch motion. In order to deliver radiation treatment safely and 
accurately, collision avoidance is very important to protect patients from undesired 
injuries. The patient setup and gantry-couch orientation for upright treatments may add 
to the complexity of treatment delivery process and could potentially increase the risks 
of collisions between the patient and the surrounding equipment. Conventionally 
patients lay supine or prone on the treatment couch for imaging and irradiation while 
the gantry rotates around them. However, for upright treatments, patients are in a seated 
position in the treatment chair which is mounted on one end of the couch, leaning 
slightly forward. During imaging, the on-board imagers are extended out to the side 
when the gantry is at 0⁰ and the couch rotates 180⁰. During irradiation, the gantry is 
fixed in a horizontal direction and delivers the radiation beam as the couch rotates to 
multiple positions. The seated position places patients in close proximity to the gantry 
and the imaging devices. Additionally, patients are in an upright position rather than 
lying on the couch top plane, increasing the likelihood of collisions between patients 
and the gantry. Thus, upright treatments have more restrictions in movements than 
conventional treatments. 
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Some treatment planning systems exhibit room’s eye view (REV) in their 
software, which shows a graphical representation of the treatment assembly, to assist 
the planner in 3-D visualization of the gantry-couch orientation. The treatment planning 
system constructs a volume of the patient body by using the acquired CT data. REV 
displays a 3-D simulation of the gantry and the treatment couch with the simulated 
volume of the patient and their orientation for a selected beam. However, it only serves 
as a guide for beam placements and does not detect collisions. Additionally, REV only 
shows the section of the patient that was simulated but not the rest of the body. Other 
parts of the patient body that may collide with the equipment cannot be visualized. 
Linear accelerators, such as Varian TrueBeam
TM
 (Varian Medical Systems, Palo Alto, 
CA), have an internal collision protection (LaserGuard II Collision Prevention System, 
Varian Medical Systems) that has a sensor at the collimator and detects proximity to the 
patient, immobilization devices, and the machine itself. The system generates an 
interlock and prevents further motion of the gantry.
44
 However, this is not designed to 
be used before the treatment planning process and collisions are often not realized until 
the patient is on the couch for the first treatment fraction. The purpose of this study is to 
develop patient-specific collision software for upright imaging and irradiation to assist 
therapists in setting up patients and avoiding potential collision between the machine 
and the patient or the treatment couch. This program will also allow physicians to 
determine if upright treatments can be delivered to a specific patient and help the 
treatment planner eliminate beam angles that are deemed unsafe. 
The collision program determines whether two objects in two-dimensional 
space, representing the machine hardware and the patient, intersect each other. This 
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software is applied at the time when the patient is set up for upright simulation. The 
therapist will take a picture of the patient setup and run the program after uploading the 
setup image to a computer. The codes then display a collision map that plots the vertical 
and longitudinal positions of the treatment couch that will either clear or result in a 
collision, or if there could be potential collisions, meaning that collisions may occur 
while translating the couch. 
 
3.2 Materials and Methods 
Concepts 
Figures 3.1 and 3.2 illustrate the setups for upright imaging and upright 
irradiation, respectively, and possible collisions in each setup. As seen from the figures, 
the most frequent scenario is collisions between the patient and the gantry or the 
imagers when the treatment couch moves longitudinally and between the gantry and the 
patient or the treatment couch when the couch moves vertically. Since all of the 
collisions can be observed through two-dimensional (2-D) images such as Figures 3.1 
and 3.2, we proposed an analytical method by using 2-D images of the treatment room 
to predict the couch positions where collisions are likely to occur. Images are taken with 
a digital camera at some distance from the isocenter, looking into the gantry, and 
include the patient and any components that have the potential for collisions. First, the 
software performs image pixel calibration to compensate for camera distortion. By 
using the calibration, regions of interest (ROI) in 2-D are created to represent separate 
components within the treatment room, including the gantry, on-board imager (OBI), 
portal imager, and the treatment couch. Then, the software prompts the user to outline 
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the patient body contours, including any immobilization devices. Collision prediction is 
to determine the couch position at which two ROIs intersect each other. If two objects 
intersect, there is collision. Otherwise, there is either potential collision that may occur 
while moving the treatment couch or no collision at all. Maps of allowed and forbidden 
areas of couch positions are created by the program. 
Computer codes were developed in a commercial programming package 
(MATLAB and Statistics Toolbox Release 2013a, The MathWorks, Inc., Natick, MA) 
to implement the proposed method. A Varian TrueBeam
TM
 linear accelerator was used 
in this study. The module can be divided into two parts: (1) image calibration and 
graphical representation of the hardware, and (2) collision prediction. 
 
 
Figure 3.1 Example of patient setup and possible collisions for upright CBCT imaging 
 
Vertical with gantry 
Longitudinal with detector Longitudinal with tube 
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Figure 3.2 Example of patient setup and possible collisions for upright irradiation 
 
Image Calibration 
Perspective errors and camera lens aberration cause object distortions and 
deformations when an image is taken with a camera. Objects on an image may look 
different from how they actually are in real life. If length measurements are done 
directly on the image without calibration, not only will the results be incorrect, but they 
will also be inconsistent across the image array because the pixel size changes at 
different locations in the image plane perpendicular to the central axis. Since collision 
prediction relies heavily on distance and displacement measurements, these 
deformations need to be addressed to ensure that information extracted from the images 
are accurate. Image calibration involves determining the relationship between pixel size 
and physical length and allows measurements made in pixel units to be converted to 
Longitudinal with gantry 
Longitudinal with portal imager 
Vertical between couch and gantry 
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physical units. As long as the position of the camera stays constant, the calibration 
analysis only needs to be performed once and can be applied to different images. 
Since the pixel size changes across the image, calibration at multiple pixel 
locations is required to provide correct measurements. A calibration method by utilizing 
the treatment couch, which can move to several positions across the camera’s field of 
view, is used. First, the couch is rotated to 90° and an object with a detectable mark that 
can act as a reference point is attached to the top of the couch. The reference point is 
positioned at the isocenter and a picture of the setup is taken (Figure 3.3). The reference 
point can be seen as the red cross on the white block. Then, the couch is moved 
longitudinally and vertically to several positions and a picture is taken at each position 
while the camera is stationary for the entirety of the process. The pixel location of the 
reference point in each image is identified and assigned to the longitudinal and vertical 
positions of the treatment couch in the images. Approximately 20 to 30 calibration 
points are obtained. The program then uses the longitudinal and vertical couch positions 
and the pixel length between any two points to calculate the pixel size that is specific to 
the pixels between these two points. For any given pixel position within the calibration 
range, the program can determine the couch coordinates by interpolating among the 
calibration points. 
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Figure 3.3 An example of image calibration setup for collision prediction 
 
Since one of the calibration points is at the isocenter, the pixel position of any 
objects with a known distance from the isocenter, such as the gantry and the OBI, can 
be determined by using the calibration. The software codes are based on the layout of a 
Varian TrueBeam
TM
 linear accelerator. Dimensions of the gantry, the OBI, and the 
portal imager as well as distances from the surfaces of the components to the isocenter 
were determined manually by in-room measurements, shown in Table 3.1 and Figures 
3.4 and 3.5. 
The distance between the isocenter and the gantry (A) was measured from the 
isocenter to the pins that were protruding from the gantry surface because the patient is 
more likely to collide with the pins. The surface of the gantry was not uniform and flat 
and, as a result, the radius of the gantry head varied across the surface. Therefore, we 
measured the radius (B) from the center of the gantry to the widest part that may collide 
with another object when the gantry is horizontal. The position of the OBI detector that 
is displayed on the machine does not provide the correct distance between the isocenter 
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and the detector assembly because it indicates the distance between the isocenter and 
the OBI detector plane, which is at a depth of the detector assembly. Therefore, we 
measured the distance between the surface of the OBI and the detector plane (E) and 
subtracted that from the value provided by the machine to obtain the distance from the 
isocenter to the OBI detector surface. The distance from the isocenter perpendicular to 
the OBI tube surface was also measured (C). (D) and (F) were the lengths of the OBI 
tube and the detector from the center, which is the point that is projected perpendicular 
to the surface from the isocenter, to the bottom of the assembly when the gantry is at 0⁰. 
Similar to measurement (E), the depth of the detector plane from the surface of the 
portal imager was measured (G). The lengths of the portal imager from the center to the 
bottom and the top of the imager assembly were assessed when the gantry was at 90⁰ (H 
and I). 
 
Table 3.1 In-room measurements of dimensions and distances of the hardware equipment of a Varian 
TrueBeamTM linear accelerator 
 Measurement Distance 
(cm) 
A Distance from the isocenter to the gantry surface 40 
B Radius of the gantry 45 
C Distance from the isocenter to the OBI tube surface 78 
D Length of the OBI tube from the isocenter to the bottom of the tube 23 
E Distance between the OBI detector surface to the detector plane 5.4 
F Length of OBI detector from the isocenter to the bottom of the detector 27.5 
G Distance between the portal imager surface to the detector plane 5 
H Length from the isocenter to the bottom of the portal imager 26 
I Length from the isocenter to the top of the portal imager 32 
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Figure 3.4 Illustration of the distance and dimension measurements of the linac for collision prediction of 
upright CBCT imaging 
 
 
Figure 3.5 Illustration of the distance and dimension measurements of the linac for collision prediction of 
upright irradiation 
A 
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The measurements in Table 3.1 are converted to pixel units and the pixel 
position of each machine component relative to the isocenter is determined. A 2-D 
rectangular binary ROI representation of each is generated (Figures 3.6 and 3.7) and 
placed in the coordinate system of the image array, with the origin in the upper left 
corner. The pixels inside the ROIs have a value of 1, and for everywhere else, a value of 
0. 
 
Figure 3.6 Binary ROIs of the gantry and the on-board imagers in the coordinate system of the image array 
when the gantry is in the upright imaging position 
 
Gantry 
OBI Detector OBI Tube 
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Figure 3.7 Binary ROIs of the gantry and the portal imager in the coordinate system of the image array when 
the gantry is at 90⁰ for upright irradiation 
 
Collision Prediction 
After the patient is positioned in the treatment chair, a picture of the setup is 
captured, such as Figure 3.2. In order to relate measurements extracted from this image 
to the calibration, the camera must be kept at the same exact location as in the 
calibration process. The user imports the setup picture into a computer and runs the 
computer codes. The program then asks the user to enter the couch position that the 
patient was set up in and outline the patient body contours and the treatment chair on 
the image (Figure 3.8). Figure 3.9 shows an example of the outline of the patient body 
and the treatment couch. 
 
Gantry Portal imager 
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Figure 3.8 The collision software allows the user to outline the patient by clicking around the body contours 
and then enter the couch position of the patient setup 
 
 
Figure 3.9 Outline of patient body on the patient setup image for collision prediction 
 
Similar to the ROIs of the machine equipment, the patient ROI has a value of 1 
inside and a value of 0 everywhere else. Since all images are acquired under the same 
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conditions, the ROIs of the machine components and the patient with the 
immobilization devices can be arranged in the same coordinate system of the image 
array (Figures 3.10 and 3.11). 
 
 
Figure 3.10 The patient binary ROI from the setup image and the ROIs of the machine equipment in the 
coordinate system of the image array for upright imaging 
 
 
Figure 3.11 The binary ROIs of the patient and the machine equipment in the coordinate system of the image 
array for upright irradiation 
Gantry 
OBI detector OBI tube 
Gantry Portal Imager 
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The software simulates couch translation longitudinally and vertically from the 
original setup position. As the binary ROIs of the patient and the immobilization device 
are shifted to different positions, the collision software determines the value of each 
pixel at each step. When any two ROIs intersect each other, the overlapping pixels will 
have an output value of 2 and the codes will mark that pixel coordinates as the collision 
position. When the output value is 1, there is no overlap and no collision, then the 
program continues shifting the patient position. The pixel location where collision 
occurs is then converted to couch coordinates by using the calibration. This will give 
the collision positions when the couch is positioned at 90°. To determine the collision 
points when the couch is at 270°, the ROIs of the machine equipment are mirrored 
along the isocenter and the patient ROI is again translated to multiple positions. 
After the couch positions for all collisions are found, the codes plot the results 
on a map that has the longitudinal and vertical couch positions as the axes. 
Simultaneously, areas of the map are filled with different colors to indicate the 
likelihood of collisions. Red indicates absolute collisions; green means that it’s 
collision-free; yellow tells the user that there may be potential collisions when moving 
the treatment couch (explained in Uncertainties section). As collision points vary with 
couch angles, separate charts are created for couch positions at 90⁰, 270⁰, and 
combination of both for upright imaging and upright irradiation individually. 
 
Uncertainties 
During image calibration, the reference point is positioned at the same position 
on the top of the couch throughout the process and therefore, the calibration applies 
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solely to that image plane perpendicular to the couch top. The binary ROIs also lay on 
the same plane of reference because they are generated by using the calibration points. 
After the patient contour is outlined, the codes predict collisions by intersecting the 
patient ROI with other binary ROIs and determine the couch positions by using the 
calibration points. As a result, the predicted collision positions are under the assumption 
that collisions occur on the same reference plane as the calibration points and the ROIs. 
Discrepancies may arise when actual collisions take place on a different image plane. 
To account for this variation, uncertainties are calculated and incorporated into the 
collision results. 
Figure 3.12 shows an overhead view of the camera setup when the treatment 
couch is positioned at 90°. The figure illustrates a scenario where the actual collision 
point is on the edge of the couch, instead of the midline where the image calibration is 
performed. The green star represents the isocenter. The dash line in the figure is the 
midline of the couch. Point A is the actual collision point, and Point B is the collision 
point perceived by the camera. x is the lateral distance between Point B and the 
isocenter, and s is the distance between the camera and the isocenter. The width of the 
treatment couch is 26.5 cm. The absolute lateral uncertainty is calculated as follows: 
         
 
 
 Equation 3.1 
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Figure 3.12 Diagram illustrating uncertainty calculation in the lateral direction 
 
The absolute uncertainty in the vertical direction can be determined using the same 
equation, except that x is substituted with y, which is the vertical distance between Point 
B and the isocenter. The situation in Figure 3.12 depicts the worst-case scenario in 
which the collision points are on the edge of the treatment couch, and the actual 
uncertainty may be less than that calculated by using Equation 3.1. 
As mentioned previously, results are plotted and color-coded according to the 
likelihood of collisions. The red area indicates absolute collisions, which are the couch 
positions computed by the software where two ROIs intersect. The yellow area informs 
the user that there could be potential collisions when moving the treatment couch in this 
area. It indicates when the lateral and vertical extents of the patient ROI plus the 
uncertainties intersect other ROIs. In other words, the range of the yellow areas is 
equivalent to the uncertainty. The green areas are clear in collision and are other regions 
outside the red and the yellow areas. 
 
26.5 cm x 
A 
B 
Camera 
s 
Couch 
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3.3 Results 
The validity of the methods was tested on three artificially created cases on 
Varian TrueBeam
TM
 linear accelerators. The first case used a mannequin as the patient 
positioned in the treatment chair and the other two cases substituted the patient presence 
with immobilization devices. Figure 3.13 shows the patient setup images for all the 
cases and their couch positions at setup. These are the pictures that the therapist will be 
taking before upright simulation and use to outline the patient contour. Results were 
compared to the actual collision positions verified manually in the treatment room and 
expressed as the difference between the actual and the computed values.  
 
   
Case 1 Case 2 Case 3 
Vertical: 65.93 cm 
Longitudinal: 46.19 cm 
Vertical: 52.16 cm 
Longitudinal: 75.76 cm 
Vertical: 65.53 cm 
Longitudinal: 79.87 cm 
Figure 3.13 Patient setup images of the three tested cases and the couch positions in those images for collision 
prediction 
 
Upright Imaging 
Table 3.2 shows the couch positions that would result in collisions when the 
couch was positioned at 90° and the gantry was at 0° for upright imaging. Possible 
collisions in this position include patient-OBI detector and chair-OBI tube collisions in 
the longitudinal direction and patient-gantry collision in the vertical direction. The 
position of the OBI detector varied among the tested cases and is shown in the column 
Patient Patient 
Treatment 
chair base 
 68 
 
next to the patient-OBI detector collision data. The differences were between 0.5 cm 
and 2.1 cm. Figure 3.14 shows the collision map for each case and an illustration of the 
location of each collision.  As explained above, the extent of the yellow area is 
equivalent to the uncertainty. The purpose of the yellow areas is to caution users to be 
mindful when translating the treatment couch because there could be unexpected 
collisions. According to Table 3.2, the differences between the actual and the computed 
couch positions were less than the uncertainties, meaning that although the software 
overestimated some of the collisions, the actual collisions occurred within the yellow 
areas of the maps. 
 
Table 3.2 Comparison of couch positions that would result in collisions when the couch was at 90° for upright 
imaging 
Collision 
Case Computed 
(cm) 
Uncertainty 
(cm) 
Actual 
(cm) 
Difference 
(cm) 
Longitudinal 
Patient-Detector 
80 1 95.0 2.9 94.6 0.5 
50 2 99.9 4.3 102.0 -2.1 
40 3 103.2 5.4 105.2 -2.0 
Longitudinal 
Patient/Chair-Tube 
1 18.2 4.2 17.4 0.8 
2 33.5 3.2 34.0 -0.5 
3 25.1 2.1 23.4 1.7 
Vertical Patient-
Gantry 
1 56.8 2.9 57.8 -1.0 
2 44.7 3.0 43.1 1.6 
3 41.8 2.4 43.2 -1.4 
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Figure 3.14 Collision map when the couch was at 90⁰ for upright imaging. X-axis and y-axis are the 
longitudinal and vertical couch positions. Red zone indicated absolute collisions; yellow zone meant that there 
could be potential collisions; green zone was clear in collision 
 
 Table 3.3 reports the collision points when the couch was at 270° with the 
patient facing the OBI tube direction for upright imaging. The vertical collision between 
the patient and the gantry were the same as when the couch was positioned at 90°. The 
differences in couch positions were between 0.3 cm and 2.2 cm. The longitudinal 
collisions for Case 1 were overestimated while those for Case 2 were underestimated. 
The computed results were mapped in Figure 3.15. Similar to the scenario when the 
couch was at 90⁰, the differences between the couch positions were less than the 
Patient-Gantry 
Patient-Detector Patient/Chair-Tube 
Longitudinal 
Vertical 
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uncertainty. Since the range of the yellow areas corresponds to the uncertainties, the 
actual collision positions were within the range of the yellow area.  
 
Table 3.3 Comparison of couch positions that would result in collisions when the couch was at 270° for upright 
imaging 
Collision 
Case Computed 
(cm) 
Uncertainty 
(cm) 
Actual 
(cm) 
Difference 
(cm) 
Longitudinal 
Patient/Chair-
Detector 
80 1 22.2 4.2 20.8 1.4 
50 2 66.7 3.2 67.0 -0.3 
40 3 67.9 2.1   
Longitudinal Patient-
Tube 
1 98.3 2.9 97.1 1.2 
2 133.4 4.3 135.6 -2.2 
3 149.6 5.4   
Vertical Patient-
Gantry 
1 56.8 2.9 57.8 -1.0 
2 44.7 3.0 43.1 1.6 
3 41.8 2.4 43.2 -1.4 
 
 71 
 
Case 
 
1 
 
2 
 
3 
 
Figure 3.15 Collision map when the couch was at 270⁰ for upright imaging. X-axis and y-axis are the 
longitudinal and vertical couch positions. Red zone indicated absolute collisions; yellow zone meant that there 
could be potential collisions; green zone was clear in collision 
 
 Figure 3.16 shows the collision maps for the overall upright imaging process for 
the three tested cases. They were created by combining the collisions maps for the 90⁰ 
and 270⁰ couch positions in Figures 3.14 and 3.15 together. Case 1 had the largest 
longitudinal range of collision-free couch positions (73 cm), compared to Cases 2 and 3 
(33 cm and 55 cm, respectively). This was because that the OBI in Case 3 had the 
Patient-Gantry 
Patient/Chair-Tube 
Patient-Detector 
Vertical 
Longitudinal 
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largest distance from the isocenter. In contrast, the vertical range of motion was limited 
in Case 3 due to the height of the mannequin. 
Longitudinal couch movements were mainly restricted by the OBI detector 
because the detector surface was closer to the isocenter than the surface of the OBI tube. 
Vertical collisions occurred between the patient head and the gantry before the couch 
could be moved up high enough to collide with the OBI and were largely affected by 
the patient’s size. Although the computer program overestimated some couch positions, 
the discrepancies were compensated by the calculated uncertainties and the actual 
collision positions were always within the yellow and the red areas and never in the 
green area.  
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Figure 3.16 Collision map for overall upright imaging. X-axis and y-axis are the longitudinal and vertical 
couch positions. Red zone indicated absolute collisions; yellow zone meant that there could be potential 
collisions; green zone was clear in collision 
 
Upright Irradiation 
Table 3.4 shows the couch positions where collisions occurred when the patient 
was facing the gantry for upright irradiation. Types of collisions investigated included 
patient-gantry and chair-portal imager collisions longitudinally and couch-gantry 
collision vertically. Like to the OBI, the position of the portal imager can be adjusted to 
several locations relative to the isocenter. The position of the portal imager for each 
case is shown next to the portal imager collision data. The differences in couch 
positions ranged between 0.2 cm and 2.8 cm. Figure 3.17 shows of the collision maps 
for each case and a graph of the type of collisions at each location. The differences 
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between the computed and the actual couch positions were less than and accounted for 
by the uncertainties. The actual collisions all occurred in the yellow and the red areas. 
 
Table 3.4 Comparison of couch positions that would result in collisions when the patient was facing the gantry 
for upright irradiation 
Collision 
Case Computed 
(cm) 
Uncertainty 
(cm) 
Actual 
(cm) 
Difference 
(cm) 
Longitudinal Patient-
Gantry 
1 60.0 2.9 59.0 1.0 
2 95.1 4.3 97.8 -2.7 
3 108.5 5.4 111.3 -2.8 
Longitudinal 
Patient/Chair-
Portal 
80 1 21.9 4.2 20.9 1.0 
50 2 66.4 3.2 68.3 -1.9 
50 3 58.2 2.1 57.5 0.7 
Vertical Couch-Gantry 
1 45.0 2.9 45.5 -0.5 
2 57.2 3.7 58.7 -1.5 
3 45.8 2.4 46 -0.2 
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Figure 3.17 Collision map when patient was facing the gantry for upright irradiation. X-axis and y-axis are the 
longitudinal and vertical couch positions. Red zone indicated absolute collisions; yellow zone meant that there 
could be potential collisions; green zone was clear in collision 
 
Table 3.5 summarizes the couch positions for collisions when patient was facing 
away from the gantry. The portal imager position is shown next to the data for patient-
portal imager collision. The differences in couch positions between the computation and 
the actual measurements ranged between 0.2 cm and 4.1 cm. Couch position for couch-
gantry collision in Case 1 was overestimated by 4.1 cm. It is unlikely that this was due 
to an error in the computer codes because other results were calculated using the same 
codes and did not obtain such large differences. Despite the large difference, the actual 
Couch-Gantry 
Patient-Gantry 
Patient/Chair-Portal Imager 
Longitudinal 
Vertical 
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collision took place within the range of the uncertainty in the yellow area. Figure 3.18 
displays the collision maps for all cases. 
 
Table 3.5 Comparison of couch positions that would result in collisions when the patient was facing away from 
the gantry for upright irradiation 
Collision 
Case Computed 
(cm) 
Uncertainty 
(cm) 
Actual 
(cm) 
Difference 
(cm) 
Longitudinal Patient-
Portal 
1 94.9 2.9 93.0 1.9 
2 100.1 4.3 102.3 -2.2 
3 114.6 5.4   
Longitudinal 
Patient/Couch-
Gantry 
80 1 57.0 4.2 52.9 4.1 
50 2 70.8 3.2 71.9 -1.1 
50 3 63.2 2.1 61.6 1.6 
Vertical Couch-Gantry 
1 45.0 2.9 45.5 -0.5 
2 57.2 3.7 58.7 -1.5 
3 45.8 2.4 46 -0.2 
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Figure 3.18 Collision map when patient was facing away from the gantry for upright irradiation. X-axis and y-
axis are the longitudinal and vertical couch positions. Red zone indicated absolute collisions; yellow zone 
meant that there could be potential collisions; green zone was clear in collision 
 
 Figure 3.19 shows the combined collision maps for overall upright irradiation 
from the maps at the 90⁰ and 270⁰ couch positions in Figures 3.17 and 3.18. The 
dimension of the gantry was the limiting factor in upright irradiation. The gantry surface 
was about 40 cm from the isocenter longitudinally, which means that there is an 80-cm 
of longitudinal space between gantry angles at 90° and 270°. For Case 1, the lateral 
extension of the patient was 78 cm, meaning that there was only 2 cm of couch 
movements available. Since the uncertainties were greater than 2 cm, the program 
Couch-Gantry 
Patient-Portal Imager Patient/Chair-Gantry 
Longitudinal 
Vertical 
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displayed the 2-cm space in yellow to indicate that there may be collisions. The lateral 
extents for Cases 2 and 3 were not as large as that for Case 1. Therefore, there was a 
greater degree of longitudinal movements. 
 
Case  
1 
 
2 
 
3 
 
Figure 3.19 Collision map for overall upright irradiation. X-axis and y-axis are the longitudinal and vertical 
couch positions. Red zone indicated absolute collisions; yellow zone meant that there could be potential 
collisions; green zone was clear in collision 
 
3.4 Discussion 
Due to the complexity in patient setup and beam administration, upright 
treatments exhibit more restrictions in couch movements than conventional treatments. 
The purpose of this study was to develop collision-avoidance software with the use of 
2-D images of the treatment room to predict couch positions that would result in 
collisions. The advantage of the program is that this collision prediction is patient-
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specific and is performed before any treatment planning or even simulation. This allows 
the radiation oncology team to assess the feasibility of upright treatments for a specific 
patient. The module can also be used to guide therapists in patient positioning and in 
accompanying the treatment planning process. This software is consisted of two 
procedures: image calibration and collision prediction. Results from collision prediction 
were compared to actual collision measurements in the treatment room and presented as 
maps with color-coded areas. Red areas represent collision zones; yellow areas account 
for the uncertainties that are due to the assumptions that collisions occur on one image 
plane and inform users that there could be potential collisions in this range of couch 
positions; green areas indicate no collision. 
Disagreements between the software results and the actual measurements ranged 
between 0.2 cm and 4.1 cm. Upright imaging was shown to have greater freedom of 
longitudinal movements of the treatment couch than upright irradiation. The on-board 
imagers allow greater displacements of the couch because they are further away from 
the isocenter than the irradiation devices. The OBI tube is about 78 cm from the 
isocenter, and the distance between the detector and the isocenter can be adjusted to as 
high as 80 cm. This adds up to a total of 118 cm of longitudinal space for upright 
imaging. In contrast, the gantry face is about 40 cm from the isocenter. Between gantry 
angles of 90⁰ and 270⁰, there is only 80 cm of longitudinal space. Overall, longitudinal 
translation of the treatment couch for upright treatments (upright imaging and upright 
irradiation) is primarily restricted by the gantry size because the gantry is much close to 
the isocenter than any other machine components. The vertical range of motion during 
the imaging process usually occurred between the patient’s head and the gantry before 
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the couch could be raised high enough to collide with the OBI. Vertical collision during 
upright irradiation arises between the gantry and the treatment couch or the treatment 
chair and is not largely affected by the patient’s size. Although some of the differences 
in couch positions were quite large, the collision maps accounted for these differences 
by incorporating the calculated uncertainties into the results and displayed an area on 
the map that warns the user that collisions could happen. All the actual collisions were 
predicted within the yellow and the red areas of the maps.  
Upright treatment may not seem like a feasible treatment technique for Case 1. 
However, there are ways to mitigate these issues. This software performs collision 
predictions when the patient is facing both directly and away from the gantry, where the 
couch positions have the most restrictions in motion. However, not all treatments 
require anterior-posterior (AP) beams with the patient facing the gantry, and posterior-
anterior beams (PA) with the patient facing away from the gantry. If the patient in Case 
1 was to be treated with opposed lateral beams where the couch is positioned at 0° 
throughout the treatment, the results from the software would not apply to this patient. 
If AP and PA beams are required for treatment, one way to increase longitudinal motion 
is to reduce the angle of the head piece of the treatment chair. The head piece allows 
adjustments to several angles to accommodate different patient positions. By reducing 
the angle that the patient is tilted forward, the later extent of the patient can be reduced, 
affording more longitudinal space for couch movements. An extended source-to-surface 
(SSD) distance can also be employed to mitigate the problem. The portal imager is not 
always fully extended during the irradiation process. Therefore, the longitudinal motion 
is only restricted by the gantry head and the couch can be shifted to increase the SSD. 
 81 
 
For AP beams, the treatment couch can translate backwards to increase the SSD. For 
PA beams, the couch can move forward longitudinally. Another solution is to utilize 
multiple isocenters with extended SSD for different treatment fields. 
The program is very conservative because it calculates collisions between the 
machine and the most lateral and vertical parts of the patient. Discrepancies between the 
computed and the actual values could be due to that in-room measurements of the 
equipment and distances were conservative. We did not directly collide the equipment 
during actual collision assessment. Instead, when two objects were in close proximity, 
we manually measured the distance between them. This may have contributed to the 
errors in the software results. This software does not check for collisions during 
transitions between couch positions. Unless the patient’s elbows are protruding beyond 
the edge of the treatment couch, collisions are not likely to occur between beams. 
Furthermore, transitions between beams are usually done with a therapist in the room to 
watch out for collisions. 
The software was computationally fast. Image calibration takes approximately 3 
minutes, depending on the number of calibration points, and collision prediction can be 
done in a couple minutes. Although the codes were written for a particular treatment 
unit, they can be easily modified and adapted for other machines as well. Modification 
requires measuring the dimension of the gantry and distances between faces of each 
component and the isocenter. Several improvements can be made to better the software. 
Instead of using the most lateral and vertical extents of the patient to perform collision 
predictions, collisions with other parts of the patient should also be simulated to provide 
more accurate and patient-specific results. Multiple imaging calibrations performed at 
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different image planes can reduce the size of the uncertainties. Future work can 
incorporate collision detection into the treatment planning system to provide acceptance 
or rejection of unwanted beam angles. This will greatly assist in the treatment planning 
process and allow the planner to visualize and determine the beam angles for optimal 
dose coverage. In order to confirm the clinical feasibility of the software, more 
extensive tests need to be performed on actual patient cases. 
 
3.5 Conclusion 
In this study we developed an analytical method to predict collision for upright 
treatments. The software creates maps of allowable and forbidden longitudinal and 
vertical couch positions. The maps include colored areas in red for definite collisions, in 
yellow for potential collisions, and in green for no collision. The predicted results were 
compared to the actual measurements in the treatment room. Our program safely 
estimated collisions in three tested cases. The actual collisions occurred in the yellow 
and the red areas of the maps. Although the collision positions were sometimes 
overestimated, they were accounted for by the uncertainties and placed in the yellow 
area, which allows the user to realize that there could be potential collisions. 
 
  
 83 
 
Chapter 4 
FEASIBILITY OF UPRIGHT IMRT TREATMENT PLANNING 
4.1 Introduction 
For three-dimensional conformal radiation therapy (3DCRT), treatment planning 
systems (TPS) use patient data acquired with CT or other modalities in conjunction with 
CT. After patient data is imported into the TPS, physicians and dosimetrists outline 
relevant anatomical features, such as tumor and critical structures, and place the 
radiation beams at various angles, shaped around the target volume. The TPS calculates 
the doses and displays the dose distribution in three dimensions. If the results are 
unsatisfactory, the planner can modify the beam angles, beam weighting, and by adding 
accessories (e.g. blocks, wedges, and compensators) until desired dose distribution is 
obtained. IMRT is an extension of 3DCRT and allows delivery of nonuniform beam 
intensities. This technique produces a steep dose gradient around the target by 
modulating dose across each treatment field. 
Treatment planning is greatly dependent on patient position during the 
acquisition of the pre-treatment data since the radiation beam is planned based on those 
images. A change in patient position will affect the shape of the tumor and organs at 
risk (OAR), angle of the beams entering the patient, and the volume and type of normal 
tissues in the path of the beams. Upright treatments not only differ from conventional 
treatments in patient position but also in the administration of radiation. Rather than 
rotating the gantry, upright treatments rotate the treatment couch while the gantry is 
fixed at 90⁰ and 270⁰. Due to complexity of IMRT treatments, those differences may 
influence the treatment planning results. 
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Shah et al performed a 3D conformal treatment planning in a commercial TPS 
and irradiation in the upright position.
45
 However, there was no quantitative evaluation 
or discussion of the quality of the treatment plan. Other studies reported 3DCRT 
treatment planning in the upright position using hand calculations and manual 
delineation of radiation fields on films.
11, 15
 To this date, the feasibility of creating 
upright IMRT treatment plans using current TPS technology remains unclear. The focus 
of this specific aim is to retrospectively generate IMRT treatment plans in the upright 
position for lung and H&N cancer patients. We hypothesized that the upright treatment 
plans can be clinically acceptable and deliver target coverage that is within ±10% of the 
original plans and tolerable doses to normal tissues. 
 
4.2 Materials and Methods 
4.2.1 Patient Planning CT 
 Original planning CT data from five lung and five H&N patients who had 
undergone radiation therapy were randomly selected for this study. The patient plans 
will be referred to as THOR1, THOR2…HN1, HN2...etc. Disease staging and 
anatomies were distinctly different among the cases. The H&N patients were previously 
treated with IMRT while the lung patients were treated with either IMRT or stereotactic 
body radiation therapy (SBRT). 
As previously mentioned, treatment planning is essentially based on the 
orientation of the planning images. Therefore, to generate treatment plans in the upright 
position, the original patient images must be converted to the upright position. The final 
images should look as if patients were simulated while seated in the treatment chair. In 
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order to make those adjustments to the images, the original data were imported into a 
commercial programming software package (MATLAB and Statistics Toolbox Release 
2013a, The MathWorks, Inc., Natick, MA). The dimension of the data matrix was 
rearranged and flipped columnwise left to right. The final images were then imported 
back into the TPS. 
When in a sitting position, the upright axial plane corresponds to the 
conventional coronal plane and vice versa. Since TPS is not programmed for imaging 
positions other than the conventional ones, it will only display images according to the 
conventional directional planes. Thus, in the TPS the upright axial images of the 
converted CT images were presented in the coronal window and the upright coronal 
images were presented in the axial window. The left and right sides of the converted 
images displayed the true left and right sides of the patient. The sagittal images 
remained in the same viewing window but the orientation was rotated counterclockwise. 
An example of the converted images as seen in the TPS is shown in Figure 4.1. 
 
   
Axial window Sagittal window Coronal window 
Figure 4.1 Slices of patient CT images that were converted from the supine to the upright position for upright 
treatment planning study. These slices were shown in the corresponding windows in the treatment planning 
system. 
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4.2.2 Planning Techniques and Objectives 
All upright treatment plans were retrospectively re-planned in a commercial 
treatment planning system, Philips Pinnacle
3
 Version 9.0 (Philips Medical Systems, 
Fitchburg, WI) using step-and-shoot IMRT and exclusively 6-MV photons. Isocenters 
of the upright plans were set to similar position as those of the original plans. Some of 
the upright plans had the same beam angles as the original plans while others had nine 
equally spaced beams around the patient. Photon beams had a fixed dose rate of 600 
MU/min and were administered horizontally with the gantry at 90° and 270°. The 
treatment couch was rotated to several positions between 90° and 270°. Gantry at 90° 
with couch rotation delivers beams from the right side of the patient while gantry at 
270° produces beams that incident on the left side of the patient. The dose calculation 
algorithm used was Adaptive Convolution with heterogeneous correction. The IMRT 
objectives, values, and weights were adjusted to obtain clinically acceptable treatment 
plans. Dose description for each patient is summarized in Table 4.1. The upright 
treatment plans had the same prescriptions as the original plans. 
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Table 4.1 Dose descriptions for patient cases in the treatment planning study 
Plan Initial treatment 
modality 
Dose prescription (Gy) 
PTV/# fractions 
# IMRT 
field 
Tumor 
location 
THOR1 SBRT 50/4 6 RML 
THOR2 IMRT 66/33 10 RUL 
THOR3 IMRT 74/37 9 LUL 
THOR4 IMRT 74/37 9 RUL 
THOR5 IMRT 66/33 9 RUL 
HN1 IMRT 60/30 9 Tongue 
HN2 IMRT 70/33 9 Tonsil 
HN3 IMRT 60/30 9 Thyroid 
HN4 IMRT 60/30 9 Thyroid 
HN5 IMRT 60/30 9 Larynx 
 
The gross tumor volume (GTV) is defined as the visualization of any gross 
disease, and the clinical target volume (CTV) accounts for any microscopic disease 
around the GTV. The planning target volume (PTV) includes the CTV plus geometric 
uncertainties. The GTV was contoured by a physician in the originals plans and, along 
with the OARs, were transferred directly to the upright plans. Other contours that were 
used for planning purposes (false structures) were created as needed. 
 
Thoracic Plans 
The upright lung plans had six to ten fixed beams, delivering between 50 and 74 
Gy to 95-98% of the PTV. Table 4.2 lists the gantry and couch angles for the beams 
used in each treatment plan. The CTV was consisted of the GTV with a 0.8-cm margin, 
and the PTV was defined as the CTV plus a 0.5-cm expansion. All treatment plans were 
normalized to ensure the GTV is covered by the 100% isodose line, and hot spots with 
110% of the prescribed dose outside the PTV were eliminated. 
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Table 4.2 Couch and gantry angles for the photon beams used in the upright lung treatment plans 
THOR1 THOR2 THOR3 THOR4 THOR5 
Couch Gantry Couch Gantry Couch Gantry Couch Gantry Couch Gantry 
290 90 283 270 290 90 290 90 270 270 
330 90 57 270 330 90 330 90 283 270 
10 90 70 270 10 90 10 90 300 270 
50 90 83 270 50 90 50 90 60 270 
280 270 290 90 90 90 90 90 290 90 
320 270 303 90 310 270 310 270 303 90 
  317 90 350 270 350 270 317 90 
  330 90 30 270 30 270 330 90 
  10 90 70 270 70 270 60 90 
  37 90       
 
The goal of treatment planning was to obtain maximum dose coverage to the 
target while limiting normal tissue toxicities. Table 4.3 lists the dose constraints to 
normal tissues used in the optimization process. The spinal cord and the total lung are 
the main limiting tissues for lung treatment planning and usually have the first priority 
over the PTV dose coverage. 
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Table 4.3 Normal tissue dose constraints for lung treatment planning 
Normal Tissue Dose Constraints 
Spinal Cord Dmax < 45 Gy 
Lung MLD ≤ 20 Gy 
 V20 ≤ 35% 
 V10 ≤ 45% 
 V5 ≤ 65% 
Heart V20 ≤ 45% 
 Mean dose < 26 Gy 
Esophagus Dmax ≤ 80 Gy 
 V70 < 20% 
 V40 < 40% 
 Mean dose < 34 Gy 
Brachial plexus Dmax < 65 Gy 
Contralateral lung Dmean < 6 Gy 
 
Head and Neck Plans 
 The upright H&N plans were optimized using nine 6-MV fields. The photon 
beams were equally spaced around the patient. The couch and gantry angles for the 
treatment plans are shown in Table 4.4. The original prescription doses ranged between 
60 and 70 Gy to 97-98% of the PTV. In addition to the GTV, the CTVs were also 
delineated by a physician in the original images and transferred to the upright plans. 
Each plan had multiple delineated CTVs with different prescription doses. A planning 
CTV was created for each delineated CTV by reducing from the delineated CTV to 3 
mm under the surface of the skin for adequate buildup. Then, a PTV was created for 
each planning CTV by adding a 3-mm expansion to the planning CTV while 
maintaining the 3-mm buildup region between the target volume and the skin. The GTV 
must have 100% coverage while keeping the hot spots under 120% of the prescribed 
dose, and all planning CTVs need to have 99-100% coverage. 
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Table 4.4 Couch and gantry angles for the photon beams used in the upright H&N treatment plans 
Couch angles Gantry angles 
290 90 
330 90 
10 90 
50 90 
90 90 
310 270 
350 270 
30 270 
70 270 
 
Table 4.5 below summarizes the dose constraints to normal tissues for H&N 
cancers. Oral avoidance, larynx, and esophagus were contoured when appropriate and 
doses to those structures were kept as low as reasonably achievable without 
compromising the coverage to PTVs. 
 
Table 4.5 Normal tissue dose constraints for H&N treatment planning 
Normal Tissue Dose 
Constraints 
Normal Tissue Dose Constraints 
Spinal cord Dmax < 45 Gy Chiasm Dmax < 54 Gy 
Brain Dmax < 54 Gy Brainstem Dmax < 54 Gy 
Mandible Dmax < 70 Gy Total lung V20 < 40 % 
Left/Right cochlea Dmax < 35 Gy Left/Right eye Dmax < 50 Gy 
Left/Right lens Dmax < 10 Gy Left/Right 
parotids 
Mean dose < 26 
Gy 
Left/Right optic 
nerves 
Dmax < 54 Gy   
 
4.2.3 Plan Evaluation 
All upright treatment plans were reviewed by dosimetrists and medical 
physicists, and were approved to be clinically acceptable by radiation oncologists. The 
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final plans were exported from Pinnacle into PDF files by using a script created by the 
author’s institution. The PDF files included information such as treatment description, 
DVH, and slice-by-slice axial dose distribution. Since the conventional axial plane is 
not equivalent to the upright axial plane, a separate script option was created for 
exporting upright treatment plans. This allows the isodose distribution to be displayed 
on the upright axial plane, mimicking the views that users are familiar with. 
Dosimetric parameters obtained from the DVHs were evaluated and compared 
between the upright and the original plans. Results in this chapter focus on comparisons 
in terms of target coverage and doses to normal tissues. To determine the quality of 
target coverage, the maximum, mean, and minimum doses to the target volumes and 
conformity index (CI) were determined for each plan based on the DVH. The maximum 
dose is defined as the dose received by 1% of the volume, and the minimum dose is the 
dose received by 99% of the volume. CI was calculated using Equation 4.1 shown 
below. Vprescription is the volume of the PTV enclosed by the prescribed isodose, and 
VPTV is the volume of the PTV. A high CI value means that a larger volume of the 
prescribed dose is delivered outside the PTV. 
    
             
    
 Equation 4.1 
Analysis for the OARs depended on the normal-tissue constraint parameters in 
Tables 4.3 and 4.5. Those parameters included the maximum dose, the mean dose, and 
Vx (volume of the OAR that received specified dose, x). 
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4.3 Results 
4.3.1 Thoracic Plans 
 Figure 4.2 shows the isodose distributions and the DVH for one of the upright 
lung treatment plans (THOR3). This upright plan had nine equally spaced beams. The 
prescription isodose was conformal to the PTV in all three planes. The GTV and the 
CTV were able to achieve 100% coverage. Dmax to the spinal cord (40.7 Gy) was less 
than the dose constraint. Most normal tissues received doses within normally accepted 
tolerances. The mean lung dose (MLD) and Dmax to the brachial plexus received 20.3 
Gy and 69.6 Gy, which were greater than the dose constraints but had less than 1% 
differences compared to the original doses. Additional isodose distributions and DVHs 
for other treatment plans are presented in Appendix C. 
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Figure 4.2 Isodose distributions and DVH for one of the upright lung treatment plans (THOR3) 
 
Target Coverage 
Figure 4.3 demonstrates the relative differences of the maximum, mean, and 
minimum doses received by the PTV, CTV, and GTV for each upright plan. The 
relative differences are expressed as a percentage of the original target dose. The ±10% 
limit is shown in the figure as dotted lines. All upright lung treatment plans obtained 
relative differences of less than ±10% (-5.2% to 3.8%). The minimum doses exhibited 
the largest variation, which ranged between -5.2% and 3.8%, while the maximum and 
the mean doses had smaller variations (-4% to 1%). THOR1 obtained the highest 
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agreement in target doses between the upright and the original plans. Target volumes 
for THOR2 and THOR3 appeared to be underdosed compared to their original plans. 
 
 
Figure 4.3 Relative differences of the maximum, mean, and minimum target doses between the upright and the 
original lung treatment plans. The target volumes included the GTV, CTV, and PTV. 
 
The conformity index evaluates the quality of PTV coverage by determining the 
fraction of the PTV that is enclosed by the prescribed isodose. Table 4.6 shows the CI 
values for the upright and the original lung plans. As illustrated in Figure 4.3 and Table 
4.6, the relative difference of the minimum dose to the PTV was associated with the 
value of CI. THOR2 and THOR3 acquired lower minimum doses to the PTV than the 
original plans (relative differences of -2.1% and -5.2%) and, therefore, had lower CI 
values compared to the original ones. In contrast, THOR4 and THOR5 obtained larger 
CI values and better PTV conformity than the original plans because of the higher 
minimum doses (relative differences of 3.4% and 3.8%). The CI for THOR1 was 
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comparable to that of the original plan since the PTV doses were similar between the 
upright and the original plans (relative difference of 0.8%). 
 
Table 4.6 PTV conformity indices for the upright and the original lung treatment plans 
Plan CIupright CIoriginal 
THOR1 0.96 0.96 
THOR2 0.90 0.94 
THOR3 0.82 0.91 
THOR4 0.96 0.93 
THOR5 0.93 0.89 
 
 Table 4.7 shows the standard deviations of the target doses (cGy) for the upright 
treatment plans. THOR2, THOR4, and THOR5 had relatively normal values for the 
standard deviations compared to what is commonly observed in practice. THOR1 
received high standard deviations for all target volumes. The reason could be because 
that THOR1 was treated with SBRT, a technique that delivers large fractional doses (5-
34 Gy) for few fractions (less than 5) to ablate tumors.
46
 Dose uniformity inside the 
PTV is not a priority when planning an SBRT treatment and heterogeneity is sometimes 
considered potentially advantageous.
47
 The original THOR1 plan also had similar dose 
inhomogeneity inside the PTV. THOR3 exhibited a slightly higher standard deviation of 
the PTV dose than normal. This could be caused by the bulkiness of the disease and its 
location near the chest wall and the brachial plexus. The original plan for THOR3 also 
obtained a high PTV standard deviation (287.3 cGy). 
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Table 4.7 Standard deviations of the target doses for upright lung treatment plans. 
Parameter THOR1 THOR2 THOR3 THOR4 THOR5 
PTV 327.7 190.4 266.1 180.5 188.3 
CTV 272.4 91.8 101.9 92.1 80.5 
GTV 172.8 84.3 87.7 102.5 55.0 
 
Normal Tissues 
 Values for the normal-tissue constraint parameters were retrieved from the 
DVHs and compared to the dose constraints in Table 4.3. Most normal tissues for the 
upright plans had acceptable doses within the dose tolerances, and the values are listed 
in Appendix C. However, a few normal tissue doses exceeded the dose constraints and 
are displayed in Table 4.8. Doses to the total lung and the brachial plexus were the most 
common constraints to be exceeded. The MLD was about 2 Gy greater than the 
constraint while the brachial plexus received 5 Gy more than the constraints. Table 4.8 
also shows the corresponding values for each parameter in the original plans. As shown 
in the table, the upright plans obtained similar values as the original plans, except for 
one parameter. The relative differences of those normal tissue values between the 
upright and the original plans were within 3.5%. 
 
Table 4.8 Dosimetric parameters that exceeded the normal tissue dose constraints in the upright lung 
treatment plans 
Parameter Upright Supine  Relative difference (%) 
THOR2 MLD (Gy) 21.6 21.4 0.8 
THOR2 lung V20 (%) 35.7 32.3 10.5 
THOR3 MLD (Gy) 20.5 20.3 0.7 
THOR3 brachial plexus Dmax (Gy) 69.6 68.5 1.7 
THOR4 esophagus V40 (%) 42.4 41.0 3.5 
THOR5 brachial plexus Dmax (Gy) 69.9 69.6 0.5 
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 Figures 4.4 to 4.6 illustrate the relative differences of the normal tissue doses 
between the upright and the original treatment plans. In Figure 4.4, the relative 
differences for the total lung parameters varied considerably from plan to plan. Most of 
the upright plans had an increase of greater than 10% in V20 compared to the original 
plans. V5 and V10 were reduced in all upright plans except THOR3. Relative differences 
of the MLD did not vary as much and were within 10% of the original values. In this 
study, anatomical differences between the upright and the supine positions were not 
accounted for in the planning images. The lung volume could be increased by 30% 
when in an upright position and this may result in associated decrease in the total lung 
dose for the upright plans. The esophagus (Figure 4.5) in general showed decreases in 
parameter values in the upright plans. The maximum dose and V70 were reduced in all 
cases, and the largest reduction was by 100%. There were slight increases for Dmean, but 
not as substantial. 
Figure 4.6 shows the relatives differences for the rest of the normal tissues. 
Large improvements in the heart doses were found in the upright plans. The parameter 
values were decreased by more than 20% in most cases. The spinal cord received 
approximately 5% less dose in four out of the five treatment plans, while the fifth plan 
had a minor increase in dose. The relative differences for the brachial plexus were 
modest (less than 2%). The contralateral lung exhibited a large fluctuation in Dmean. 
Three upright plans received fewer doses than the original. One plan had a 41.2% 
increase compared to the original plan, which could be due to the different beam 
placements between the plans. The original plan avoided beams originating from the 
contralateral lung side, but the beams in the upright plan were placed all around the 
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patient. Despite the large relative difference of the Dmean, the dose constraint was not 
exceeded. 
 
 
Figure 4.4 Relative differences of values of the total lung dose constraint parameters between the upright and 
the original lung treatment plans 
 
Figure 4.5 Relative differences of values of the esophagus dose constraint parameters between the upright and 
the original lung treatment plans 
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Figure 4.6 Relative differences of values of the normal-tissue constraint parameters between the upright and 
the original lung treatment plans 
 
4.3.2 Head and Neck Plans 
 Figure 4.7 below displays an example of the isodose distributions and the DVH 
for one of the upright H&N treatment plans (HN4). The tumor site was the thyroid and 
there were nine equally-spaced beams. The prescribed isodose lines were highly 
conformal to the target volumes. Most critical structures received acceptable doses, 
except that the right parotid got a mean dose of 45.5 Gy. The original HN4 plan had 
similar dose to the right parotid. The right parotid for this patient case was in close 
proximity to the targets and received a considerable amount of the prescription dose. 
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Figure 4.7 Isodose distributions and DVH for one of the upright H&N treatment plans (HN4) 
 
Target Coverage 
 Figure 4.8 compares the target doses between the upright and the supine 
treatment plans. Target doses included the maximum, mean, and minimum doses to 
multiple PTVs and CTVs, and one GTV volume. HN1, HN3-HN5 each had three PTVs 
and three CTVs while HN2 had four of each. The mean doses obtained the smallest 
relative differences out of the three dose parameters (-1% to 1.7%). Most of the 
maximum doses in the upright plans were greater than those in the original plans, with 
relative differences of -1% to 5.7%. The minimum doses had the largest variation in 
relative differences. Three of the minimum doses were greater than the 10% limit: HN1, 
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HN2, and HN5 with relative differences of -10.5%, -37.9%, and -20.3%, respectively. 
Those that exceeded the limit were all minimum doses to the PTVs. 
 
Figure 4.8 Relative differences of the maximum, mean, and minimum target doses between the upright and the 
original H&N treatment plans. Except for HN2, target volumes included three PTVs, three CTVs, and one 
GTV. HN2 had four PTVs, four CTVs, and one GTV. 
 
 Figure 4.9 shows the CI values for the upright and the original treatment plans. 
Except HN2, all treatment plans had three PTV volumes and, thus, three CI values. 
HN2 had four PTV volumes and CI values. In general, the CI values were similar 
between the two types of treatment plans. HN3 and HN4 had comparable CI values and 
PTV coverage between the upright and the original plans, which is in agreement with 
the smaller relative differences of the PTV doses in Figure 4.8. HN1 and HN5 had 
lower CI values, corresponding to the negative relative differences. HN2 had a greater 
CI than the original, which was unexpected because HN2 had a -37.9% relative 
difference of the minimum dose to the PTV. 
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Figure 4.9 PTV conformity indices for the upright and the original H&N treatment plans. There are three CI 
for HN1, HN3-HN5 because each upright treatment plan had three PTVs. HN2 was the only treatment plan 
that had four PTVs. 
 
Figure 4.10 illustrates the standard deviations of the target doses for the upright 
H&N treatment plans. Several target volumes exhibited very large standard deviations. 
HN1, HN2, and HN5 obtained standard deviations above 300 cGy and as large as 468 
cGy. The large standard deviations were most likely due to low doses inside the targets, 
as reflected in Figure 4.8. Different from those upright plans, the corresponding original 
patient plans did not result in the same large standard deviations. On the other hand, 
HN3 and HN4 were within the normal range for standard deviations. 
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Figure 4.10 Standard deviations of the target doses for the upright H&N treatment plans. Except HN2, each 
treatment plan had three PTVs, three CTVs, and one GTV. HN2 had four PTVs, four CTVs, and one GTV. 
 
Normal Tissues 
 Table 4.9 displays the critical structures that received doses which were above 
the dose constraints in the upright H&N plans. Depending on the location of the tumor, 
it is inevitable that a fraction of the parotids will usually receive some of the prescribed 
dose due to its location near the tumor. Therefore, at least one of the parotids in every 
upright plan obtained substantially higher doses than the dose constraint. Similar trend 
was observed in several original plans, as shown in Table 4.9. However, the doses were 
much lower in the original plans than in the upright plans. The relative differences 
ranged between -6% and 38%.  
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Table 4.9 Dosimetric parameters that exceeded the normal tissue dose constraints in the upright H&N 
treatment plans 
Parameter Upright Original Relative difference (%) 
HN2 Lt parotid Dmean 40.5 24.6 64.5 
HN5 Lt parotid Dmean 34.2 33.3 2.6 
HN1 Rt parotid Dmean 44.2 37.7 37.7 
HN2 Rt parotid Dmean 61.7 65.6 -6.0 
HN3 Rt parotid Dmean 32.0 28.4 12.5 
HN4 Rt parotid Dmean 45.5 45.2 0.16 
HN2 Rt cochlea Dmax 36.0 27.2 32.5 
 
 Figure 4.11 shows the relative differences of doses for normal-tissue constraint 
parameters. Unlike the lung plans, upright H&N plans had remarkably large increases in 
doses compared to the original plans. Very few tissues had a negative value for relative 
differences (dose decrease). The spinal cord and the right parotid had the lowest relative 
differences (-8% to 17%). The brainstem, left parotid, and the left and right cochleae 
had a wide range of values and had at least one plan that obtained a relative difference 
of greater than 100%. These treatment plans could potentially be further optimized to 
reduce normal tissue toxicities. 
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Figure 4.11 Relative differences of the normal tissue doses between the upright and the original H&N 
treatment plans 
 
4.3.3 Total MUs and Treatment Time 
Total MUs 
  Table 4.10 reports the total monitor units (MUs) for each upright and original 
treatment plan and the relative differences. The differences ranged between -28% and 
46%. Three out of the ten upright plans obtained total MUs that were more than 25% 
greater than the original plans. Seven out of the ten plans had less total MUs than the 
original, and these relative differences ranged between -28% and -0.2%. Most of the 
H&N plans received fewer MUs, and this is probably because they were not fully 
optimized. MUs of three upright lung plans were within -10% of the original values 
while the other two MUs were 25 to 46% greater than the original. Since treatment 
planning is subjective and planner-dependent, the overall variation in relative 
differences could be due to different planning styles of individual planners. 
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Table 4.10 Comparison of total monitor units between the upright and original treatment plans 
 Upright Original Relative difference (%) 
THOR1 2257 1800 25.4 
THOR2 779 869 -10.4 
THOR3 628 430 46.0 
THOR4 683 684 -0.15 
THOR5 552 599 -7.8 
HN1 696 504 38.1 
HN2 652 781 -16.5 
HN3 558 561 -0.53 
HN4 604 732 -17.5 
HN5 695 966 -28.1 
 
Treatment Time 
 Photon beams in conventional treatments are delivered by rotating the gantry 
around the patient while the treatment couch is fixed and sometimes with couch kicks. 
In contrast, in upright treatments the only gantry angles used are 90⁰ and 270⁰ and the 
couch rotates to multiple positions. The gantry’s rotation speed is approximately twice 
that of the treatment couch’s. It moves 360⁰ in one minute while the couch moves 180⁰ 
in the same amount of time. The time it takes for the linac to position from beam to 
beam between irradiations may be different between conventional and upright 
treatments since one focuses on gantry rotation and the other requires both couch and 
gantry rotations. This part of the study investigates if upright treatments require more 
treatment time than conventional treatments due to beam setup. 
 To solely compare time in beam positioning, the calculated times included only 
the time intervals between one beam position to the next, and all other factors (i.e. MUs, 
beam angles) were assumed to be the same. Time between positions was calculated 
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using the known rotation speeds. Finally, all time intervals were added together to 
obtain the total beam setup time. 
Table 4.11 displays the total beam setup time for the upright and the original 
plans. Upright treatments on average required 3 times more time than conventional 
treatments. While most conventional treatments can be delivered with one gantry 
rotation, upright treatments often require the treatment couch to move 180° first and 
then back to apply beams around the patient. In addition to couch rotation, the gantry 
also had to rotate 270° for every upright treatment. 
 
Table 4.11 Total time that the gantry and the treatment couch take to position from beam to beam for the 
upright and the original plans. The original plans were assumed to have the same beam angles and MUs as the 
upright plans. 
 Upright (sec) Original (sec) Difference (sec) 
THOR1 118 53 65 
THOR2 149 51 98 
THOR3 168 53 115 
THOR4 168 53 115 
THOR5 162 55 107 
All H&N 168 53 115 
Average 161 53 108 
 
4.4 Discussion 
Modern treatment planning is primarily based on planning images of the patient 
acquired in a laying-down position before the start of radiation treatment. It is crucial 
that the patient is positioned in the exact same way for treatment as when the planning 
data was acquired. Therefore, to treat in the upright position, patients also need be 
imaged in the upright manner.  The change in patient position from conventional to 
upright could lead to changes in the type and amount of normal tissues in the path of the 
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radiation beams. In this study we retrospectively re-planned five lung cases and five 
H&N cases in Philips Pinnacle
3
 Version 9.0 using step-and-shoot IMRT. Treatment 
planning was performed on the converted, upright CT images, and all final plans were 
approved by radiation oncologists. 
The five thoracic and five H&N patient data were randomly selected for this 
IMRT treatment planning study. The upright lung plans demonstrated excellent 
agreement with the original plans in target coverage with relative differences ranged 
between -5.2% and 3.8%. Some normal tissues exceeded the dose constraints; however, 
these doses were comparable to those in the original plans. The total lung had a wide 
range of relative differences among the treatment plans, and the upright plans did not 
seem to have either greater or less lung doses than the original plans. The spinal cord 
received doses similar to the original doses with relative differences of less than 10%. 
Overall treatment planning for lung cases in the upright position was successful and 
feasible, was able to achieve target coverage within 10% of the supine plans, and 
obtained results comparable to the supine plans. 
Studies have found that the thoracic internal geometries were significantly 
different between the supine and the upright positions.
12, 45, 48, 49
 When patients are 
positioned in the upright position, lung volume can be increased by 27% and lung 
motion can be reduced by 3 mm on average.
13
 This indicates that if the change in lung 
volume between positions was accounted for, the actual MLD would be lower than 
those from the retrospectively re-planned treatment plans. Therefore, upright treatments 
could potentially result in associated reduction in doses to the lung and amount of 
normal tissue irradiated. 
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The upright H&N plans had good agreement in the maximum and mean doses to 
the targets. However, the minimum doses to the PTVs were significantly lower in three 
out of the five plans. The upright target doses also exhibited high standard deviations, 
which is most likely influenced by the author’s inexperience in treatment planning. The 
normal tissues had a broader range of relative differences than the lung treatment plans. 
The spinal cord and the right parotid had the smallest dose differences (between -8% 
and 17%). Other structures obtained relative differences above 100% and as high as 
340%, but the dose constraints were not exceeded for those structures. These results 
indicate that the H&N plans were clinically acceptable but could still be further 
optimized by experienced dosimetrists, with respect to the dose delivered to the target 
volume and critical structures. Despite the fact that the upright H&N plans had notably 
larger normal tissue doses than the original plans, treatment planning for H&N cancers 
was achievable and could result in plans with adequate target coverage and normal 
tissue doses. 
In this study, we converted the original CT images in the supine position for 
upright treatment planning, which limited our results to the treatment planning study 
without accounting for the different anatomy position between the conventional and the 
upright positions. The effect of changes in thoracic morphology was mentioned 
previously and could have the potential benefit for lung dose reduction. For H&N 
cancers, unlike the thoracic region of the body, there is a lack of organ motion. 
However, the patients' head is positioned differently between various positions. During 
supine simulation their head position is either hyperextended or neutral, but it is slightly 
lowered during upright simulation. Since H&N tumors often occur in close proximity in 
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multiple critical structures, displacement in head position could affect the relative 
position between tumor and other organs and result in dose deviations. Future work may 
be able to utilize patient images obtained in the upright position to account for any 
anatomy change and generate more accurate treatment plans. Expanding the number of 
patient plans and variety of disease sites could also further validate the results of this 
study. 
 
4.5 Conclusion 
 By re-planning ten lung and H&N treatment plans in the upright position, the 
goal of this study was to investigate the feasibility of upright treatment planning using a 
commercial treatment planning system. The upright lung plans exhibited great target 
coverage that is within 10% of the original plans and delivered acceptable doses to the 
normal tissues. The H&N plans, however, had relatively large relative differences in 
terms of target and normal tissue doses. Despite the large differences, upright H&N 
treatment planning was shown to be feasible and, with proper planning techniques, able 
to provide similar results as the supine treatment plans. This study demonstrated that 
there are no fundamental reasons to expect discrepancies in plan quality between 
upright and conventional treatments and that an experienced planner should be able to 
obtain similar results between the two treatments. 
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Chapter 5 
END-TO-END TESTS 
5.1 Introduction 
In this study end-to-end testing, including CBCT imaging, treatment planning, 
dose irradiation, and dosimetry verification, was performed to assess the feasibility of 
treating in the upright position. An anthropomorphic lung phantom, supplied by the 
Imaging and Radiation Oncology Core (IROC) in Houston, was used for testing on 
Varian TrueBeam
TM
 linac. Upright CBCT imaging of phantoms using the OBI on 
Varian TrueBeam
TM
 has been demonstrated to generate images with good spatial 
linearity and contrast resolution.
50
 Upright treatment planning was found to be feasible 
in Chapter 4 and exhibited adequate target coverage and acceptable normal tissue doses. 
By performing a complete treatment protocol using these upright techniques, we are 
able to assess the efficacy of upright treatments and examine any complications and 
issues that may arise during the process. We hypothesized that upright treatments can 
deliver doses to the target and normal tissues within the criteria set by IROC Houston. 
 
5.2 Materials and Methods 
Figure 5.1 below shows a cross-sectional view of the anthropomorphic lung 
phantom. The phantom has a plastic outer shell and includes inserts to represent critical 
structures in the thorax, such as the right and left lung, heart, and the spinal cord. The 
target is located in the left lung and its dimension is approximately 3 cm by 5 cm. The 
rest of the tissue space is filled with water to simulate soft tissue. The dosimetry inserts 
contain four TLDs that are normal to the axial plane and films through the center of the 
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target in the axial, coronal, and sagittal directions. Two TLD capsules are in the target 
volume and are within 0.5 cm of the center of the target in the superior and inferior 
directions, and the heart and the spinal cord each had one TLD in its center. The TLDs 
are about 10 mm long and 2 mm wide. 
 
 
Figure 5.1 A cross-sectional view of the anthropomorphic lung phantom, supplied by IROC Houston 
 
5.2.1 Upright Cone-Beam Computed Tomography 
Upright Imaging 
A script was created by the author’s group for upright CBCT imaging by using 
the Developer Mode in Varian TrueBeam
TM
 to deliver non-standard beams.
50
 The 
conventional CBCT image has a field of view (FOV) of 26.7 cm by 20 cm, where the 
long axis is the width. When upright imaging is performed, the FOV dimension is 
rotated and becomes 20 cm by 26.7 cm, which is not sufficient to cover the width of the 
patient. To extend the FOV, the detector was offset 14.5 cm towards and away from the 
Right lung 
Left lung 
Spinal cord 
Heart 
GTV 
Coronal film 
Sagittal film 
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gantry. Each offset captures projection images of half of the phantom (left and right). 
The projections were then stitched (explained further in the next section) to produce 
projections of the whole phantom. 
In the script, the gantry was positioned at 0° and stayed stationary throughout 
the process. The OBI was extended out to their imaging positions and the detector was 
offset 14.5 cm away from the gantry. The treatment couch was first positioned at 95°, 
and as the OBI was turned on and started taking projections, the couch was rotated 180° 
to the 265° position. The detector was then offset 14.5 cm from its initial position 
toward the gantry, and another set of projections was obtained by repeating the couch 
motion from 95⁰ to 265⁰. Details of the script are presented in Appendix D. 
 After the script was loaded on the machine console, the anthropomorphic lung 
phantom was positioned in the upright position on top of a box on the treatment couch. 
As shown in Figure 5.2, the elevation of the phantom ensures that the region of interest 
in the phantom was included in the FOV. After the setup was confirmed, radiopaque 
markers were placed on the outer shell of the phantom to mark the location of the lasers. 
The script was run to take projection images as mentioned above. Following the 
phantom projections, airnorm images were taken by removing the phantom and any 
setup devices from the treatment couch and running the same script. These images were 
to compensate for the lack of bowtie filter and the extended FOV in upright imaging 
and were later used in the reconstruction process (next section). 
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Figure 5.2 Phantom setup for upright CBCT imaging 
 
Image Reconstruction 
Varian iTools 1.5 reconstruction software was used to perform reconstruction. 
Before the projections could be imported into the software, their orientations were 
modified in MATLAB to have the same orientation as a supine CT scan. Several 
computer codes were written by the author’s group to achieve this.50 The codes first 
switch the gantry rotation values with the couch rotation values in the header of the 
image files to make it appear that the projection images were acquired by rotating the 
gantry and keeping the treatment couch stationary. The image matrixes were transposed 
to rotate the projections to the orientation that the supine projections would be in. Since 
the upright images were acquired with only 190° of couch rotation and iTools software 
requires a gantry rotation of at least 200° during image acquisition to perform 
reconstruction, the codes added an additional 20° of image data by duplicating the last 
image file and multiplying the pixels by zero to create blank images. After these steps 
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were applied to each set of projections for the phantom and the airnorm files, the codes 
combined the two halves of projections by stitching them at the center of the final 
image and removed any overlaps. The stitched airnorm images were then averaged to 
create a file for reconstruction calibration. 
 Following the orientation modifications, the stitched projections were imported 
into the iTools software. The default airnorm calibration file in the software was 
replaced with the average airnorm file obtained from MATLAB. The images were 
exported after reconstruction was completed and had the same orientation as a supine 
CT scan. To generate a treatment plan in the upright position, the orientation had to be 
converted to the upright position. The images were imported back into MATLAB, and a 
computer code rearranged the dimensions of the image matrix from the supine position 
to the upright position, similar to the conversion in Chapter 4. 
 
5.2.2 Treatment Planning 
Treatment Planning 
An IMRT treatment plan was generated on a commercial treatment planning 
system, Pinnacle
3
 version 9.6 (Philips Medical Systems, Andover, MA), according to 
the specifications provided by IROC Houston. Contouring was done on the now upright 
images. The treatment technique was step-and-shoot IMRT with 6-MV photon beams. 
There were a total of 6 photon beams, and Table 5.1 below lists the gantry and couch 
angles for each beam. The dose algorithm used was Adaptive Convolve with 
heterogeneity correction. 
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Table 5.1 Couch and gantry angles for 6-MV photon beam in upright IMRT treatment plan of the 
anthropomorphic lung phantom 
Couch angles (degrees) Gantry angles (degrees) 
290 90 
90 90 
310 270 
350 270 
30 270 
70 270 
 
CBCT has been known to exhibit inaccurate Hounsfield unit (HU) values and 
cannot be used for dose calculation directly without any calibration.
51, 52
 Therefore, 
densities of the ROIs were overridden in the treatment planning system by manually 
entering a density value for each ROI. Table 5.2 summarizes the density overrides for 
the phantom contours. The density value for each ROI was determined from the supine 
CT scan of the phantom and was approximately the mean of the density range of the 
ROI. 
 
Table 5.2 Density overrides of the contours for the CBCT images in the treatment planning system 
ROI Density (g/cm
3
) 
GTV 0.98 
Total lung 0.38 
Heart 1.07 
Spinal cord 1.12 
Chest wall 1.00 
Outside of the phantom 0 
 
The CTV was equivalent to the GTV, which was the tumor volume visible on 
the CT images. The PTV was the GTV with a 0.5-cm expansion in the left-right and 
anterior-inferior directions and an 1-cm expansion in the superior-inferior direction. The 
prescription was 6 Gy to 97% of the PTV for 1 fraction. The planning objectives were 
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that 95% of the PTV must be enclosed by the prescribed isodose line and the minimum 
dose (dose received by 99% of the volume) to the PTV must be at least 5.4 Gy. 
Hotspots of greater than 110% of the prescribed dose outside the PTV must be 
eliminated. The critical structures in the lung phantom included the spinal cord, heart 
and the total lung. Table 5.3 shows the dose constraints to those normal tissues. The 
TLDs in the GTV, heart, and spinal cord were contoured for dosimetric verification 
purposes. 
 
Table 5.3 Dose constraints to the normal tissues for upright IMRT treatment plan of the anthropomorphic 
lung phantom 
ROI Dose constraints 
PTV V6 ≥ 95% 
V5.4 ≥ 99% 
Spinal cord Dmax ≤ 5 Gy 
Heart V6 < 33% 
V4.5 < 66% 
V4 < 100% 
Total lung V2 < 37% 
 
IMRT Quality Assurance 
The aim of patient-specific QA is to detect any issues that may merge from the 
IMRT process, which includes the treatment planning system, treatment planning, 
treatment plan transmission, and treatment delivery.
53
 Patient-specific QA is performed 
by comparing dose distributions from phantom measurements to the expected values 
from the TPS calculations. While there are many steps in the IMRT process that could 
affect treatment outcome, studies found that majority of the discrepancies between 
measured and calculated values came from TPS commissioning data, which could in 
turn affect TPS dose calculation.
54, 55
 Similar to other steps in the treatment process, the 
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TPS undergoes commissioning for dosimetric accuracy. The goal of commissioning is 
to develop an understanding of the dosimetric uncertainties so that clinical plans can be 
meaningfully evaluated. This allows the user to determine the level of accuracy that is 
feasible for a specific TPS and that can be expected in clinical situations. The criteria of 
acceptability of TPS dose calculations are dependent on inaccuracies and 
reproducibility of the measured and calculated values and whether the region of interest 
is in low or high dose gradient and can be determined through the commissioning 
process.
56
 
The upright treatment plan was copied in the treatment planning system and 
applied to a new plan with a CT scan of a body phantom. The gantry and couch angles 
were kept the same as the upright treatment plan and the monitor units were reduced by 
half to prevent overexposure of the film. The treatment planning system recalculated the 
plan dose on the phantom geometry. To deem the plan satisfactory, the ROI of the ion 
chamber must have a standard deviation of less than 1% of the mean dose. If the plan 
did not meet this criterion, shifts to the phantom were applied. Otherwise, it was 
exported to the treatment console. The planned dose to the ion chamber and the dose 
distribution from the treatment plan was compared to the measured ones. 
A radiographic EDR2 film (Kodak Carestream, Rochester, NY) and Wellhofer 
cc04 ion chamber (CNMC, Nashville, TN) were placed in the I’mRT body phantom 
(IBA dosimetry, Schwarzenbruck, Germany). The ion chamber provided point-dose 
measurements while the film offered a planar dose distribution. The film was parallel to 
the beam path, and the ion chamber was perpendicular and 2 cm from the film plane. 
The body phantom was set up on the treatment couch and was irradiated on Varian 
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TrueBeam
TM
 linac according to the treatment plan. After the phantom was properly 
positioned on the couch top, it was realized that the couch position was too high and 
some of the beam configurations would result in collisions between the gantry and the 
couch. To overcome the issue, couch rotation was replaced by body phantom rotation. 
The treatment couch stayed at the 0° position for the entirety of the QA. For each beam 
the collimator was rotated to align with the couch angle on the treatment plan and the 
phantom was positioned to line up with the light field after collimator rotation. 
The ion chamber measured the amount of collected charges per beam and the 
absolute dose was determined by applying a dose factor to the electrometer reading. The 
dose factor was assessed daily to account for variations in the output of the linac. After 
completion of phantom irradiation, the total accumulated dose obtained by the ion 
chamber was compared to that of the ion chamber ROI in the IMRT QA treatment plan. 
The dose ratio was calculated as follows: 
            
                  
                     
 Equation 5.1 
 
The passing criterion for the dose ratio is between 0.95 and 1.05. 
The film was developed right after irradiation and scanned on VIDAR VXR-16 
Dosimetry Pro (VIDAR Systems Corporation, Herndon, VA). Dose distributions were 
compared to those from the phantom treatment plan in Omnipro I’mRT software (IBA 
Dosimetry, Schwarzenbruck, Germany) using gamma analysis. This method combines 
the dose difference and distance-to-agreement concepts to obtain the percentage of 
pixels passing the criteria.
57
 The dose difference calculates the percentage difference 
between the measured dose at one point on the film and the reference dose at its 
corresponding point in the treatment plan. However, it is sensitive to steep dose gradient 
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regions where if there is a displacement between the two dose distributions, the dose 
difference may not be representative of the dose correspondence between the two plans. 
Distance-to-agreement (DTA) is a tool that provides more accurate measurements at 
steep dose gradients by determining the distances between a point on the treatment plan 
and a point on the film that has the same dose as the point from the treatment plan. It 
essentially measures the distance between the two dose distributions. The dose 
difference and DTA can be combined mathematically to provide a single quantitative 
test.
57
 The passing criteria for gamma analysis were 3%/3mm for 90% of the pixels at 
the author’s institution. 
 
5.2.3 Upright Irradiation 
Treatment Delivery 
Phantom irradiation was performed on Varian TrueBeam
TM
 linac according to 
the treatment plan. The phantom was set up equivalent to the position in the upright 
CBCT process and the radiopaque markers on the shell of the phantom were aligned 
with the room lasers. The treatment couch was offset laterally and longitudinally 
according to the treatment plan to place the isocenter inside the target volume. After 
each beam was delivered, the couch and the gantry were rotated to the next beam 
configuration in the treatment room to ensure that there was no collision. Figure 5.3 
shows the setup for one of the photon beams. After completion of the treatment plan, 
the lung phantom was returned to IROC Houston for analysis. 
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Figure 5.3 Gantry and couch setup for one of the photon beams during irradiation of the anthropomorphic 
lung phantom 
 
Post-Irradiation Dosimetric Verification 
IROC Houston credentialing test is routinely performed by institutions that wish 
to participate in clinical trials. This ensures that the institutions are delivering radiation 
treatments that are comparable to those delivered by other participating institutions in 
the cooperative groups. For IMRT benchmark, standardized anthropomorphic phantoms 
are provided to each institution to verify tumor dose delivery and evaluate the 
institution’s ability to deliver treatments by the protocol. The phantoms are analyzed 
and the dose distribution is considered acceptable if it passes the analysis criteria. The 
passing criteria specified by IROC Houston are based on previous commissioning data 
of the phantoms. IROC performed reproducibility tests on those phantoms and 
determined the level of accuracy and gamma analysis index that can be achieved.
58, 59
 
As part of the commissioning process, phantoms were irradiated by different institutions 
to aid in evaluation of variations in the delivery of IMRT among institutions and 
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determination of the criteria threshold that is suitable for the credentialing process.
59
 
Adjustments to the passing criteria were made according to the trends in the collected 
data from many institutions. 
The measured TLD doses in the phantom were compared to the mean doses to 
the TLDs in the treatment plan. The TLD doses in the PTV were calculated as a fraction 
of the planned dose (Equation 5.1) and the passing criterion was 0.92 to 1.02. The dose 
profiles through the center of the target volume in the axial and sagittal planes were 
exported from the treatment planning system. They were compared to the measured 
dose profiles from the films inserts in the lung phantom using the gamma analysis 
method. The dose difference was calculated for each pixel within 4 cm from the center 
of the target across the profiles. A computer code was written to perform the DTA 
analysis. It interpolates between the doses of the film dose profiles to find the positions 
of the points that have the same doses as those from the treatment plan. Then it finds the 
absolute difference between the computed positions and those from the treatment plan. 
The threshold criterion is 8%/5mm. Pixels that had both a dose difference of greater 
than 8% and a DTA of more than 5 mm failed the criteria. The percentage of pixels that 
did not pass the criteria was calculated for each dose profile plane. To pass the gamma 
analysis, each film plane needs to have an 80% gamma passing and a collective 85% 
passing from all three planes. 
 
5.2.4 Complete Upright Treatment Protocol 
1. Obtain a CT scan of the phantom. 
Upright Imaging 
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1. Position and center the phantom on the treatment table. Add additional support 
below the phantom to elevate the phantom if needed. 
2. Adjust the phantom position so that the lasers are approximately at the center of 
the phantom. 
3. Move the couch to 90⁰ and extend the imager arms. 
4. Open the positive imaging script (that moves the detector to 14.5 cm). 
5. Take a projection to make sure that the region of interest is in the field of view. 
6. Run the positive imaging script. 
7. Open the negative imaging script (that moves the detector to 985.5 cm) and run 
the script. 
8. Mark where the lasers are for phantom setup. 
9. Remove the phantom and any support devices from the couch. 
10. Take the airnorm images by running both positive and negative scripts without 
the phantom. 
11. Export data. Separate each set of projections into different folders (i.e. phantom 
projections with the positive script, phantom projections with the negative script, 
airnorm with the positive script, airnorm with the negative script). 
Reconstruction: MATLAB 
1. The exported data should include two folders for the phantom projections (Img1 
& Img2) and two for the airnorm projections (AN1 & AN2). 
2. AN1 and AN2 only need 100 projections each. The rest can be deleted. 
3. Run XIMfixnFake.m for all folders (Img1, Img2, AN1, and AN2) and a new 
directory (“FixedData”) is created in each folder. The code switches the gantry 
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rotation values with the couch rotation values, transposes the projections, and 
adds additional 20⁰ of data. 
4. In the “FixedData” folder for AN1 and AN2, delete files that end with ‘a’ and 
‘b’ in the filename. 
5. Run XIMstitch.m for “FixedData” in Img1 and Img2 and a “StitchedData” 
directory is created. This code stitches the two halves of projections together. 
6. When the window for file selection opens up, select “FixedData” for Img1 first 
and then that for Img2. 
7. A preview window of a stitched projection will appear. If the stitched image is 
correct, enter “Y”. If not, enter “N” and run the stitching code again but select 
“FixedData” for Img2 first. 
8. Repeat steps 5 to 7 for AN1 and AN2. 
9. Run XIMflip.m for the stitched phantom and the stitched airnorm data. 
Projections are saved in a new directory, “FlippedData”. 
10. This step is for the airnorm projections only. Run XIMaverage.m for 
“FlippedData” and an “AveragedData” folder will be created. 
Reconstruction: iTools 1.5 
1. Select File and then Import scan. Enter a scan name. Browse and select 
“FlippedData” of the phantom. Import. 
2. On the View tab, select Show Overview. Scan information will appear on the 
right. Under Trajectory, change from HALF to FULL. 
3. On the left under the list of scans, click on the name of the current scan. On the 
right, copy the Directory path. 
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4. Open a new computer window and paste the path to the location bar. 
5. Open C_AIR-100KV-Bowtie-Full in Calibration. Delete the AirNorm.m file in 
the folder and replace it with the AirNorm.m file in the “AveragedData” folder. 
6. Back in iTools under the scan name, expand the Reconstruction tab. Right click 
on Full fan and select Start Reconstruction. 
7. After reconstruction is completed, export the scan by clicking File  Export 
Reconstructed Volume and selecting the location and then Save. 
Image Conversion 
1. Convert the images from DICOM format to Pinnacle format in IGRT Utils. 
2. In MATLAB, run FlipImag.m for the images in Pinnacle format. 
3. Import the converted images into Pinnacle. 
Treatment Planning 
1. Generate an IMRT treatment plan according to the guidelines provided by IROC 
Houston. 
2. From the CT scan of the phantom, determine the approximate mean of densities 
of each contour. 
3. For the upright images, override the densities for each ROI by using the values 
obtained from step 2. 
Treatment Delivery 
1. Set up the phantom the same way as Upright Imaging. Use the markers on the 
phantom for alignment with the lasers. 
2. Deliver the treatment according to the plan. 
Dosimetry Verification 
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1. After receiving the analysis results from IROC, export the dose profiles through 
the center of the target from Pinnacle. 
2. Perform gamma analysis. 
 
5.3 Results 
Treatment Planning 
 Figures 5.4 to 5.7 show the dose distributions in three planes and the DVH of 
the upright treatment plan. The prescribed isodose line was conformal to the target 
volume and the PTV coverage by the prescribed dose was 99%. Table 5.4 reports the 
values for the normal-tissue constraint parameters. The maximum dose to the spinal 
cord was 89 cGy, and the volume of the total lung that received 2 Gy was 12.5%. The 
maximum dose to the heart was less than 2 Gy. Thus, the volumes for the normal-tissue 
constraint parameters were all zero. 
Figure 5.4 Coronal isodose distribution of the upright IMRT treatment plan of the anthropomorphic lung 
phantom 
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Figure 5.5 Axial isodose distribution of the upright IMRT treatment plan of the anthropomorphic lung 
phantom 
 
Figure 5.6 Sagittal isodose distribution of the upright IMRT treatment plan of the anthropomorphic lung 
phantom 
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Figure 5.7 DVH of the upright IMRT treatment plan of the anthropomorphic lung phantom 
  
Table 5.4 Values of the normal-tissue constraint parameters from the upright IMRT treatment plan of the 
anthropomorphic lung phantom 
Normal tissue Parameter Dose (Gy)/Percentage (%) 
PTV V6 99 
 V5.4 100 
Spinal cord Dmax 0.89 
Heart V6 0 
 V4.5 0 
 V4 0 
Total lung V2 12.5 
 
IMRT QA 
The measured dose from the ion chamber was 191.5 cGy, and the expected dose 
from the treatment plan was 189.8 cGy. The ratio of the two doses was 1.01, which is 
within the passing criteria (0.95-1.05). The analysis of the film obtained a gamma index 
of 89%, which was slightly below the passing criterion of 90%. Figure 5.8 shows the 
dose distribution results from the film reading. 
GTV 
PTV 
Heart 
Cord 
Total lung 
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Figure 5.8 Dose distributions obtained from IMRT QA with film and ion chamber for the upright IMRT 
treatment plan of the anthropomorphic lung phantom 
 
Dosimetric Verification 
 Table 5.5 shows the measured and the planned TLD doses for the PTV and the 
critical structures. The ratio of TLD doses of the PTV was 0.98, which is within the 
passing criterion of 0.92-1.02. The measured doses to the heart and the spinal cord were 
52 cGy and 15 cGy, respectively, and were within the acceptability. 
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Table 5.5 Comparison of TLD doses between the measured doses from IROC Houston and the doses from the 
treatment planning system for the anthropomorphic lung phantom 
TLD TPS Doses (cGy) Measured Doses (cGy) Measured/TPS 
PTV superior 619 609 0.98 
PTV inferior 616 601 0.98 
   Acceptability (cGy) 
Heart 53 52 9-94 
Spinal cord 18 15 0-57 
 
Figures 5.9 to 5.11 show the dose profiles in the left-right and the anterior-
posterior directions on the axial plane and the superior-inferior direction on the sagittal 
plane from the films in the lung phantom and the IMRT treatment plan. The dose 
profiles from the films and the TPS were comparable and had similar curve shape. The 
gamma index was 100% in all three planes. 
 
 
Figure 5.9 Comparison of left-to-right dose profiles through the center of the target between the film and the 
treatment planning system 
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Figure 5.10 Comparison of poster-to-anterior dose profiles through the center of the target between the film 
and the treatment planning system 
 
Figure 5.11 Comparison of inferior-to-superior dose profiles through the center of the target between the film 
and the treatment planning system 
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5.4 Discussion 
 Radiation treatments in the upright position could have many benefits for 
patients who cannot tolerate the conventional treatment positions. However, the 
feasibility of performing an upright treatment from simulation and treatment planning to 
dose delivery has not been investigated. In this study, we performed an end-to-end test 
and delivered an upright treatment protocol to an anthropomorphic lung phantom. 
Upright CBCT imaging of the phantom was successful and obtained adequate image 
quality for treatment planning. The acquired projection images required several 
modifications to convert the image orientation to the proper position before they could 
be reconstructed and used for treatment planning. Since the CT numbers of CBCT 
images were inaccurate, the densities of the regions of interests in the phantom needed 
to be manually overridden. The density values were approximately the mean of the 
range of CT numbers in a supine CT scan. An IMRT treatment plan was generated on 
Pinnacle and IMRT QA was performed using a body phantom with a radiographic film 
and an ion chamber. The treatment plan passed the criteria of 0.95-1.05 for the ion 
chamber point dose and 90% for the gamma analysis of the film. Due to the unique 
gantry-couch orientations of the treatment plan, some of the beam configurations could 
not be applied because of potential collisions between the gantry and the treatment 
couch. The phantom was rotated instead to simulate couch rotation. After phantom 
irradiation, the TLDs and the films were analyzed for dosimetry verification. The ratio 
of the measured dose to the TLDs and the calculated dose in the treatment plan was 
0.98, which was within the passing criterion of 0.92-1.02. The dose profiles in the left-
right, anterior-posterior, and superior-inferior directions through the center of the PTV 
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were exported from the treatment plan and compared to those extracted from the 
radiographic films. The dose profile curves were highly comparable between the films 
and the treatment plan and passed the gamma analysis criteria of 8%/5mm. All of the 
pixels either had a dose difference of less than 8% or obtained a distance-to-agreement 
of less than 5 mm. 
Instead of having a range of densities, the ROIs in the treatment plan were 
assigned one specific density, which could have caused some inaccuracies in dose 
calculations. Deformable registration was attempted to transfer the CT numbers from a 
supine CT scan to the upright CBCT scan. The transfer of the ROIs and CT numbers 
was unsuccessful due to the lack of bony anatomy in the phantom and caused geometric 
distortions of the upright images, deeming the images not suitable for use in treatment 
planning. Rigid registration could have been a better option because the phantom 
volume does not change with positions. However, if this upright technique was to be 
implemented in clinical settings, deformable registration would have to be employed 
because of the anatomical changes of patients between positions. HU mapping and 
deformable registration of several contours using patient CT images and a different lung 
phantom that exhibited more bony anatomies were demonstrated to be feasible.
50
 Future 
work will need to include patient trials to test accuracy of this technique. Another 
complication that we experienced was export of the treatment plan in DICOM format. 
The ROIs and dose information could not be extracted from the treatment planning 
system, so we exported the dose files through the center of the target volume and 
performed the analysis ourselves. 
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Results in this study showed that upright treatments can be a feasible treatment 
technique for patients. Doses were delivered to the phantom as planned and any 
discrepancies were within the passing criteria. The clinical feasibility of treating 
patients with step-and-shoot IMRT in an upright position must be further assessed in 
future clinical studies. 
 
5.5 Conclusion 
 In this study we performed an end-to-end test, including upright CBCT imaging, 
treatment planning, IMRT QA, phantom irradiation, and dosimetry verification, on an 
anthropomorphic lung phantom provided by IROC Houston. Upright CBCT imaging, 
treatment planning, and phantom irradiation were found to be feasible. The treatment 
plan passed the IMRT QA criteria prior to the irradiation. The measured ion chamber 
dose was 1.01% of the calculated dose from the treatment plan, and the film obtained a 
gamma analysis index of 89%. After delivery of the treatment plan, the TLD doses and 
the dose distributions were analyzed and compared to the values from the treatment 
plan. The TLDs received 98% of the calculated doses and the dose distributions passed 
the gamma analysis criteria of 8%/5mm. 
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Chapter 6 
OVERALL CONCLUSIONS 
6.1 Overall Conclusions 
 The overall hypothesis for this research that upright treatments using the Varian 
TrueBeam
TM
 linear accelerator can be a feasible treatment alternative for lung and head 
and neck cancer patients who cannot tolerate the supine treatment position was 
accepted. This study investigated several clinical aspects of radiation treatments, which 
were radiation shielding for various fixed beams, collision avoidance for upright 
imaging and upright irradiation, treatment planning in the upright position, and an end-
to-end test with an anthropomorphic lung phantom. 
 Shielding evaluation for multiple fixed-beam scenarios showed that unless all 
patients are treated with the upright techniques, a pre-existing treatment vault is 
unlikely to require additional shielding. The increase in primary barrier was 20-26 cm 
for a fixed beam that was pointing in one direction while it was 10-13 cm for a split 
fixed beam that was pointing in two directions. Secondary shielding for the barrier in 
the beam direction required an additional 2-12 cm of shielding. Other secondary 
barriers either had no change or reductions in shielding requirements. The working 
hypothesis for this specific aim that upright treatments can be performed in an existing 
treatment vault without additional shielding was passed. 
The second specific aim was to develop collision software for the upright 
protocol. The computed results from the software differed from the actual 
measurements by 0.2-4.1 cm. These discrepancies were compensated by the 
uncertainties included in the collision maps. The actual collisions occurred in the yellow 
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zone indicating potential collisions and the red zone indicating absolute collisions. The 
software was able to safely predict collisions for both upright imaging and irradiation 
processes. 
The retrospectively re-planned upright treatment plans for five lung patient cases 
and five H&N patient cases were clinically acceptable with conformal target coverage 
and tolerable normal tissue doses. The treatment plans for the lung patients obtained 
target doses within 10% of the original plans, meeting the hypothesized requirement. A 
few normal tissues exceeded the dose constraints but were comparable to those in the 
original plans. Some of the target volumes in the upright H&N treatment plans had 
insufficient target coverage and greater normal tissues doses than the original plans. 
However, since treatment planning is subjective and planner-dependent and the author 
was relatively inexperienced in treatment planning, the upright treatment plans can 
potentially achieve similar results and quality as the supine treatment plans. 
The end-to-end test with an anthropomorphic lung phantom was found to be 
feasible. The IMRT QA had a dose difference of 0.09% and gamma analysis index of 
89.25%. Both were within the passing criteria at the author’s institution. Dosimetry 
verification after phantom irradiation showed that the TLDs received 98% of the 
calculated doses and the dose distribution passed the gamma analysis criteria of 
8%/5mm used by IROC Houston. The hypothesis for this study that upright treatments 
can deliver doses to the target and normal tissues within the criteria by IROC Houston 
was accepted.  
The results in this research demonstrated potential for implementation of upright 
treatments for lung and H&N cancers. Each specific aim represented a treatment 
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component that needs to be considered when adopting a new radiation therapy 
technique. It was shown that not only can upright treatments be performed in a current 
treatment vault, but they can also provide quality treatments comparable to conventional 
techniques. Although it remains to be proven clinically, upright treatments may be a 
feasible and beneficial treatment option for lung and H&N cancer patients. 
 
6.2 Future Work 
As the ultimate goal is to treat patients with upright treatments in clinical 
settings, clinical studies would be greatly beneficial for further validation of this work. 
Future work may also expand this treatment technique to other cancer sites. Although 
the software developed in this study safely predicted collisions during upright 
treatments, the results were very conservative and not representative of the actual 
situation. A collision program that can simulate the treatment room and the patient may 
provide more accurate and precise predictions. 
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Appendix A Additional shielding calculation data 
 
Shielding thickness for single-energy conventional beam direction: 
Thickness (cm)/Barrier C D E Ceiling 
Primary 115.6 145.4  126.1 
Patient scatter 37.1 60.6 40.3 50.9 
Leakage scatter 49.0 75.1 82.4 64.4 
Total secondary 59.2 85.4 82.4 74.6 
 
 
Shielding thickness for single-energy beam direction at wall C: 
Thickness (cm)/Barrier C D E Ceiling 
Primary 135.5    
Patient scatter 52.7 26.9 40.3 31.8 
Leakage scatter 46.6 83.3 82.4 68.0 
Total secondary 62.9 83.3 82.4 68.0 
 
Shielding thickness for single-energy beam direction at wall D: 
Thickness (cm)/Barrier C D E Ceiling 
Primary  165.3   
Patient scatter 13.4 76.2 40.3 31.8 
Leakage scatter 57.2 72.8 82.4 68.0 
Total secondary 57.2 86.4 82.4 68.0 
 
Shielding thickness for single-energy beam direction at walls C & D: 
Thickness (cm)/Barrier C D E Ceiling 
Primary 125.5 155.4   
Patient scatter 44.9 68.4 35.2 26.7 
Leakage scatter 41.4 67.6 73.7 59.3 
Total secondary 55.1 78.6 73.7 59.3 
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Shielding thickness for dual-energy conventional beam direction: 
Thickness (cm)/Barrier C D E Ceiling 
Primary 149.6 188.5  163.3 
Patient scatter 55.6 84.5 45.0 72.6 
Leakage scatter 62.1 92.8 101.2 80.1 
Total secondary 72.8 103.6 101.2 91.0 
 
Shielding thickness for dual-energy beam direction at wall C: 
Thickness (cm)/Barrier C D E Ceiling 
Primary 175.5    
Patient scatter 74.9 27.7 45.0 35.6 
Leakage scatter 59.4 102.5 101.4 84.5 
Total secondary 85.7 102.5 101.4 84.5 
 
Shielding thickness for dual-energy beam direction at wall D: 
Thickness (cm)/Barrier C D E Ceiling 
Primary  214.4   
Patient scatter 14.1 104.0 45.0 35.6 
Leakage scatter 71.8 90.1 101.4 84.5 
Total secondary 71.8 114.2 101.4 84.5 
 
Shielding thickness for dual-energy beam direction at walls C & D: 
Thickness (cm)/Barrier C D E Ceiling 
Primary 162.6 201.4   
Patient scatter 65.3 94.2 39.3 29.8 
Leakage scatter 53.3 84.1 91.1 74.2 
Total secondary 75.5 104.4 91.1 74.2 
 
 
Photon dose equivalent components for each scenario: 
Beam Direction Conventional Wall C Wall D Walls C & D 
Linac Single Dual Single Dual Single Dual Single Dual 
HS 1.2 2 7.2 8.9 5.5 7.1 6.4 8 
HLS 11 14 16.8 21.8 24.1 31.3 20.4 26.5 
Hps 73 92 110.5 139.5 25 25.8 65.7 81.5 
HLT 1.3 4.6 2 7 1.5 5.3 1.8 6.2 
HTot 86.5 113 131.1 171.3 51.9 64.8 89.5 116.9 
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Scatter angle for single-energy beam direction at wall C: 
Angle/Barrier C Angle/Barrier E Ceiling 
 Patient 
scatter 
 Patient 
scatter 
Leakage 
scatter 
Patient 
scatter 
Leakage 
scatter 
10⁰ 92.5 90⁰ 40.3 82.4 31.8 68.0 
20⁰ 77.9 60⁰ 53.1 78.8 42.7 64.4 
30⁰ 52.7 45⁰ 59.4 73.7 48.0 59.3 
45⁰ 35.8 30⁰ 67.1 64.9 54.2 50.6 
 
Scatter angle for single-energy beam direction at wall D: 
Angle/Barrier D Angle/Barrier E Ceiling 
 Patient 
scatter 
 Patient 
scatter 
Leakage 
scatter 
Patient 
scatter 
Leakage 
scatter 
10⁰ 123.2 90⁰ 40.3 82.4 31.8 68.0 
20⁰ 106.2 60⁰ 53.1 78.8 42.7 64.4 
30⁰ 76.2 45⁰ 59.4 73.7 48.0 59.3 
45⁰ 56.6 30⁰ 67.1 64.9 54.2 50.6 
 
 
Scatter angle for single-energy beam direction at walls C & D: 
Angle/Barrier C D Angle/Barrier E Ceiling 
 Patient 
scatter 
Patient 
scatter 
 Patient 
scatter 
Leakage 
scatter 
Patient 
scatter 
Leakage 
scatter 
10⁰ 82.2 112.9 90⁰ 35.2 73.7 26.7 59.3 
20⁰ 68.5 96.8 60⁰ 46.8 70.0 36.4 55.7 
30⁰ 44.9 68.4 45⁰ 52.4 64.9 41.1 50.6 
45⁰ 28.9 49.7 30⁰ 59.2 56.2 46.4 41.8 
 
 
Scatter angle for dual-energy beam direction at wall C: 
Angle/Barrier C Angle/Barrier E Ceiling 
 Patient 
scatter 
 Patient 
scatter 
Leakage 
scatter 
Patient 
scatter 
Leakage 
scatter 
10⁰ 127.9 90⁰ 45.0 101.4 35.6 84.5 
20⁰ 109.8 60⁰ 59.7 97.1 48.3 80.3 
30⁰ 74.9 45⁰ 73.6 91.1 60.2 74.2 
45⁰ 45.9 30⁰ 92.6 80.9 76.7 64.1 
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Scatter angle for dual-energy beam direction at wall D: 
Angle/Barrier D Angle/Barrier E Ceiling 
 Patient 
scatter 
 Patient 
scatter 
Leakage 
scatter 
Patient 
scatter 
Leakage 
scatter 
10⁰ 167.6 90⁰ 45.0 101.4 35.6 84.5 
20⁰ 146.0 60⁰ 59.7 97.1 48.3 80.3 
30⁰ 104.0 45⁰ 73.6 91.1 60.2 74.2 
45⁰ 70.4 30⁰ 92.6 80.9 76.7 64.1 
 
Scatter angle for dual-energy beam direction at walls C & D: 
Angle/Barrier C D Angle/Barrier E Ceiling 
 Patient 
scatter 
Patient 
scatter 
 Patient 
scatter 
Leakage 
scatter 
Patient 
scatter 
Leakage 
scatter 
10⁰ 127.9 154.3 90⁰ 39.3 91.1 29.8 74.2 
20⁰ 97.8 133.9 60⁰ 52.7 86.9 41.3 70.0 
30⁰ 65.3 94.2 45⁰ 65.5 80.9 52.1 64.0 
45⁰ 37.8 62.2 30⁰ 82.9 70.6 67.1 53.8 
 
 
Shielding calculations 
Reference tables are in NCRP Report No. 151 
 
Calculations for single-energy linac with a conventional beam: 
 
Wall C Primary 
    Parameters Unit Value 
 Area   Uncontrolled 
   P mSv/wk 0.02 
   d m 6.2 
   W mGy/wk 400000 
   U   0.25 
   T Parking lot 0.025 Table B.1 
B   0.00041472 
   n   3.38224502 
   t(pri) cm 115.6 TVLs for 6 MV, Table B.2 
    
Wall C (Point A) Patient Scatter 
   Parameters Unit Value 
 Area   Uncontrolled 
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P mSv/wk 0.02 
   W mGy/wk 400000 
   d(sca) m 1 
   d(sec) m 7.2 
   U   0.25 
   T Parking lot 0.025 Table B.1 
F cm^2 1600 Assumed the largest FOV (40x40) 
α (30˚) fraction 2.77E-03 For 30˚, Table B.4 
B   3.74E-02 
   n   1.426784781 
   t(sca) cm 37.1 TVL(30˚)=26, Table B.5a 
    
Wall C (Point A) Leakage Scatter 
   Parameters Unit Value 
 Area   Uncontrolled 
   P mSv/wk 0.02 
   W mGy/wk 1360000 
   d(L) m 7.2 from isocenter 
 T Parking lot 0.025 Table B.1 
B   0.030494118 
   n   1.515783929 
   t(leakage) cm 49.0 TVLs for 6 MV, Table B.7 
     
Wall D Primary 
    Parameters Unit Value 
 Area   Controlled 
   P mSv/wk 6.2 
   d m 6.2 
   W mGy/wk 400000 
   U   0.25 
   T Control Room 1 Table B.1 
B   0.00005184 
   n   4.285335007 
   t(pri) cm 145.4 TVLs for 6 MV, Table B.2 
    
Wall D (Point B) Patient Scatter 
   Parameters Unit Value 
   Area   Controlled 
   P mSv/wk 6.2 
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W mGy/wk 400000 
   d(sca) m 1 
   d(sec) m 7.2 
   U   0.25 
   T Control Room 1 Table B.1 
 F cm^2 1600 Assumed the largest FOV (40x40) 
α (30˚) fraction 2.77E-03 For 30˚, Table B.4 
 B   4.68E-03 
   n   2.329874768 
   t(sca) cm 60.6 TVL(30˚)=26, Table B.5a 
    
Wall D (Point B) Leakage Scatter 
   Parameters Unit Value 
   Area   Controlled 
   P mSv/wk 6.2 
   W mGy/wk 1360000 
   d(L) m 7.2 from isocenter 
 T Control Room 1 Table B.1 
 B   0.003811765 
   n   2.418873916 
   t(leakage) cm 75.1 TVLs for 6 MV, Table B.7 
     
Wall E Patient Scatter 
    Parameters Unit Value 
   Area   Uncontrolled 
   P mSv/wk 0.02 
   W mGy/wk 400000 
   d(sca) m 1 
   d(sec) m 5.4 
   T Reading Room 0.2 Table B.1 
  F cm^2 1600 Assumed the largest FOV (40x40) 
α (90˚) fraction 4.26E-04 For 90˚, Table B.4 
 B   4.28E-03 
   n   2.368742062 
   t(sca) cm 40.3 TVL(90˚)=17, Table B.5a 
     
Wall E Leakage Scatter 
    Parameters Unit Value  
Area   Uncontrolled 
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P mSv/wk 0.02 
   W mGy/wk 1360000 
   d(L) m 5.4 
   T Reading Room 0.2 Table B.1 
B   0.002144118 
   n   2.668751389 
   t(leakage) cm 82.4 TVLs for 6 MV, Table B.7 
     
Ceiling Primary 
    Parameters Unit Value 
 Area   Uncontrolled 
   P mSv/wk 0.02 
   d m 4 
   W mGy/wk 400000 
   U   0.25 
   T Unoccupied area 0.025 Table B.1 
B   0.0002 
   n   3.698970004 
   t(pri) cm 126.1 TVLs for 6 MV, Table B.2 
     
Ceiling Patient Scatter 
    Parameters Unit Value 
   Area   Uncontrolled 
   P mSv/wk 0.02 
   W mGy/wk 400000 
   d(sca) m 1 
   d(sec) m 3.9 
   U 
 
0.25 
   T Unoccupied area 0.025 
   F cm^2 1600 Assumed the largest FOV (40x40) 
α (30˚) fraction 2.77E-03 For 30˚, Table B.4 
 B   1.10E-02 
   n   1.959320559 
   t(sca) cm 50.9 TVL(30˚)=26, Table B.5a 
     
Ceiling Leakage Scatter 
    Parameters Unit Value 
   Area   Uncontrolled 
   P mSv/wk 0.02 
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W mGy/wk 1360000 
   d(L) m 3.9 
   T Unoccupied area 0.025 
   B   0.008947059 
   n   2.048319707 
   t(leakage) cm 64.4 TVLs for 6 MV, Table B.7 
     
Leakage and Scattered Radiation at Door   
  Wall-Scattered 
    Parameters Unit Value 
   Area   Controlled 
   W mGy/wk 400000 
   U   0.25 
   α(0)   2.70E-03 Table B.8a, normal incidence, 75˚ reflection for 6 MV 
A(0) m^2 2.82 
   α(z)   8.00E-03 Table B.8a, normal incidence, 75˚ reflection for 0.5 MeV 
A(z) m^2 8.4 
   d(h) m 4.2 
   d(_r) m 5.9 
   d(z) m 6.8 
   H(s) mSv/wk 0.001802029 
     µSv/wk 1.8 
    
Head Leakage Scatter 
   Parameters Unit Value 
   Area   Controlled 
   W mGy/wk 1360000 
   L(f) fraction 0.001 
   U   0.25 
   α(1)   6.40E-03 Table B.8a, 45˚ incidence, 0⁰ reflection for 6 MV 
A(1) m^2 11.8 
   d(LS) m 7.9 
   d(zz) m 9.9 
   H(LS) mSv/wk 0.004197748 
     µSv/wk 4.2 
     
Patient Scatter 
    Parameters Unit Value 
   Area   Controlled 
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W mGy/wk 400000 
   U   0.25 
   α(θ)   1.39E-03 Table B.4, 45˚ scatter for 6 MV 
A(1) m^2 11.8 
   α(1)   2.20E-02 Table B.8b, 45˚ incidence, 0˚ reflection for 0.5 MeV 
F m^2 1600 
   d(sca) m 1 
   d(sec) m 7.3 
   d(zz) m 9.9 
   H(s) mSv/wk 0.027635248 
     µSv/wk 27.6 
     
Transmitted Leakage 
    Parameters Unit Value 
   Area   Controlled 
   W mGy/wk 1360000 
   U   0.25 
   L(f) fraction 0.001 
   B (6 MV)   7.27895E-05 t(s)=125 cm, TVLs from Table B.7 
d(L) m 7.1 
   H(LT) mSv/wk 0.000490943 
     µSv/wk 0.5 
    
Calculations for single-energy beam with beam direction at wall C: 
 
Wall C Primary 
     Parameters Unit Value 
  Area   Uncontrolled 
    P mSv/wk 0.02 
    d m 6.2 
    W mGy/wk 400000 
    U   1 
    T Parking lot 0.025 Table B.1 
 B   0.00010368 
    n   3.984305011 
    t(pri) cm 135.4820654 TVLs for 6 MV, Table B.2 
      
Wall C (Point A) Patient Scatter 
     (for 10˚ scatter) 
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Parameters Unit Value 
  Area   Uncontrolled 
    P mSv/wk 0.02 
    W mGy/wk 400000 
    d(sca) m 1 
    d(sec) m 6.3 Calculated 
  T Parking lot 0.025 Table B.1 
 F cm^2 1600 Assumed the largest FOV (40x40) 
 α (10˚) fraction 1.04E-02 For 10˚, Table B.4 
 B   1.91E-03 
    n   2.719382236 
    t(sca) cm 92.5 TVL(15˚)=34, Table B.5a 
 (for 20˚ scatter) 
     d(sec) m 6.6 Calculated 
  α (20˚) fraction 6.73E-03 For 20˚, Table B.4 
 B   3.24E-03 
    n   2.489957189 
    t(sca) cm 77.9 TVL(20˚)=31.3 (interpolated), Table B.5a 
(for 30˚ scatter) 
     d(sec) m 7.2 Given in NCRP 
  α (30˚) fraction 2.77E-03 For 30˚, Table B.4 
  B   9.36E-03 
    n   2.028844772 
    t(sca) cm 52.7 TVL(30˚)=26, Table B.5a 
 (for 45˚ scatter) 
     d(sec) m 8.8 Calculated 
  α (45˚) fraction 1.39E-03 For 45˚, Table B.4 
  B   2.79E-02 
    n   1.555079452 
    t(sca) cm 35.8 TVL(45˚)=23, Table B.5a 
     
Wall C (Point A) Leakage Scatter 
    Parameters Unit Value 
    Area   Uncontrolled 
    P mSv/wk 0.02 
    W mGy/wk 1360000 
    d(L) m 7.9 Calculated 
  T Parking lot 0.025 Table B.1 
   B   0.036711765 
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n   1.435194739 
    t(leakage) cm 46.6 TVLs for 6 MV, Table B.7 
      
Wall D Patient Scatter 
     Parameters Unit Value 
    Area   Controlled 
    P mSv/wk 6.2 
    W mGy/wk 400000 
    d(sca) m 1 
    d(sec) m 8.77 Calculated 
  T Control Room 1 Table B.1 
   F cm^2 1600 Assumed the largest FOV (40x40) 
α (135˚) fraction 3.00E-04 For 135˚, Table B.4 
 B   1.60E-02 
    n   1.795242051 
    t(sca) cm 26.9 TVL(135˚)=15, Table B.5a 
      
Wall D Leakage Scatter 
     Parameters Unit Value 
    Area   Controlled 
    P mSv/wk 6.2 
    W mGy/wk 1360000 
    d(L) m 5.2 
    T Control Room 1 Table B.1 
   B   0.001988235 
    n   2.701532221 
    t(leakage) cm 83.3 TVLs for 6 MV, Table B.7 
       
Wall E Patient Scatter 
     (for 90˚ scatter) 
Parameters Unit Value 
    Area   Uncontrolled 
    P mSv/wk 0.02 
    W mGy/wk 400000 
    d(sca) m 1 
    d(sec) m 5.4 
    T Reading Room 0.2 Table B.1 
   F cm^2 1600 Assumed the largest FOV (40x40) 
α (90˚) fraction 4.26E-04 For 90˚, Table B.4 
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B   4.28E-03 
    n   2.368742062 
    t(sca) cm 40.3 TVL(90˚)=17, Table B.5a 
 (for 60˚ scatter) 
     d(sec) m 6.2 Calculated 
  α (60˚) fraction 8.24E-04 For 60˚, Table B.4 
  B   2.95E-03 
    n   2.530320938 
    t(sca) cm 53.1 TVL(60˚)=21, Table B.5a 
 (for 45˚ scatter) 
     d(sec) m 7.6 Calculated 
  α (45˚) fraction 1.39E-03 For 45˚, Table B.4 
  B   2.62E-03 
    n   2.581317268 
    t(sca) cm 59.4 TVL(45˚)=23, Table B.5a 
 (for 30˚ scatter) 
     d(sec) m 10.8 Calculated 
  α (30˚) fraction 2.77E-03 For 30˚, Table B.4 
  B   2.63E-03 
    n   2.579752241 
    t(sca) cm 67.1 TVL(30˚)=26, Table B.5a 
      
Wall E Leakage Scatter 
     (90° scatter position) 
Parameters Unit Value 
    Area   Uncontrolled  
   P mSv/wk 0.02 
    W mGy/wk 1360000 
    d(L) m 5.4 
    T Reading Room 0.2 Table B.1 
   B   0.002144118 
    n   2.668751389 
    t(leakage) cm 82.4 TVLs for 6 MV, Table B.7 
 (60° scatter position) 
 Parameters Unit Value 
d(L) m 6.2 
B   0.002858824 
n   2.543812652 
t(leakage) cm 78.8 
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(45° scatter position) 
 Parameters Unit Value 
d(L) m 7.6 
B   0.004288235 
n   2.367721393 
t(leakage) cm 73.7 
(30° scatter position) 
 Parameters Unit Value 
d(L) m 10.8 
B   0.008576471 
n   2.066691397 
t(leakage) cm 64.9 
      
Ceiling Patient Scatter 
     (for 90˚ scatter) 
Parameters Unit Value 
    Area   Uncontrolled 
    P mSv/wk 0.02 
    W mGy/wk 400000 
    d(sca) m 1 
    d(sec) m 3.38 Calculated 
  U 
 
1 
    T Unoccupied area 0.025 
    F cm^2 1600 Assumed the largest FOV (40x40) 
α (90˚) fraction 4.26E-04 For 90˚, Table B.4 
  B   1.34E-02 
    n   1.873249117 
    t(sca) cm 31.8 TVL(90˚)=17, Table B.5a 
 (for 60˚ scatter) 
     d(sec) m 3.90 Given 
   α (60˚) fraction 8.24E-04 For 60˚, Table B.4 
  B   9.23E-03 
    n   2.034827993 
    t(sca) cm 42.7 TVL(60˚)=21, Table B.5a 
 (for 45˚ scatter) 
     d(sec) m 4.78 Calculated 
  α (45˚) fraction 1.39E-03 For 45˚, Table B.4 
  B   8.21E-03 
    n   2.085824323 
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t(sca) cm 48.0 TVL(45˚)=23, Table B.5a 
 (for 30˚ scatter) 
     d(sec) m 6.75 Calculated 
  α (30˚) fraction 2.77E-03 For 30˚, Table B.4 
  B   8.24E-03 
    n   2.084259296 
    t(sca) cm 54.2 TVL(30˚)=26, Table B.5a 
       
Ceiling Leakage Scatter 
     (90° scatter position) 
     Parameters Unit Value 
    Area   Uncontrolled 
    P mSv/wk 0.02 
    W mGy/wk 1360000 
    d(L) m 3.38 
    T Unoccupied area 0.025 
    B   0.006710294 
    n   2.173258444 
    t(leakage) cm 68.0 TVLs for 6 MV, Table B.7 
 (60° scatter position) 
 Parameters Unit Value 
d(L) m 3.9 
B   0.008947059 
n   2.048319707 
t(leakage) cm 64.4 
(45° scatter position) 
 Parameters Unit Value 
d(L) m 4.78 
B   0.013420588 
n   1.872228448 
t(leakage) cm 59.3 
(30° scatter position) 
 Parameters Unit Value 
d(L) m 6.75 
B   0.026841176 
n   1.571198453 
t(leakage) cm 50.6 
      
Leakage and Scattered Radiation at Door 
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Wall-Scattered 
       Parameters Unit Value 
      Area   Controlled 
      W mGy/wk 400000 
      U   1 
      α(0)   2.70E-03 Table B.8a, normal incidence, 75˚ reflection for 6 MV 
 A(0) m^2 2.82 
      α(z)   8.00E-03 Table B.8a, normal incidence, 75˚ reflection for 0.5 MeV 
A(z) m^2 8.4 
      d(h) m 4.2 
      d(_r) m 5.9 
      d(z) m 6.8 
      H(s) mSv/wk 0.007208115 
        µSv/wk 7.2 
             
Head Leakage Scatter 
      Parameters Unit Value 
      Area   Controlled 
      W mGy/wk 1360000 
      L(f) fraction 0.001 
      U   1 
      α(1)   6.40E-03 Table B.8b, 45˚ incidence, 0⁰ reflection for 6 MV 
A(1) m^2 11.8 
      d(LS) m 7.9 
      d(zz) m 9.9 
      H(LS) mSv/wk 0.016790991 
        µSv/wk 16.8 
              
Patient Scatter 
       Parameters Unit Value 
      Area   Controlled 
      W mGy/wk 400000 
      U   1 
      α(θ)   1.39E-03 Table B.4, 45˚incidence for 6 MV 
  A(1) m^2 11.8 
      α(1)   2.20E-02 Table B.8b, 45˚ incidence, 0˚ reflection for 0.5 MeV
 F m^2 1600 
      d(sca) m 1 
      d(sec) m 7.3 
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d(zz) m 9.9 
      H(ps) mSv/wk 0.110540993 
        µSv/wk 110.5 
            
Transmitted Leakage 
     Parameters Unit Value 
    Area   Controlled 
    W mGy/wk 1360000 
    U   1 
    L(f) fraction 0.001 
    B (6 MV)   7.27895E-05 t(s)=125 cm, TVLs from Table B.7 
d(L) m 7.1 
    H(LT) mSv/wk 0.001963773 
      µSv/wk 2.0 
     
Calculations for single-energy beam with beam direction at wall D: 
 
Wall D Primary 
    Parameters Unit Value 
 Area   Controlled 
   P mSv/wk 0.1 
   d(D) m 6.2 
   W mGy/wk 400000 
   U   1 
   T Control Room 1 Table B.1 
B   0.00001296 
   n   4.887394998 
   t(pri) cm 165.3 TVLs for 6 MV, Table B.2 
    
Wall D (Point B) Patient Scatter 
   (for 10˚ scatter)  
Parameters Unit Value 
 Area   Controlled 
   P mSv/wk 0.1 
   W mGy/wk 400000 
 d(sca) m 1 
   d(sec) m 6.3 Calculated 
  T Control Room 1 Table B.1 
F cm^2 1600 Assumed the largest FOV (40x40) 
 154 
 
α (10˚) fraction 1.04E-02 For 10˚, Table B.4 
B   2.38E-04 
   n   3.623072861 
   t(sca) cm 123.2 TVL(15˚)=34, Table B.5a 
(for 20˚ scatter) 
    d(sec) m 6.6 Calculated 
  α (20˚) fraction 6.73E-03 For 20˚, Table B.4 
B   4.04E-04 
   n   3.393323301 
   t(sca) cm 106.2 TVL(20˚)=31.3 (interpolated), Table B.5a 
(for 30˚ scatter) 
    d(sec) m 7.2 Given in NCRP 
 α (30˚) fraction 2.77E-03 For 30˚, Table B.4 
B   1.17E-03 
   n   2.931934759 
   t(sca) cm 76.2 TVL(30˚)=26, Table B.5a 
(for 45˚ scatter) 
    d(sec) m 8.8 Calculated 
  α (45˚) fraction 1.39E-03 For 45˚, Table B.4 
B   3.46E-03 
   n   2.461321408 
   t(sca) cm 56.6 TVL(45˚)=23, Table B.5a 
    
Wall D (Point B) Leakage Scatter 
   Parameters Unit Value 
   Area   Controlled  
P mSv/wk 0.1 
   W mGy/wk 1360000 
   d(L) m 7.9 Calculated 
  T Control Room 1 Table B.1 
B   0.004588971 
   n   2.338284726 
   t(leakage) cm 72.8 TVLs for 6 MV, Table B.7 
  
Wall C Patient Scatter 
 Parameters Unit Value 
 Area   Uncontrolled 
  P mSv/wk 0.02 
  W mGy/wk 400000 
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d(sca) m 1 
  d(sec) m 8.77 Calculated 
 T Parking lot 0.025 Table B.1 
F cm^2 1600 Assumed the largest FOV (40x40) 
α (135˚) fraction 3.00E-04 For 135˚, Table B.4 
B   1.28E-01 
  n   0.892152064 
  t(sca) cm 13.4 TVL(135˚)=15, Table B.5a 
 
Wall C Leakage Scatter 
   Parameters Unit Value 
  Area   Uncontrolled 
 P mSv/wk 0.02 
  W mGy/wk 1360000 
  d(L) m 5.2 
  T Parking lot 0.025 Table B.1 
B   0.015905882 
  n   1.798442234 
  t(leakage) cm 57.2 TVLs for 6 MV, Table B.7 
  
Wall E Patient Scatter 
 (for 90˚ scatter)   
Parameters Unit Value 
  Area   Uncontrolled 
 P mSv/wk 0.02 
  W mGy/wk 400000 
 d(sca) m 1 
  d(sec) m 5.4 Given 
 T Reading Room 0.2 Table B.1 
F cm^2 1600 Assumed the largest FOV (40x40) 
α (90˚) fraction 4.26E-04 For 90˚, Table B.4 
B   4.28E-03 
  n   2.368742062 
  t(sca) cm 40.3 TVL(90˚)=17, Table B.5a 
(for 60˚ scatter) 
 d(sec) m 6.2 Calculated 
 α (60˚) fraction 8.24E-04 For 60˚, Table B.4 
 B   2.95E-03 
  n   2.530320938 
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t(sca) cm 53.1 TVL(60˚)=21, Table B.5a 
(for 45˚ scatter) 
 d(sec) m 7.6 Calculated 
 α (45˚) fraction 1.39E-03 For 45˚, Table B.4 
 B   2.62E-03 
  n   2.581317268 
  t(sca) cm 59.4 TVL(45˚)=23, Table B.5a
   (for 30˚ scatter) 
   d(sec) m 10.8 Calculated 
 α (30˚) fraction 2.77E-03 For 30˚, Table B.4 
 B   2.63E-03 
  n   2.579752241 
  t(sca) cm 67.1 TVL(30˚)=26, Table B.5a 
    
Wall E Leakage Scatter 
   (90° scatter position) 
Parameters Unit Value 
  Area   Uncontrolled 
 P mSv/wk 0.02 
  W mGy/wk 1360000 
 d(L) m 5.4 Given 
 T Reading Room 0.2 Table B.1 
 B   0.002144118 
  n   2.668751389 
  t(leakage) cm 82.4 TVLs for 6 MV, Table B.7 
(60° scatter position) 
   Parameters Unit Value 
  d(L) m 6.2 
  B   0.002858824 
  n   2.543812652 
  t(leakage) cm 78.8 
  (45° scatter position) 
   Parameters Unit Value 
  d(L) m 7.6 
  B   0.004288235 
  n   2.367721393 
  t(leakage) cm 73.7 
  (30° scatter position) 
   
 157 
 
Parameters Unit Value 
  d(L) m 10.8 
  B   0.008576471 
  n   2.066691397 
  t(leakage) cm 64.9 
      
Ceiling Patient Scatter 
   (for 90˚ scatter) 
Parameters Unit Value 
  Area   Uncontrolled 
  P mSv/wk 0.02 
  W mGy/wk 400000 
  d(sca) m 1 
  d(sec) m 3.38 Calculated 
 U 
 
1 
  T Unoccupied area 0.025 
  F cm^2 1600 Assumed the largest FOV (40x40) 
α (90˚) fraction 4.26E-04 For 90˚, Table B.4 
 B   1.34E-02 
  n   1.873249117 
  t(sca) cm 31.8 TVL(90˚)=17, Table B.5a 
(for 60˚ scatter) 
   d(sec) m 3.9 Given 
 α (60˚) fraction 8.24E-04 For 60˚, Table B.4 
 B   9.23E-03 
  n   2.034827993 
  t(sca) cm 42.7 TVL(60˚)=21, Table B.5a 
(for 45˚ scatter) 
   d(sec) m 4.78 Calculated 
 α (45˚) fraction 1.39E-03 For 45˚, Table B.4 
 B   8.21E-03 
  n   2.085824323 
  t(sca) cm 48.0 TVL(45˚)=23, Table B.5a 
(for 30˚ scatter) 
   d(sec) m 6.75 Calculated 
 α (30˚) fraction 2.77E-03 For 30˚, Table B.4 
 B   8.24E-03 
  n   2.084259296 
  t(sca) cm 54.2 TVL(30˚)=26, Table B.5a 
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Ceiling Leakage Scatter 
   (90° scatter position) 
   Parameters Unit Value 
  Area   Uncontrolled 
  P mSv/wk 0.02 
  W mGy/wk 1360000 
  d(L) m 3.38 
  T Unoccupied area 0.025 
  B   0.006710294 
  n   2.173258444 
  t(leakage) cm 68.0 TVLs for 6 MV, Table B.7 
(60° scatter position) 
   Parameters Unit Value 
  d(L) m 3.90 Given 
 B   0.008947059 
  n   2.048319707 
  t(leakage) cm 64.4 
  (45° scatter position) 
   Parameters Unit Value 
  d(L) m 4.78 
  B   0.013420588 
  n   1.872228448 
  t(leakage) cm 59.3 
  (30° scatter position) 
   Parameters Unit Value 
  d(L) m 6.75 
  B   0.026841176 
  n   1.571198453 
  t(leakage) cm 50.6 
  
        Leakage and Scattered Radiation at Door 
    Wall-Scattered 
      Parameters Unit Value 
     Area   Controlled 
     W mGy/wk 400000 
     U   1 
     α(0)   4.87E-03 Table B.8a, normal incidence, 40˚ reflection for 6 MV 
A(0) m^2 2.82 Same as NCRP 
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α(z)   2.20E-02 Table B.8b, 45˚ incidence, 0˚ reflection for 0.5 MeV 
 A(z) m^2 5.9 Assume half of A(1) (given) 
  d(h) m 4.2 
     d(r) m 8.9 Calculated 
    d(z) m 9.6 Calculated 
    H(s) mSv/wk 0.005537219 
       µSv/wk 5.5 
     
        
Head Leakage Scatter 
     Parameters Unit Value 
     Area   Controlled 
     W mGy/wk 1360000 
     L(f) fraction 0.001 
     U   1 
     α(1)   6.40E-03 Table B.8b, 45˚ incidence,  0˚ reflection for 6 MV 
 A(1) m^2 11.8 Same as NCRP 
   d(LS) m 6.6 Calculated 
    d(zz) m 9.9 Same as NCRP 
   H(LS) mSv/wk 0.024057064 
       µSv/wk 24.1 
     
        Patient Scatter 
      Parameters Unit Value 
     Area   Controlled 
     W mGy/wk 400000 
     U   1 
     α(θ)   3.14E-04 Table B.4, 130˚ scatter for 6 MV, interpolated 
 A(1) m^2 11.8 Same as NCRP 
   α(1)   2.20E-02 Table B.8b, 45˚ incidence, 0˚ reflection for 0.5 MeV 
 F m^2 1600 
     d(sca) m 1 
     d(sec) m 7.3 Same as NCRP 
   d(zz) m 9.9 Same as NCRP 
   H(ps) mSv/wk 0.024971131 
       µSv/wk 25.0 
     
        Transmitted Leakage 
      Parameters Unit Value 
     
 160 
 
Area   Controlled 
     W mGy/wk 1360000 
     U   1 
     L(f) fraction 0.001 
     B (6 MV)   7.27895E-05 t(s)=125 cm, TVLs from Table B.7 
  d(hd) m 8.1 Calculated 
    H(LT) mSv/wk 0.001508821 
       µSv/wk 1.5 
      
Calculations for single-energy beam with beam direction at walls C and D: 
 
Wall C Primary 
     Parameters Unit Value 
  Area   Uncontrolled 
    P mSv/wk 0.02 
    d m 6.2 
    W mGy/wk 400000 
    U   0.5 
    T Parking lot 0.025 Table B.1 
 B   0.00020736 
    n   3.683275016 
    t(pri) cm 125.5480755 TVLs for 6 MV, Table B.2 
      
Wall C (Point A) Patient Scatter 
    (for 10˚ scatter)  
Parameters Unit Value 
  Area   Uncontrolled 
    P mSv/wk 0.02 
    W mGy/wk 400000 
    d(sca) m 1 
    d(sec) m 6.3 Calculated 
   U   0.5 
    T Parking lot 0.025 Table B.1 
 F cm^2 1600 Assumed the largest FOV (40x40) 
 α (10˚) fraction 1.04E-02 For 10˚, Table B.4 
 B   3.81E-03 
    n   2.418952878 
    t(sca) cm 82.2 TVL(15˚)=34, Table B.5a 
 (for 20˚ scatter) 
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d(sec) m 6.6 Calculated 
   α (20˚) fraction 6.73E-03 For 20˚, Table B.4 
 B   6.47E-03 
    n   2.189203318 
    t(sca) cm 68.5 TVL(20˚)=31.3 (interpolated), Table B.5a 
(for 30˚ scatter) 
     d(sec) m 7.2 Given in NCRP 
  α (30˚) fraction 2.77E-03 For 30˚, Table B.4 
  B   1.87E-02 
    n   1.727814776 
    t(sca) cm 44.9 TVL(30˚)=26, Table B.5a 
 (for 45˚ scatter) 
     d(sec) m 8.8 Calculated 
   α (45˚) fraction 1.39E-03 For 45˚, Table B.4 
  B   5.53E-02 
    n   1.257201426 
    t(sca) cm 28.9 TVL(45˚)=23, Table B.5a 
      
Wall C (Point A) Leakage Scatter 
    Parameters Unit Value 
  Area   Uncontrolled 
    P mSv/wk 0.02 
    W mGy/wk 1360000 
    d(L) m 6.86 Calculated 
   U   0.5 
    T Parking lot 0.025 Table B.1 
 B   0.055364235 
    n   1.256770694 
    t(leakage) cm 41.4 TVLs for 6 MV, Table B.7 
      
Wall D Primary 
    Parameters Unit Value 
 Area   Controlled 
   P mSv/wk 0.1 
   d m 6.2 
   W mGy/wk 400000 
   U   0.5 
   T Control Room 1 Table B.1 
B   0.00002592 
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n   4.586365003 
   t(pri) cm 155.4 TVLs for 6 MV, Table B.2 
 
Wall D (Point B) Patient Scatter 
    (for 10˚ scatter) 
Parameters Unit Value 
   Area   Controlled 
   P mSv/wk 0.1 
   W mGy/wk 400000 
   d(sca) m 1 
   d(sec) m 6.3 
   U   0.5 
   T Control Room 1 Table B.1 
  F cm^2 1600 Assumed the largest FOV (40x40) 
α (10˚) fraction 1.04E-02 For 10˚, Table B.4 
 B   4.77E-04 
   n   3.321442227 
   t(sca) cm 112.9 TVL(15˚)=34, Table B.5a 
       (for 20˚ scatter) 
     d(sec) m 6.6 Calculated 
   α (20˚) fraction 6.73E-03 For 20˚, Table B.4 
  B   8.09E-04 
    n   3.09201718 
    t(sca) cm 96.8 TVL(20˚)=31.3 (interpolated), Table B.5a 
       (for 30˚ scatter) 
     d(sec) m 7.2 Given in NCRP 
  α (30˚) fraction 2.77E-03 For 30˚, Table B.4 
 B   2.34E-03 
    n   2.630904763 
    t(sca) cm 68.4 TVL(30˚)=26, Table B.5a 
 
       (for 45˚ scatter) 
     d(sec) m 8.8 Calculated 
   α (45˚) fraction 1.39E-03 For 45˚, Table B.4 
 B   6.91E-03 
    n   2.160291413 
    t(sca) cm 49.7 TVL(45˚)=23, Table B.5a 
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Wall D (Point B) Leakage Scatter 
   Parameters Unit Value 
   Area   Controlled 
   P mSv/wk 0.1 
   W mGy/wk 1360000 
   d(L) m 6.86 Calculated 
  U   0.5 
   T Control Room 1 Table B.1 
  B   0.006920529 
   n   2.159860681 
   t(leakage) cm 67.6 TVLs for 6 MV, Table B.7 
 
Wall E Patient Scatter 
     (90° scatter position) 
Parameters Unit Value 
    Area   Uncontrolled 
    P mSv/wk 0.02 
    W mGy/wk 400000 
    d(sca) m 1 
    d(sec) m 5.4 Given 
   U 
 
0.5 
    T Reading Room 0.2 Table B.1 
   F cm^2 1600 Assumed the largest FOV (40x40) 
α (90˚) fraction 4.26E-04 For 90˚, Table B.4 
  B   8.56E-03 
    n   2.067712066 
    t(sca) cm 35.2 TVL(90˚)=17, Table B.5a 
 
       (for 60˚ scatter) 
     d(sec) m 6.2 Calculated 
  α (60˚) fraction 8.24E-04 For 60˚, Table B.4 
  B   5.90E-03 
    n   2.229290942 
    t(sca) cm 46.8 TVL(60˚)=21, Table B.5a 
 
       (for 45˚ scatter) 
     d(sec) m 7.6 Calculated 
  α (45˚) fraction 1.39E-03 For 45˚, Table B.4 
  B   5.24E-03 
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n   2.280287272 
    t(sca) cm 52.4 TVL(45˚)=23, Table B.5a 
 
       (for 30˚ scatter) 
     d(sec) m 10.8 Calculated 
  α (30˚) fraction 2.77E-03 For 30˚, Table B.4 
  B   5.26E-03 
    n   2.278722245 
    t(sca) cm 59.2 TVL(30˚)=26, Table B.5a 
  
Wall E Leakage Scatter 
    (90° scatter position) 
Parameters Unit Value   
Area   Uncontrolled 
   P mSv/wk 0.02 
   W mGy/wk 1360000 
   d(L) m 5.4 Given 
  U   0.5 
   T Reading Room 0.2 Table B.1 
B   0.004288235 
   n   2.367721393 
   t(leakage) cm 73.7 TVLs for 6 MV, Table B.7 
      (60° scatter position) 
    Parameters Unit Value 
   d(L) m 6.2 
   B   0.005717647 
   n   2.242782656 
   t(leakage) cm 70.0 
   
      (45° scatter position) 
    Parameters Unit Value 
   d(L) m 7.6 
   B   0.008576471 
   n   2.066691397 
   t(leakage) cm 64.9 
   
      (30° scatter position) 
    Parameters Unit Value 
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d(L) m 10.8 
   B   0.017152941 
   n   1.765661402 
   t(leakage) cm 56.2 
    
Ceiling Patient Scatter 
     (for 90˚ scatter) 
Parameters Unit Value 
    Area   Uncontrolled 
    P mSv/wk 0.02 
    W mGy/wk 400000 
    d(sca) m 1 
    d(sec) m 3.38 Calculated 
  U 
 
0.5 
    T Unoccupied area 0.025 
    F cm^2 1600 Assumed the largest FOV (40x40) 
α (90˚) fraction 4.26E-04 For 90˚, Table B.4 
  B   2.68E-02 
    n   1.572219122 
    t(sca) cm 26.7 TVL(90˚)=17, Table B.5a 
 
       (for 60˚ scatter) 
     d(sec) m 3.9 Given 
   α (45˚) fraction 8.24E-04 For 60˚, Table B.4 
  B   1.85E-02 
    n   1.733797998 
    t(sca) cm 36.4 TVL(60˚)=21, Table B.5a 
 
       (for 45˚ scatter) 
     d(sec) m 4.78 Calculated 
  α (45˚) fraction 1.39E-03 For 45˚, Table B.4 
  B   1.64E-02 
    n   1.784794327 
    t(sca) cm 41.1 TVL(45˚)=23, Table B.5a 
 
       (for 30˚ scatter) 
     d(sec) m 6.75 Calculated 
  α (30˚) fraction 2.77E-03 For 30˚, Table B.4 
  B   1.65E-02 
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n   1.7832293 
    t(sca) cm 46.4 TVL(30˚)=26, Table B.5a 
  
Ceiling Leakage Scatter 
    (90° scatter position) 
    Parameters Unit Value 
   Area   Uncontrolled 
   P mSv/wk 0.02 
   W mGy/wk 1360000 
   d(L) m 3.38 
   U   0.5 
   T Unoccupied area 0.025 
   B   0.013420588 
   n   1.872228448 
   t(leakage) cm 59.3 TVLs for 6 MV, Table B.7 
      (60° scatter position) 
    Parameters Unit Value 
   d(L) m 3.9 
   B   0.017894118 
   n   1.747289712 
   t(leakage) cm 55.7 
   
      (45° scatter position) 
    Parameters Unit Value 
   d(L) m 4.78 
   B   0.026841176 
   n   1.571198453 
   t(leakage) cm 50.6 
   
      (30° scatter position) 
    Parameters Unit Value 
   d(L) m 6.75 
   B   0.053682353 
   n   1.270168457 
   t(leakage) cm 41.8 
    
Leakage and Scattered Radiation at Door 
     When gantry points at wall C… 
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Wall-Scattered 
       Parameters Unit Value 
      Area   Controlled 
      W mGy/wk 400000 
      U   0.5 
      α(0)   2.70E-03 Table B.8a, normal incidence, 75˚ reflection for 6 MV 
A(0) m^2 2.82 
      α(z)   8.00E-03 Table B.8a, normal incidence, 75˚ reflection for 0.5 MeV 
A(z) m^2 8.4 
      d(h) m 4.2 
      d(_r) m 5.9 
      d(z) m 6.8 
      H(s) mSv/wk 0.003604058 
        µSv/wk 3.6 
       
Head Leakage Scatter 
      Parameters Unit Value 
      Area   Controlled 
      W mGy/wk 1360000 
      L(f) fraction 0.001 
      U   0.5 
      α(1)   6.40E-03 Table B.8a, 45˚ incidence, 0⁰ reflection for 6 MV 
A(1) m^2 11.8 
      d(LS) m 7.9 
      d(zz) m 9.9 
      H(LS) mSv/wk 0.008395495 
        µSv/wk 8.4 
       
Patient Scatter 
      Parameters Unit Value 
     Area   Controlled 
     W mGy/wk 400000 
     U   0.5 
     α(θ)   1.34E-03 Table B.4, 45˚incidence for 6 MV 
 A(1) m^2 11.8 
     α(1)   2.20E-02 Table B.8b, 45˚ incidence, 0˚ reflection for 0.5 MeV 
F m^2 1600 
     d(sca) m 1 
     d(sec) m 7.3 
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d(zz) m 9.9 
     H(ps) mSv/wk 0.053242586 
       µSv/wk 53.2 
      
Transmitted Leakage 
     Parameters Unit Value 
    Area   Controlled 
    W (6 MV) mGy/wk 1360000 
    U   0.5 
    L(f) fraction 0.001 
    B (6 MV)   7.27895E-05 t(s)=125 cm, TVLs from Table B.7 
d(L) m 7.1 
    H(LT) mSv/wk 0.000981886 
      µSv/wk 1.0 
     
When gantry points at wall D… 
      Wall-Scattered 
       Parameters Unit Value 
      Area   Controlled 
      W (6 MV) mGy/wk 400000 
      U   0.5 
      α(0)   4.87E-03 Table B.8a, normal incidence, 40˚ reflection for 6 MV 
A(0) m^2 2.82 Same as NCRP 
    α(z)   2.20E-02 Table B.8b, 45˚ incidence, 45˚ reflection for 0.5 MeV 
A(z) m^2 5.9 Assume half of A(1) (given) 
   d(h) m 4.2 
      d(_r) m 8.9 Calculated 
    d(z) m 9.6 Calculated 
    H(s) mSv/wk 0.002768609 
        µSv/wk 2.8 
       
Head Leakage Scatter 
     Parameters Unit Value 
     Area   Controlled 
     W (6 MV) mGy/wk 1360000 
     L(f) fraction 0.001 
     U   0.5 
     α(1)   6.40E-03 Table B.8b, 45˚ incidence, 0˚ reflection for 6 MV 
A(1) m^2 11.8 Same as NCRP 
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d(LS) m 6.6 Calculated 
   d(zz) m 9.9 Same as NCRP 
   H(LS) mSv/wk 0.012028532 
       µSv/wk 12.0 
      
Patient Scatter 
      Parameters Unit Value 
     Area   Controlled 
     W (6 MV) mGy/wk 400000 
     U   0.5 
     α(θ)   3.14E-04 Table B.4, 130˚ scatter for 6 MV, interpolated 
A(1) m^2 11.8 Same as NCRP 
   α(1)   2.20E-02 Table B.8b, 45˚ incidence, 0˚ reflection for 0.5 MeV 
F m^2 1600 
     d(sca) m 1 
     d(sec) m 7.3 Same as NCRP 
   d(zz) m 9.9 Same as NCRP 
   H(ps) mSv/wk 0.012485565 
       µSv/wk 12.5 
      
Transmitted Leakage 
     Parameters Unit Value 
    Area   Controlled 
    W (6 MV) mGy/wk 1360000 
    U   0.5 
    L(f) fraction 0.001 
    B (6 MV)   7.27895E-05 t(s)=125 cm, TVLs from Table B.7 
d(hd) m 8.1 Calculated 
  H(LT) mSv/wk 0.000754411 
      µSv/wk 0.8 
     
Calculations for dual-energy linac with a conventional beam (from NCRP Report No. 
151 Section 7.1): 
 
Wall C Primary 
 Parameters Unit Value 
Area   Uncontrolled 
Energy MV 18 
P mSv/wk 0.02 
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d m 6.2 
W mGy/wk 450000 
U   0.25 
T Parking lot 0.025 
B   0.00036864 
n   3.433397543 
t(pri) cm 149.6 
 
Wall C (Point A) Patient Scatter 
 Parameters Unit Value 
 Area   Uncontrolled 
 P mSv/wk 0.02 
 W mGy/wk 450000 18 MV 
W mGy/wk 225000 6 MV 
d(sca) m 1 
 d(sec) m 7.2 
 T Parking lot 0.025 
 F cm^2 1600  
U   0.25 
 α (30˚) fraction 2.53E-03 18 MV 
α (30˚) fraction 2.77E-03 6 MV 
t(sca) cm 55.6 
  
Wall C (Point A) Leakage Scatter 
 Parameters Unit Value 
 Area   Uncontrolled 
 P mSv/wk 0.02 
 W mGy/wk 1170000 18 MV 
W mGy/wk 945000 6 MV 
d(L) m 7.2 
 T Parking lot 0.025 
 U   1 
 t(leakage) cm 62.1 
  
Wall D Primary 
 Parameters Unit Value 
Area   Controlled 
Energy MV 18 
P mSv/wk 0.1 
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d m 6.2 
W mGy/wk 450000 
U   0.25 
T Control Room 1 
B   0.00004608 
n   4.33648753 
t(pri) cm 188.5 
 
Wall D (Point B) Patient Scatter 
 Parameters Unit Value 
 Area   Controlled 
 P mSv/wk 0.1 
 W mGy/wk 450000 18 MV 
W mGy/wk 225000 6 MV 
d(sca) m 1 
 d(sec) m 7.2 
 T Control Room 1  
F cm^2 1600 
 U   0.25 
 α (30˚) fraction 2.53E-03 18 MV 
α (30˚) fraction 2.77E-03 6 MV 
t(sca) cm 84.5 
 
    Wall D (Point B) Leakage Scatter 
 Parameters Unit Value 
 Area   Controlled 
 P mSv/wk 0.1 
 W mGy/wk 1170000 18 MV 
W mGy/wk 945000 6 MV 
d(L) m 7.2 
 T Control Room 1 
 U   1 
 t(leakage) cm 92.8 
  
Wall E Patient Scatter 
  Parameters Unit Value 
 Area   Uncontrolled 
 P mSv/wk 0.02 
 W mGy/wk 450000 18 MV 
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W mGy/wk 225000 6 MV 
d(sca) m 1 
 d(sec) m 5.4 
 U   1 
 T Reading Room 0.2  
F cm^2 1600 
 α (90˚) fraction 1.89E-04 18 MV 
α (90˚) fraction 4.26E-04 6 MV 
t(sca) cm 45.0   
 
Wall E Leakage Scatter 
  Parameters Unit Value  
Area   Uncontrolled 
 P mSv/wk 0.02 
 W mGy/wk 1170000 18 MV 
W mGy/wk 945000 6 MV 
U   1 
 d(L) m 5.4 
 T Reading Room 0.2 
 t(leakage) cm 101.2 
  
Ceiling Primary 
 Parameters Unit Value 
Area   Uncontrolled 
Energy MV 18 
P mSv/wk 0.02 
d m 4 
W mGy/wk 450000 
U   0.25 
T Unoccupied area 0.025 
B   0.000177778 
n   3.750122527 
t(pri) cm 163.3 
 
Ceiling Patient Scatter 
  Parameters Unit Value 
 Area   Uncontrolled 
 P mSv/wk 0.02 
 W mGy/wk 450000 18 MV 
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W mGy/wk 225000 6 MV 
d(sca) m 1 
 d(sec) m 3.9 
 U 
 
0.25 
 T Unoccupied area 0.025 
 F cm^2 1600 
 α (30˚) fraction 2.53E-03 18 MV 
α (30˚) fraction 2.77E-03 6 MV 
t(sca) cm 72.6 
  
Ceiling Leakage Scatter 
  Parameters Unit Value 
 Area   Uncontrolled 
 P mSv/wk 0.02 
 W mGy/wk 1170000 18 MV 
W mGy/wk 945000 6 MV 
d(L) m 3.9 
 U   1 
 T Unoccupied area 0.025 
 t(leakage) cm 80.1 
  
Leakage and Scattered Radiation at Door 
     Wall-Scattered 
       Parameters Unit Value 
      Area   Controlled 
      W (18 MV) mGy/wk 450000 
      W (6 MV) mGy/wk 225000 
      U   0.25 
      α(0)   1.60E-03 Table B.8a, normal incidence, 75˚ reflection for 18 MV 
α(0)   2.70E-03 Table B.8a, normal incidence, 75˚ reflection for 6 MV 
A(0) m^2 2.82 
      α(z)   8.00E-03 Table B.8a, normal incidence, 75˚ reflection for 0.5 MeV 
A(z) m^2 8.4 
      d(h) m 4.2 
      d(_r) m 5.9 
      d(z) m 6.8 
      H(s) mSv/wk 0.002214994 
        µSv/wk 2.2 
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Head Leakage Scatter 
       Parameters Unit Value 
       Area   Controlled 
       W (18 MV) mGy/wk 1170000 
       W (6 MV) mGy/wk 945000 
       L(f) fraction 0.001 
       U   0.25 
       α(1)   4.50E-03 Table B.8a, 45˚ incidence, 0⁰ reflection for 18 MV 
 α(1)   6.40E-03 Table B.8a, 45˚ incidence, 0⁰ reflection for 6 MV 
 A(1) m^2 11.8 
       d(LS) m 7.9 
       d(zz) m 9.9 
       H(LS) mSv/wk 0.005456011 
         µSv/wk 5.5 
        
Patient Scatter 
       Parameters Unit Value 
      Area   Controlled 
      W (18 MV) mGy/wk 450000 
      W (6 MV) mGy/wk 225000 
      U   0.25 
      α(θ)   8.64E-04 Table B.4, 45˚ incidence for 18 MV 
  α(θ)   1.39E-03 Table B.4, 45˚incidence for 6 MV 
  A(1) m^2 11.8 
      α(1)   2.20E-02 Table B.8b, 45˚ incidence, 0˚ reflection for 0.5 MeV 
 F m^2 1600 
      d(sca) m 1 
      d(sec) m 7.3 
      d(zz) m 9.9 
      H(ps) mSv/wk 0.034869619 
        µSv/wk 34.9 
       
Transmitted Leakage 
     Parameters Unit Value 
    Area   Controlled 
    W (18 MV) mGy/wk 1170000 
    W (6 MV) mGy/wk 945000 
    U   0.25 
    L(f) fraction 0.001 
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B (18 MV)   0.000241186 t(s)=125 cm, TVLs from Table B.7 
B (6 MV)   7.27895E-05 t(s)=125 cm, TVLs from Table B.7 
d(L) m 7.1 
    H(LT) mSv/wk 0.001740599 
      µSv/wk 1.7 
     
Calculations for dual-energy beam with beam direction at wall C: 
 
Wall C Primary 
     Parameters Unit Value 
  Area   Uncontrolled 
    Energy MV 18 
    P mSv/wk 0.02 
    d m 6.2 
    W mGy/wk 450000 
    U   1 
    T Parking lot 0.025 Table B.1
 B   0.00009216 
    n   4.035457534 
    t(pri) cm 175.5 TVLs for 18 MV, Table B.2 
  
Wall C (Point A) Patient Scatter 
    (for 10˚ scatter)  
Parameters Unit Value 
  Area   Uncontrolled 
    P mSv/wk 0.02 
    W mGy/wk 450000 18 MV 
   W mGy/wk 225000 6 MV 
   d(sca) m 1 
    d(sec) m 6.3 Calculated 
  T Parking lot 0.025 Table B.1 
 F cm^2 1600 Assumed the largest FOV (40x40) 
α (10˚) fraction 1.42E-02 18 MV, Table B.4 
 α (10˚) fraction 1.04E-02 6 MV, Table B.4 
 n (18 MV)   2.905789764 
    t(sca) 18 MV cm 127.8547496 TVL(15˚)=44, Table B.5a 
 n (6 MV)   2.469504763 
    t(sca) 6 MV cm 83.96316194 TVL(15˚)=34, Table B.5a 
 t(sca, tot) cm 127.9 
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(for 20˚ scatter) 
    d(sec) m 6.6 Calculated 
 α (20˚) fraction 5.39E-03 18 MV, Table B.4 
α (20˚) fraction 6.73E-03 6 MV, Table B.4 
n (18 MV)   2.444683412 
   t(sca) 18 MV cm 97.78733649 TVL(20˚)=40, Table B.5a 
n (6 MV)   2.240079716 
   t(sca) 6 MV cm 70.1144951 TVL(20˚)=31.3, Table B.5a 
t(sca, tot) cm 109.8 
   
      (for 30˚ scatter) 
    d(sec) m 7.2 Given in NCRP 
 α (30˚) fraction 2.53E-03 18 MV, Table B.4 
 α (30˚) fraction 2.77E-03 6 MV, Table B.4 
n (18 MV)   2.04E+00 
   t(sca) 18 MV cm 65.30041749 TVL(30˚)=32, Table B.5a 
n (6 MV)   1.778967299 
   t(sca) 6 MV cm 46.25314976 TVL(30˚)=26, Table B.5a 
t(sca, tot) cm 74.9 
   
      (for 45˚ scatter) 
    d(sec) m 8.8 Calculated 
 α (45˚) fraction 8.64E-04 18 MV, Table B.4 
 α (45˚) fraction 1.39E-03 6 MV, Table B.4 
n (18 MV)   1.399730916 
   t(sca) 18 MV cm 37.79273474 TVL(45˚)=27, Table B.5a 
n (6 MV)   1.305201978 
   t(sca) 6 MV cm 30.0196455 TVL(45˚)=23, Table B.5a 
t(sca, tot) cm 45.9 
    
Wall C (Point A) Leakage Scatter 
   Parameters Unit Value 
 Area   Uncontrolled 
   P mSv/wk 0.02 
   W mGy/wk 1170000 18 MV 
  W mGy/wk 945000 6 MV 
  d(L) m 7.9 Calculated 
 T Parking lot 0.025 Table B.1 
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n (18 MV)   1.369841692 
   t(leakage) cm 48.57461753 TVLs for 18 MV, Table B.7 
n (6 MV)   1.277087639 
   t(leakage) cm 42.03554153 TVLs for 6 MV, Table B.7 
t(leak, tot) cm 59.4 
    
Wall D Patient Scatter 
     Parameters Unit Value 
    Area   Controlled 
    P mSv/wk 0.1 
    W mGy/wk 450000 18 MV 
   W mGy/wk 225000 6 MV 
   d(sca) m 1 
    d(sec) m 8.77 
    T Control Room 1 Table B.1 
   F cm^2 1600 Assumed the largest FOV (40x40) 
α (135˚) fraction 1.24E-04 18 MV, Table B.4 
  α (135˚) fraction 3.00E-04 6 MV, Table B.4 
 n (18 MV)   1.462695004 
    t(sca, 18 MV) cm 21.94042505 TVL(135˚)=15, Table B.5a 
 n (6 MV)   1.545364577 
    t(sca, 6 MV) cm 23.18046866 TVL(135˚)=15, Table B.5a 
 t(sca, tot) cm 27.7 
    
       Wall D Leakage Scatter 
     Parameters Unit Value 
    Area   Controlled 
    P mSv/wk 0.1 
    W mGy/wk 1170000 18 MV 
   W mGy/wk 945000 6 MV 
   d(L) m 5.2 
    T Control Room 1 Table B.1 
   n (18 MV)   2.636179174 
    t(leakage) cm 91.63009193 TVLs for 18 MV, Table B.7 
 n (6 MV)   2.543425121 
    t(leakage) cm 78.75932852 TVLs for 6 MV, Table B.7 
 t(leak, tot) cm 102.5 
     
Wall E Patient Scatter 
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(for 90˚ scatter)      
Parameters Unit Value 
    Area   Uncontrolled 
    P mSv/wk 0.02 
    W mGy/wk 450000 18 MV 
   W mGy/wk 225000 6 MV 
   d(sca) m 1 
    d(sec) m 5.4 Given 
   T Reading Room 0.2 Table B.1 
   F cm^2 1600 Assumed the largest FOV (40x40) 
α (90˚) fraction 1.89E-04 18 MV, Table B.4 
  α (90˚) fraction 4.26E-04 6 MV, Table B.4 
  n (18 MV)   2.06694679 
    t(sca, 18 MV) cm 39.271989 TVL(90˚)=19, Table B.5a 
 n (6 MV)   2.118864589 
    t(sca, 6 MV) cm 36.02069801 TVL(90˚)=17, Table B.5a 
 t(sca, tot) cm 45.0 
    
       (for 60˚ scatter) 
     d(sec) m 6.2 Calculated 
  α (60˚) fraction 4.24E-04 18 MV, Table B.4 
  α (60˚) fraction 8.24E-04 6 MV, Table B.4 
 n (18 MV)   2.292912105 
    t(sca, 18 MV) cm 52.73697843 TVL(60˚)=23, Table B.5a 
 n (6 MV)   2.280443465 
    t(sca, 6 MV) cm 47.88931276 TVL(60˚)=21, Table B.5a 
 t(sca, tot) cm 59.7 
    
       (for 45˚ scatter) 
     d(sec) m 7.6 Calculated 
  α (45˚) fraction 8.64E-04 18 MV, Table B.4 
  α (45˚) fraction 1.39E-03 6 MV, Table B.4 
 n (18 MV)   2.425968732 
    t(sca, 18 MV) cm 65.50115577 TVL(45˚)=27, Table B.5a 
 n (6 MV)   2.331439794 
    t(sca, 6 MV) cm 53.62311527 TVL(45˚)=23, Table B.5a 
 t(sca, tot) cm 73.6 
    
       (for 30˚ scatter) 
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d(sec) m 10.8 Calculated 
  α (30˚) fraction 2.53E-03 18 MV, Table B.4 
  α (30˚) fraction 2.77E-03 6 MV, Table B.4 
 n (18 MV)   2.591545515 
    t(sca, 18 MV) cm 82.92945649 TVL(30˚)=32, Table B.5a 
 n (6 MV)   2.329874768 
    t(sca, 6 MV) cm 60.57674396 TVL(30˚)=26, Table B.5a 
 t(sca, tot) cm 92.6 
     
Wall E Leakage Scatter 
    (90° scatter position)     
Parameters Unit Value 
   Area   Uncontrolled   
P mSv/wk 0.02 
   W mGy/wk 1170000 18 MV 
  W mGy/wk 945000 6 MV 
  d(L) m 5.4 Given 
  T Reading Room 0.2 Table B.1 
  n (18 MV)   2.603398342 
   t(leakage) cm 90.51554363 TVLs for 18 MV, Table B.7 
n (6 MV)   2.510644289 
   t(leakage) cm 77.80868438 TVLs for 6 MV, Table B.7 
t(leak,tot) cm 101.4 
   
      (60° scatter position) 
    Parameters Unit Value 
   d(L) m 6.2 
   n (18 MV)   2.478459605 
   t(leakage) cm 86.26762659 TVLs for 18 MV, Table B.7 
n (6 MV)   2.385705552 
   t(leakage) cm 74.18546102 TVLs for 6 MV, Table B.7 
t(leak,tot) cm 97.1 
   
      (45° scatter position) 
    Parameters Unit Value 
   d(L) m 7.6 
   n (18 MV)   2.302368346 
   t(leakage) cm 80.28052378 TVLs for 18 MV, Table B.7 
n (6 MV)   2.209614293 
   t(leakage) cm 69.0788145 TVLs for 6 MV, Table B.7 
t(leak,tot) cm 91.1 
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      (30° scatter position) 
    Parameters Unit Value 
   d(L) m 10.8 
   n (18 MV)   2.001338351 
   t(leakage) cm 70.04550393 TVLs for 18 MV, Table B.7 
n (6 MV)   1.908584298 
   t(leakage) cm 60.34894463 TVLs for 6 MV, Table B.7 
t(leak,tot) cm 80.9 
    
 
Ceiling Patient Scatter 
     (for 90˚ scatter) 
Parameters Unit Value 
    Area   Uncontrolled 
    P mSv/wk 0.02 
    W mGy/wk 450000 18 MV 
   W mGy/wk 225000 6 MV 
   d(sca) m 1 
    d(sec) m 3.38 Given in NCRP 
  U 
 
1 
    T Unoccupied area 0.025 
    F cm^2 1600 Assumed the largest FOV (40x40) 
α (90˚) fraction 1.89E-04 For 90˚, Table B.4 
  α (90˚) fraction 4.26E-04 6 MV, Table B.4 
 n (18 MV)   1.570810922 
    t(sca, 18 MV) cm 29.84540751 TVL(90˚)=19, Table B.5a 
 n (6 MV)   1.622728721 
    t(sca, 6 MV) cm 27.58638826 TVL(90˚)=17, Table B.5a 
 t(sca, tot) cm 35.6 
      
(for 60˚ scatter) 
     d(sec) m 3.9 Given 
  α (60˚) fraction 4.24E-04 18 MV, Table B.4 
 α (60˚) fraction 8.24E-04 6 MV, Table B.4 
n (18 MV)   1.797419161 
   t(sca, 18 MV) cm 41.34064069 TVL(60˚)=23, Table B.5a 
n (6 MV)   1.78495052 
   t(sca, 6 MV) cm 37.48396092 TVL(60˚)=21, Table B.5a 
t(sca, tot) cm 48.3 
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      (for 45˚ scatter) 
     d(sec) m 4.78 Calculated 
 α (45˚) fraction 8.64E-04 18 MV, Table B.4 
 α (45˚) fraction 1.39E-03 6 MV, Table B.4 
n (18 MV)   1.929840467 
   t(sca, 18 MV) cm 52.10569262 TVL(45˚)=27, Table B.5a 
n (6 MV)   1.835311529 
   t(sca, 6 MV) cm 42.21216518 TVL(45˚)=23, Table B.5a 
t(sca, tot) cm 60.2 
   
      (for 30˚ scatter) 
     d(sec) m 6.75 Calculated 
 α (30˚) fraction 2.53E-03 18 MV, Table B.4 
 α (30˚) fraction 2.77E-03 6 MV, Table B.4 
n (18 MV)   2.096695494 
   t(sca, 18 MV) cm 67.0942558 TVL(30˚)=32, Table B.5a 
n (6 MV)   1.835024746 
   t(sca, 6 MV) cm 47.71064339 TVL(30˚)=26, Table B.5a 
t(sca, tot) cm 76.7 
    
Ceiling Leakage Scatter 
     (90° scatter position) 
     Parameters Unit Value 
    Area   Uncontrolled 
    P mSv/wk 0.02 
    W mGy/wk 1170000 18 MV 
   W mGy/wk 945000 6 MV 
   d(L) m 3.38 
    T Unoccupied area 0.025 
    n (18 MV)   2.107262474 
    t(leakage) cm 73.64692412 TVLs for 18 MV, Table B.7 
 n (6 MV)   2.014508421 
    t(leakage) cm 63.42074421 TVLs for 6 MV, Table B.7 
 t(leak, tot) cm 84.5 
     
(60° scatter position) 
    Parameters Unit Value 
   d(L) m 3.90 Given 
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n (18 MV)   1.982966661 
   t(leakage) cm 69.42086646 TVLs for 18 MV, Table B.7 
n (6 MV)   1.890212607 
   t(leakage) cm 59.81616562 TVLs for 6 MV, Table B.7 
t(leak, tot) cm 80.3 
   
      (45° scatter position) 
    Parameters Unit Value 
   d(L) m 4.78 
   n (18 MV)   1.806232479 
   t(leakage) cm 63.41190427 TVLs for 18 MV, Table B.7 
n (6 MV)   1.713478425 
   t(leakage) cm 54.69087433 TVLs for 6 MV, Table B.7 
t(leak, tot) cm 74.2 
   
      (30° scatter position) 
    Parameters Unit Value 
   d(L) m 6.75 
   n (18 MV)   1.506488329 
   t(leakage) cm 53.22060319 TVLs for 18 MV, Table B.7 
n (6 MV)   1.413734276 
   t(leakage) cm 45.998294 TVLs for 6 MV, Table B.7 
t(leak, tot) cm 64.1 
    
Leakage and Scattered Radiation at Door 
   Wall-Scattered 
       Parameters Unit Value 
      Area   Controlled 
      W (18 MV) mGy/wk 450000 
      W (6 MV) mGy/wk 225000 
      U   1 
      α(0)   1.60E-03 Table B.8a, normal incidence, 75˚ reflection for 18 MV 
α(0)   2.70E-03 Table B.8a, normal incidence, 75˚ reflection for 6 MV 
 A(0) m^2 2.82 
      α(z)   8.00E-03 Table B.8a, normal incidence, 75˚ reflection for 0.5 MeV 
A(z) m^2 8.4 
      d(h) m 4.2 
      d(_r) m 5.9 
      d(z) m 6.8 
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H(s) mSv/wk 0.00885997 
        µSv/wk 8.9 
       
Head Leakage Scatter 
      Parameters Unit Value 
      Area   Controlled 
      W (18 MV) mGy/wk 1170000 
      W (6 MV) mGy/wk 945000 
      L(f) fraction 0.001 
      U   1 
      α(1)   4.50E-03 Table B.8b, 45˚ incidence, 0⁰ reflection for 18 MV
α(1)   6.40E-03 Table B.8b, 45˚ incidence, 0⁰ reflection for 6 MV 
A(1) m^2 11.8 
      d(LS) m 7.9 
      d(zz) m 9.9 
      H(LS) mSv/wk 0.02182404 
        µSv/wk 21.8 
       
Patient Scatter 
       Parameters Unit Value 
      Area   Controlled 
      W (18 MV) mGy/wk 450000 
      W (6 MV) mGy/wk 225000 
      U   1 
      α(θ)   8.64E-04 Table B.4, 45˚ incidence for 18 MV 
  α(θ)   1.39E-03 Table B.4, 45˚incidence for 6 MV 
  A(1) m^2 11.8 
      α(1)   2.20E-02 Table B.8b, 45˚ incidence, 0˚ reflection for 0.5 MeV 
 F m^2 1600 
      d(sca) m 1 
      d(sec) m 7.3 
      d(zz) m 9.9 
      H(ps) mSv/wk 0.13947848 
        µSv/wk 139.5 
       
Transmitted Leakage 
     Parameters Unit Value 
    Area   Controlled 
    W (18 MV) mGy/wk 1170000 
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W (6 MV) mGy/wk 945000 
    U   1 
    L(f) fraction 0.001 
    B (18 MV)   0.00024119 t(s)=125 cm, TVLs from Table B.7 
B (6 MV)   7.279E-05 t(s)=125 cm, TVLs from Table B.7 
d(L) m 7.1 
    H(LT) mSv/wk 0.00696239 
      µSv/wk 7.0 
     
Calculations for dual-energy beam with beam direction at wall D: 
 
Wall D Primary 
    Parameters Unit Value 
 Area   Controlled 
   Energy MV 18 
   P mSv/wk 0.1 
   d m 6.2 
   W mGy/wk 450000 
   U   1 
   T Control Room 1 Table B.1 
B   0.00001152 
   n   4.938547521 
   t(pri) cm 214.4 TVLs for 18 MV, Table B.2 
 
Wall D (Point B) Patient Scatter 
  
  
(for 10˚ scatter)   
Parameters Unit Value 
   Area   Controlled 
   P mSv/wk 0.1 
   W mGy/wk 450000 18 MV 
  W mGy/wk 225000 6 MV 
  d(sca) m 1 
 d(sec) m 6.3 
   T Control Room 1 Table B.1 
F cm^2 1600 Assumed the largest FOV (40x40) 
α (10˚) fraction 1.42E-02 18 MV, Table B.4 
α (10˚) fraction 1.04E-02 6 MV, Table B.4 
n (18 MV)   3.808879751 
 t(sca) 18 MV cm 167.590709 TVL(15˚)=44, Table B.5a 
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n (6 MV)   3.37259475 
   t(sca) 6 MV cm 114.6682215 TVL(15˚)=34, Table B.5a 
t(sca, tot) cm 167.6 
   
      (for 20˚ scatter)
    d(sec) m 6.6 Calculated 
  α (20˚) fraction 5.39E-03 18 MV, Table B.4 
α (20˚) fraction 6.73E-03 6 MV, Table B.4 
n (18 MV)   3.348049524 
 t(sca) 18 MV cm 133.921981 TVL(20˚)=40, Table B.5a 
n (6 MV)   3.143445828 
   t(sca) 6 MV cm 98.3898544 TVL(20˚)=31.3, Table B.5a 
t(sca, tot) cm 146.0 
   
      (for 30˚ scatter)
    d(sec) m 7.2 Given in NCRP 
 α (30˚) fraction 2.53E-03 18 MV, Table B.4 
α (30˚) fraction 2.77E-03 6 MV, Table B.4 
n (18 MV)   2.948670911 
 t(sca) 18 MV cm 94.35746914 TVL(30˚)=32, Table B.5a 
n (6 MV)   2.687000163 
   t(sca) 6 MV cm 69.86200424 TVL(30˚)=26, Table B.5a 
t(sca, tot) cm 104.0 
   
      (for 45˚ scatter)
    d(sec) m 8.8 Calculated 
  α (45˚) fraction 8.64E-04 18 MV, Table B.4 
α (45˚) fraction 1.39E-03 6 MV, Table B.4 
n (18 MV)   2.305972873 
 t(sca) 18 MV cm 62.26126757 TVL(45˚)=27, Table B.5a 
n (6 MV)   2.211443935 
   t(sca) 6 MV cm 50.86321051 TVL(45˚)=23, Table B.5a 
t(sca, tot) cm 70.4 
    
Wall D (Point B) Leakage Scatter 
 Parameters Unit Value 
   Area   Controlled 
   P mSv/wk 0.1 
   W mGy/wk 1170000 18 MV 
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W mGy/wk 945000 6 MV 
  d(L) m 7.9 Calculated 
  T Control Room 1 Table B.1 
n (18 MV)   2.272931679 
   t(leakage) cm 79.27967709 TVLs for 18 MV, Table B.7 
n (6 MV)   2.180177626 
   t(leakage) cm 68.22515115 TVLs for 6 MV, Table B.7 
t(leak, tot) cm 90.1 
    
Wall C Patient Scatter 
    Parameters Unit Value 
 Area   Uncontrolled 
   P mSv/wk 0.02 
   W mGy/wk 450000 18 MV 
  W mGy/wk 225000 6 MV 
  d(sca) m 1 
   d(sec) m 8.77 Calculated 
 T Parking lot 0.025 Table B.1 
F cm^2 1600 Assumed the largest FOV (40x40) 
α (135˚) fraction 1.24E-04 18 MV, Table B.4 
α (135˚) fraction 3.00E-04 6 MV, Table B.4 
n (18 MV)   0.559605017 
   t(sca, 18 MV) cm 8.394075248 TVL(135˚)=15, Table B.5a 
n (6 MV)   0.64227459 
   t(sca, 6 MV) cm 9.634118857 TVL(135˚)=15, Table B.5a 
t(sca, tot) cm 14.1 
    
Wall C Leakage Scatter 
    Parameters Unit Value 
 Area   Uncontrolled 
   P mSv/wk 0.02 
   W mGy/wk 1170000 18 MV 
  W mGy/wk 945000 6 MV 
  d(L) m 5.2 
   T Parking lot 0.025 Table B.1 
  n (18 MV)   1.733089187 
   t(leakage) cm 60.92503237 TVLs for 18 MV, Table B.7 
n (6 MV)   1.640335134 
   t(leakage) cm 52.56971889 TVLs for 6 MV, Table B.7 
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t(leak, tot) cm 71.8 
    
Wall E Patient Scatter 
    (for 90˚ scatter) 
Parameters Unit Value 
   Area   Uncontrolled 
   P mSv/wk 0.02 
   W mGy/wk 450000 18 MV 
  W mGy/wk 225000 6 MV 
  d(sca) m 1 
   d(sec) m 5.4 
   T Reading Room 0.2 Table B.1 
  F cm^2 1600 Assumed the largest FOV (40x40) 
α (90˚) fraction 1.89E-04 18 MV, Table B.4 
 α (90˚) fraction 4.26E-04 6 MV, Table B.4 
 n (18 MV)   2.06694679 
   t(sca, 18 MV) cm 39.271989 TVL(90˚)=19, Table B.5a 
n (6 MV)   2.118864589 
   t(sca, 6 MV) cm 36.02069801 TVL(90˚)=17, Table B.5a 
t(sca, tot) cm 45.0 
    
(for 60˚ scatter) 
    d(sec) m 6.2 Calculated 
 α (60˚) fraction 4.24E-04 18 MV, Table B.4 
 α (60˚) fraction 8.24E-04 6 MV, Table B.4 
n (18 MV)   2.292912105 
   t(sca, 18 MV) cm 52.73697843 TVL(60˚)=23, Table B.5a 
n (6 MV)   2.280443465 
   t(sca, 6 MV) cm 47.88931276 TVL(60˚)=21, Table B.5a 
t(sca, tot) cm 59.7 
    
(for 45˚ scatter) 
    d(sec) m 7.6 Calculated 
 α (45˚) fraction 8.64E-04 18 MV, Table B.4 
 α (45˚) fraction 1.39E-03 6 MV, Table B.4 
n (18 MV)   2.425968732 
   t(sca, 18 MV) cm 65.50115577 TVL(45˚)=27, Table B.5a 
n (6 MV)   2.331439794 
   t(sca, 6 MV) cm 53.62311527 TVL(45˚)=23, Table B.5a 
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t(sca, tot) cm 73.6 
    
(for 30˚ scatter) 
    d(sec) m 10.8 Calculated 
 α (30˚) fraction 2.53E-03 18 MV, Table B.4 
 α (30˚) fraction 2.77E-03 6 MV, Table B.4 
n (18 MV)   2.591545515 
   t(sca, 18 MV) cm 82.92945649 TVL(30˚)=32, Table B.5a 
n (6 MV)   2.329874768 
   t(sca, 6 MV) cm 60.57674396 TVL(30˚)=26, Table B.5a 
t(sca, tot) cm 92.6 
    
Wall E Leakage Scatter 
    (90° scatter position) 
Parameters Unit Value 
   Area   Uncontrolled 
   P mSv/wk 0.02 
   W mGy/wk 1170000 18 MV 
  W mGy/wk 945000 6 MV 
  d(L) m 5.4 
   T Reading Room 0.2 Table B.1 
  n (18 MV)   2.603398342 
   t(leakage) cm 90.51554363 TVLs for 18 MV, Table B.7 
n (6 MV)   2.510644289 
   t(leakage) cm 77.80868438 TVLs for 6 MV, Table B.7 
t(leak, tot) cm 101.4 
    
(60° scatter position) 
    Parameters Unit Value 
   d(L) m 6.2 
   n (18 MV)   2.478459605 
   t(leakage) cm 86.26762659 TVLs for 18 MV, Table B.7 
n (6 MV)   2.385705552 
   t(leakage) cm 74.18546102 TVLs for 6 MV, Table B.7 
t(leak, tot) cm 97.1 
   
      (45° scatter position) 
    Parameters Unit Value 
   d(L) m 7.6 
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n (18 MV)   2.302368346 
   t(leakage) cm 80.28052378 TVLs for 18 MV, Table B.7 
n (6 MV)   2.209614293 
   t(leakage) cm 69.0788145 TVLs for 6 MV, Table B.7 
t(leak, tot) cm 91.1 
   
      (30° scatter position) 
    Parameters Unit Value 
   d(L) m 10.8 
   n (18 MV)   2.001338351 
   t(leakage) cm 70.04550393 TVLs for 18 MV, Table B.7 
n (6 MV)   1.908584298 
   t(leakage) cm 60.34894463 TVLs for 6 MV, Table B.7 
t(leak, tot) cm 80.9 
    
Ceiling Patient Scatter 
     (90° scatter position) 
Parameters Unit Value 
    Area   Uncontrolled 
    P mSv/wk 0.02 
    W mGy/wk 450000 18 MV 
   W mGy/wk 225000 6 MV 
   d(sca) m 1 
    d(sec) m 3.38 Calculated 
  U 
 
1 
    T Unoccupied area 0.025 
    F cm^2 1600 Assumed the largest FOV (40x40) 
α (90˚) fraction 1.89E-04 18 MV, Table B.4 
  α (90˚) fraction 4.26E-04 6 MV, Table B.4 
 n (18 MV)   1.570810922 
    t(sca, 18 MV) cm 29.84540751 TVL(90˚)=19, Table B.5a 
 n (6 MV)   1.622728721 
    t(sca, 6 MV) cm 27.58638826 TVL(90˚)=17, Table B.5a 
 t(sca, tot) cm 35.6 
    
       (for 60˚ scatter) 
     d(sec) m 3.9 Given 
   α (60˚) fraction 4.24E-04 18 MV, Table B.4 
  α (60˚) fraction 8.24E-04 6 MV, Table B.4 
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n (18 MV)   1.797419161 
    t(sca, 18 MV) cm 41.34064069 TVL(60˚)=23, Table B.5a 
 n (6 MV)   1.78495052 
    t(sca, 6 MV) cm 37.48396092 TVL(60˚)=21, Table B.5a 
 t(sca, tot) cm 48.3 
    
       (for 45˚ scatter) 
     d(sec) m 4.78 Calculated 
  α (45˚) fraction 8.64E-04 18 MV, Table B.4 
  α (45˚) fraction 1.39E-03 6 MV, Table B.4 
 n (18 MV)   1.929840467 
    t(sca, 18 MV) cm 52.10569262 TVL(45˚)=27, Table B.5a 
 n (6 MV)   1.835311529 
    t(sca, 6 MV) cm 42.21216518 TVL(45˚)=23, Table B.5a 
 t(sca, tot) cm 60.2 
    
       (for 30˚ scatter) 
     d(sec) m 6.75 Calculated 
  α (30˚) fraction 2.53E-03 18 MV, Table B.4 
  α (30˚) fraction 2.77E-03 6 MV, Table B.4 
 n (18 MV)   2.096695494 
    t(sca, 18 MV) cm 67.0942558 TVL(30˚)=32, Table B.5a 
 n (6 MV)   1.835024746 
    t(sca, 6 MV) cm 47.71064339 TVL(30˚)=26, Table B.5a 
 t(sca, tot) cm 76.7 
     
Ceiling Leakage Scatter 
     (90° scatter position) 
     Parameters Unit Value 
    Area   Uncontrolled 
    P mSv/wk 0.02 
    W mGy/wk 1170000 18 MV 
   W mGy/wk 945000 6 MV 
   d(L) m 3.38 
    T Unoccupied area 0.025 
    n (18 MV)   2.107262474 
    t(leakage) cm 73.64692412 TVLs for 18 MV, Table B.7 
 n (6 MV)   2.014508421 
    t(leakage) cm 63.42074421 TVLs for 6 MV, Table B.7 
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t(leak, tot) cm 84.5 
    
       (60° scatter position) 
     Parameters Unit Value 
    d(L) m 3.90 Given 
   n (18 MV)   1.982966661 
    t(leakage) cm 69.42086646 TVLs for 18 MV, Table B.7 
 n (6 MV)   1.890212607 
    t(leakage) cm 59.81616562 TVLs for 6 MV, Table B.7 
 t(leak, tot) cm 80.3 
    
       (45° scatter position) 
     Parameters Unit Value 
    d(L) m 4.78 
    n (18 MV)   1.806232479 
    t(leakage) cm 63.41190427 TVLs for 18 MV, Table B.7 
 n (6 MV)   1.713478425 
    t(leakage) cm 54.69087433 TVLs for 6 MV, Table B.7 
 t(leak, tot) cm 74.2 
    
       (30° scatter position) 
     Parameters Unit Value 
    d(L) m 6.75 
    n (18 MV)   1.506488329 
    t(leakage) cm 53.22060319 TVLs for 18 MV, Table B.7 
 n (6 MV)   1.413734276 
    t(leakage) cm 45.998294 TVLs for 6 MV, Table B.7 
 t(leak, tot) cm 64.1 
     
Leakage and Scattered Radiation at Door 
    Wall-Scattered 
       Parameters Unit Value 
      Area   Controlled 
      W (18 MV) mGy/wk 450000 
      W (6 MV) mGy/wk 225000 
      U   1 
      α(0)   3.13E-03 Table B.8a, normal incidence, 40˚ reflection for 18 MV 
α(0)   4.87E-03 Table B.8a, normal incidence, 40˚ reflection for 6 MV 
A(0) m^2 2.82 
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α(z)   2.20E-02 Table B.8b, 45° incidence, 45˚ reflection for 0.5 MeV 
A(z) m^2 5.9 Assume half of A(1) (given) 
   d(h) m 4.2 
      d(_r) m 8.9 Calculated 
    d(z) m 9.6 Approximation 
    H(s) mSv/wk 0.00711837 
        µSv/wk 7.1 
       
Head Leakage Scatter 
        Parameters Unit Value 
        Area   Controlled 
        W (18 MV) mGy/wk 1170000 
        W (6 MV) mGy/wk 945000 
        L(f) fraction 0.001 
        U   1 
        α(1)   4.50E-03 Table B.8b, 45˚ incidence, 0⁰ reflection for 18 MV, interpolated 
α(1)   6.40E-03 Table B.8b, 45˚ incidence, 0⁰ reflection for 6 MV, interpolated 
 A(1) m^2 11.8 Same as NCRP 
      d(LS) m 6.6 Calculated 
      d(zz) m 9.9 Same as NCRP 
      H(LS) mSv/wk 0.0312681 
          µSv/wk 31.3 
         
Patient Scatter 
       Parameters Unit Value 
      Area   Controlled 
      W (18 MV) mGy/wk 450000 
      W (6 MV) mGy/wk 225000 
      U   1 
      α(θ)   1.31E-04 Table B.4, 130˚ scatter for 18 MV 
  α(θ)   3.14E-04 Table B.4, 130˚ scatter for 6 MV 
  A(1) m^2 11.8 Same as NCRP 
    α(1)   2.20E-02 Table B.8b, 45˚ incidence, 0˚ reflection for 0.5 MeV 
 F m^2 1600 
      d(sca) m 1 
      d(sec) m 7.3 Same as NCRP 
    d(zz) m 9.9 Same as NCRP 
    H(ps) mSv/wk 0.02576639 
        µSv/wk 25.8 
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Transmitted Leakage 
     Parameters Unit Value 
    Area   Controlled 
    W (18 MV) mGy/wk 1170000 
    W (6 MV) mGy/wk 945000 
    U   1 
    L(f) fraction 0.001 
    B (18 MV)   0.00024119 t(s)=125 cm, TVLs from Table B.7 
B (6 MV)   7.279E-05 t(s)=125 cm, TVLs from Table B.7 
d(hd) m 8.1 Calculated 
  H(LT) mSv/wk 0.0053494 
      µSv/wk 5.3 
     
Calculations for dual-energy beam with beam direction at walls C and D: 
 
Wall C Primary 
     Parameters Unit Value 
  Area   Uncontrolled 
    Energy MV 18 
    P mSv/wk 0.02 
    d m 6.2 
    W mGy/wk 450000 
    U   0.5 
    T Parking lot 0.025 Table B.1
 B   0.00018432 
    n   3.734427538 
    t(pri) cm 162.6 TVLs for 18 MV, Table B.2 
  
Wall C (Point A) Patient Scatter 
   (for 10˚ scatter)  
Parameters Unit Value 
 Area   Uncontrolled 
   P mSv/wk 0.02 
   W mGy/wk 450000 18 mV 
  W mGy/wk 225000 6 MV 
  d(sca) m 1 
   d(sec) m 6.3 
   U   0.5 
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T Parking lot 0.025 Table B.1 
  F cm^2 1600 Assumed the largest FOV (40x40) 
α (10˚) fraction 1.42E-02 18 MV, Table B.4 
 α (10˚) fraction 1.04E-02 6 MV, Table B.4 
n (18 MV)   2.604759768 
   t(sca) 18 MV cm 114.6094298 TVL(15˚)=44, Table B.5a 
 n (6 MV)   2.168474767 
   t(sca) 6 MV cm 73.72814208 TVL(15˚)=34, Table B.5a 
t(sca, tot) cm 127.9 
   
      (for 20˚ scatter) 
    d(sec) m 6.6 Calculated 
 α (20˚) fraction 5.39E-03 18 MV, Table B.4 
 α (20˚) fraction 6.73E-03 6 MV, Table B.4 
n (18 MV)   2.143653417 
 t(sca) 18 MV cm 85.74613666 TVL(20˚)=40, Table B.5a 
n (6 MV)   1.93904972 
   t(sca) 6 MV cm 60.69225623 TVL(20˚)=31.3, Table B.5a 
t(sca, tot) cm 97.8 
   
      (for 30˚ scatter) 
    d(sec) m 7.2 Given in NCRP 
 α (30˚) fraction 2.53E-03 18 MV, Table B.4 
 α (30˚) fraction 2.77E-03 6 MV, Table B.4 
n (18 MV)   1.739608051 
 t(sca) 18 MV cm 55.66745762 TVL(30˚)=32, Table B.5a 
n (6 MV)   1.477937303 
   t(sca) 6 MV cm 38.42636988 TVL(30˚)=26, Table B.5a 
t(sca, tot) cm 65.3 
   
      (for 45˚ scatter) 
    d(sec) m 8.8 Calculated 
 α (45˚) fraction 8.64E-04 18 MV, Table B.4 
 α (45˚) fraction 1.39E-03 6 MV, Table B.4 
n (18 MV)   1.098700921 
 t(sca) 18 MV cm 29.66492486 TVL(45˚)=27, Table B.5a 
n (6 MV)   1.004171983 
   t(sca) 6 MV cm 23.0959556 TVL(45˚)=23, Table B.5a 
t(sca, tot) cm 37.8 
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Wall C (Point A) Leakage Scatter 
   Parameters Unit Value 
   Area   Uncontrolled 
   P mSv/wk 0.02 
   W mGy/wk 1170000 18 MV 
  W mGy/wk 945000 6 MV 
  d(L) m 6.86 Calculated 
 U   0.5 
   T Parking lot 0.025 Table B.1
n (18 MV)   1.191417648 
   t(leakage) cm 42.50820002 TVLs for 18 MV, Table B.7 
n (6 MV)   1.098663594 
   t(leakage) cm 36.86124424 TVLs for 6 MV, Table B.7 
t(leak, tot) cm 53.3 
    
Wall D Primary 
    Parameters Unit Value 
 Area   Controlled 
   Energy MV 18 
   P mSv/wk 0.1 
   d m 6.2 
   W mGy/wk 450000 
   U   0.5 
   T Control Room 1 Table B.1
B   0.00002304 
   n   4.637517525 
   t(pri) cm 201.4 TVLs for 18 MV, Table B.2 
 
Wall D (Point B) Patient Scatter 
   (for 10˚ scatter)  
Parameters Unit Value 
   Area   Controlled 
   P mSv/wk 0.1 
   W mGy/wk 450000 18 MV 
  W mGy/wk 225000 6 MV 
  d(sca) m 1 
   d(sec) m 6.3 
   U   0.5 
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T Control Room 1 Table B.1 
  F cm^2 1600 Assumed the largest FOV (40x40) 
α (10˚) fraction 1.42E-02 18 MV, Table B.4 
 α (10˚) fraction 1.04E-02 6 MV, Table B.4 
n (18 MV)   3.507849755 
   t(sca) 18 MV cm 154.3453892 TVL(15˚)=44, Table B.5a 
n (6 MV)   3.071564754 
   t(sca) 6 MV cm 104.4332016 TVL(15˚)=34, Table B.5a 
t(sca, tot) cm 154.3 
    
(for 20˚ scatter) 
    d(sec) m 6.6 Calculated 
 α (20˚) fraction 5.39E-03 18 MV, Table B.4 
 α (20˚) fraction 6.73E-03 6 MV, Table B.4 
n (18 MV)   3.046743404 
 t(sca) 18 MV cm 121.8697361 TVL(20˚)=40, Table B.5a 
n (6 MV)   2.842139707 
   t(sca) 6 MV cm 88.95897283 TVL(20˚)=31.3, Table B.5a 
t(sca, tot) cm 133.9 
    
(for 30˚ scatter) 
    d(sec) m 7.2 Given in NCRP 
 α (30˚) fraction 2.53E-03 18 MV, Table B.4 
α (30˚) fraction 2.77E-03 6 MV, Table B.4 
n (18 MV)   2.642698038 
 t(sca) 18 MV cm 84.56633721 TVL(30˚)=32, Table B.5a 
n (6 MV)   2.38102729 
   t(sca) 6 MV cm 61.90670954 TVL(30˚)=26, Table B.5a 
t(sca, tot) cm 94.2 
    
(for 45˚ scatter) 
    d(sec) m 8.8 Calculated 
 α (45˚) fraction 8.64E-04 18 MV, Table B.4 
α (45˚) fraction 1.39E-03 6 MV, Table B.4 
n (18 MV)   2.001790908 
 t(sca) 18 MV cm 54.04835451 TVL(45˚)=27, Table B.5a 
n (6 MV)   1.90726197 
   t(sca) 6 MV cm 43.8670253 TVL(45˚)=23, Table B.5a 
t(sca, tot) cm 62.2 
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Wall D (Point B) Leakage Scatter 
   Parameters Unit Value 
   Area   Controlled 
   P mSv/wk 0.1 
   W mGy/wk 1170000 18 MV 
  W mGy/wk 945000 6 MV 
  d(L) m 6.85 Calculated 
 U   0.5 
   T Control Room 1 Table B.1 
  n (18 MV)   2.095774723 
   t(leakage) cm 73.25634059 TVLs for 18 MV, Table B.7 
n (6 MV)   2.00302067 
   t(leakage) cm 63.08759943 TVLs for 6 MV, Table B.7 
t(leak, tot) cm 84.1 
    
Wall E Patient Scatter 
     (for 90˚ scatter)     
Parameters Unit Value 
    Area   Uncontrolled 
    P mSv/wk 0.02 
    W mGy/wk 450000 18 MV 
   W mGy/wk 225000 6 MV 
   d(sca) m 1 
    d(sec) m 5.4 
    U 
 
0.5 
    T Reading Room 0.2 Table B.1 
   F cm^2 1600 Assumed the largest FOV (40x40) 
α (90˚) fraction 1.89E-04 18 MV, Table B.4 
  α (90˚) fraction 4.26E-04 6 MV, Table B.4 
  n (18 MV)   1.765916794 
    t(sca, 18 MV) cm 33.55241909 TVL(90˚)=19, Table B.5a 
 n (6 MV)   1.817834593 
    t(sca, 6 MV) cm 30.90318808 TVL(90˚)=17, Table B.5a 
 t(sca, tot) cm 39.3 
     
(for 60˚ scatter) 
    d(sec) m 6.2 Calculated 
 α (60˚) fraction 4.24E-04 18 MV, Table B.4 
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α (60˚) fraction 8.24E-04 6 MV, Table B.4 
n (18 MV)   1.99188211 
   t(sca, 18 MV) cm 45.81328852 TVL(60˚)=23, Table B.5a 
n (6 MV)   1.979413469 
   t(sca, 6 MV) cm 41.56768285 TVL(60˚)=21, Table B.5a 
t(sca, tot) cm 52.7 
    
(for 45˚ scatter) 
    d(sec) m 7.6 Calculated 
 α (45˚) fraction 8.64E-04 18 MV, Table B.4 
 α (45˚) fraction 1.39E-03 6 MV, Table B.4 
n (18 MV)   2.124938737 
   t(sca, 18 MV) cm 57.37334589 TVL(45˚)=27, Table B.5a 
n (6 MV)   2.030409799 
   t(sca, 6 MV) cm 46.69942537 TVL(45˚)=23, Table B.5a 
t(sca, tot) cm 65.5 
    
(for 30˚ scatter) 
    d(sec) m 10.8 Calculated 
 α (30˚) fraction 2.53E-03 18 MV, Table B.4 
 α (30˚) fraction 2.77E-03 6 MV, Table B.4 
n (18 MV)   2.29051552 
   t(sca, 18 MV) cm 73.29649663 TVL(30˚)=32, Table B.5a 
n (6 MV)   2.028844772 
   t(sca, 6 MV) cm 52.74996407 TVL(30˚)=26, Table B.5a 
t(sca, tot) cm 82.9 
    
Wall E Leakage Scatter 
    (90° scatter position) 
Parameters Unit Value   
Area   Uncontrolled 
   P mSv/wk 0.02 
   W mGy/wk 1170000 18 MV 
  W mGy/wk 945000 6 MV 
  d(L) m 5.4 
   U 
 
0.5 
   T Reading Room 0.2 Table B.1 
  n (18 MV)   2.302368346 
   t(leakage) cm 80.28052378 TVLs for 18 MV, Table B.7 
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n (6 MV)   2.209614293 
   t(leakage) cm 69.0788145 TVLs for 6 MV, Table B.7 
t(leak, tot) cm 91.1 
    
(60° scatter position) 
    Parameters Unit Value 
   d(L) m 6.2 
   n (18 MV)   2.17742961 
   t(leakage) cm 76.03260673 TVLs for 18 MV, Table B.7 
n (6 MV)   2.084675557 
   t(leakage) cm 65.45559114 TVLs for 6 MV, Table B.7 
t(leak, tot) cm 86.9 
    
(45° scatter position) 
    Parameters Unit Value 
   d(L) m 7.6 
   n (18 MV)   2.001338351 
   t(leakage) cm 70.04550393 TVLs for 18 MV, Table B.7 
n (6 MV)   1.908584298 
   t(leakage) cm 60.34894463 TVLs for 6 MV, Table B.7 
t(leak, tot) cm 80.9 
    
(30° scatter position) 
    Parameters Unit Value 
   d(L) m 10.8 
   n (18 MV)   1.700308355 
   t(leakage) cm 59.81048407 TVLs for 18 MV, Table B.7 
n (6 MV)   1.607554302 
   t(leakage) cm 51.61907475 TVLs for 6 MV, Table B.7 
t(leak, tot) cm 70.6 
    
Ceiling Patient Scatter 
     (for 90˚ scatter) 
Parameters Unit Value 
    Area   Uncontrolled 
    P mSv/wk 0.02 
    W mGy/wk 450000 18 MV 
   W mGy/wk 225000 6 MV 
   d(sca) m 1 
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d(sec) m 3.38 Calculated 
  U 
 
0.5 
    T Unoccupied area 0.025 
    F cm^2 1600 Assumed the largest FOV (40x40) 
α (90˚) fraction 1.89E-04 18 MV, Table B.4 
  α (90˚) fraction 4.26E-04 6 MV, Table B.4 
 n (18 MV)   1.269780926 
    t(sca, 18 MV) cm 24.1258376 TVL(90˚)=19, Table B.5a 
 n (6 MV)   1.321698725 
    t(sca, 6 MV) cm 22.46887833 TVL(90˚)=17, Table B.5a 
 t(sca, tot) cm 29.8 
     
(for 60˚ scatter) 
    d(sec) m 3.9 Given 
  α (60˚) fraction 4.24E-04 18 MV, Table B.4 
 α (60˚) fraction 8.24E-04 6 MV, Table B.4 
n (18 MV)   1.496389165 
   t(sca, 18 MV) cm 34.41695079 TVL(60˚)=23, Table B.5a 
n (6 MV)   1.483920524 
   t(sca, 6 MV) cm 31.16233101 TVL(60˚)=21, Table B.5a 
t(sca, tot) cm 41.3 
    
(for 45˚ scatter) 
    d(sec) m 4.78 Calculated 
 α (45˚) fraction 8.64E-04 18 MV, Table B.4 
 α (45˚) fraction 1.39E-03 6 MV, Table B.4 
n (18 MV)   1.628810472 
   t(sca, 18 MV) cm 43.97788274 TVL(45˚)=27, Table B.5a 
n (6 MV)   1.534281534 
   t(sca, 6 MV) cm 35.28847528 TVL(45˚)=23, Table B.5a 
t(sca, tot) cm 52.1 
    
(for 30˚ scatter) 
    d(sec) m 6.75 Calculated 
 α (30˚) fraction 2.53E-03 18 MV, Table B.4 
 α (30˚) fraction 2.77E-03 6 MV, Table B.4 
n (18 MV)   1.795665498 
   t(sca, 18 MV) cm 57.46129593 TVL(30˚)=32, Table B.5a 
n (6 MV)   1.53399475 
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t(sca, 6 MV) cm 39.8838635 TVL(30˚)=26, Table B.5a 
t(sca, tot) cm 67.1 
    
Ceiling Leakage Scatter 
    (90° scatter position) 
    Parameters Unit Value 
   Area   Uncontrolled 
   P mSv/wk 0.02 
   W mGy/wk 1170000 18 MV 
  W mGy/wk 945000 6 MV 
  d(L) m 3.38 
   U   0.5 
   T Unoccupied area 0.025 
   n (18 MV)   1.806232479 
   t(leakage) cm 63.41190427 TVLs for 18 MV, Table B.7 
n (6 MV)   1.713478425 
   t(leakage) cm 54.69087433 TVLs for 6 MV, Table B.7 
t(leak, tot) cm 74.2 
    
(60° scatter position) 
    Parameters Unit Value 
   d(L) m 3.90 Given 
  n (18 MV)   1.681936665 
   t(leakage) cm 59.18584661 TVLs for 18 MV, Table B.7 
n (6 MV)   1.589182612 
   t(leakage) cm 51.08629574 TVLs for 6 MV, Table B.7 
t(leak, tot) cm 70.0 
    
(45° scatter position) 
    Parameters Unit Value 
   d(L) m 4.78 
   n (18 MV)   1.505210086 
   t(leakage) cm 53.17714292 TVLs for 18 MV, Table B.7 
n (6 MV)   1.412456033 
   t(leakage) cm 45.96122495 TVLs for 6 MV, Table B.7 
t(leak, tot) cm 64.0 
    
(30° scatter position) 
    Parameters Unit Value 
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d(L) m 6.75 
   n (18 MV)   1.205458333 
   t(leakage) cm 42.98558334 TVLs for 18 MV, Table B.7 
n (6 MV)   1.11270428 
   t(leakage) cm 37.26842413 TVLs for 6 MV, Table B.7 
t(leak, tot) cm 53.8 
    
Leakage and Scattered Radiation at Door 
      When gantry points at wall C… 
       Wall-Scattered 
        Parameters Unit Value 
       Area   Controlled 
       W (18 MV) mGy/wk 450000 
       W (6 MV) mGy/wk 225000 
       U   0.5 
       α(0)   1.60E-03 Table B.8a, normal incidence, 75˚ reflection for 18 MV 
 α(0)   2.70E-03 Table B.8a, normal incidence, 75˚ reflection for 6 MV 
 A(0) m^2 2.82 
       α(z)   8.00E-03 Table B.8a, normal incidence, 75˚ reflection for 0.5 MeV 
 A(z) m^2 8.4 
       d(h) m 4.2 
       d(_r) m 5.9 
       d(z) m 6.8 
       H(s) mSv/wk 0.004429987 
         µSv/wk 4.4 
        
Head Leakage Scatter 
       Parameters Unit Value 
       Area   Controlled 
       W (18 MV) mGy/wk 1170000 
       W (6 MV) mGy/wk 945000 
       L(f) fraction 0.001 
       U   0.5 
       α(1)   4.50E-03 Table B.8a, 45˚ incidence, 0⁰ reflection for 18 MV 
 α(1)   6.40E-03 Table B.8a, 45˚ incidence, 0⁰ reflection for 6 MV 
 A(1) m^2 11.8 
       d(LS) m 7.9 
       d(zz) m 9.9 
       H(LS) mSv/wk 0.010912022 
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  µSv/wk 10.9 
        
Patient Scatter 
       Parameters Unit Value 
      Area   Controlled 
      W (18 MV) mGy/wk 450000 
      W (6 MV) mGy/wk 225000 
      U   0.5 
      α(θ)   8.64E-04 Table B.4, 45˚ incidence for 18 MV 
  α(θ)   1.34E-03 Table B.4, 45˚incidence for 6 MV 
  A(1) m^2 11.8 
      α(1)   2.20E-02 Table B.8b, 45˚ incidence, 0˚ reflection for 0.5 MeV 
 F m^2 1600 
      d(sca) m 1 
      d(sec) m 7.3 
      d(zz) m 9.9 
      H(s) mSv/wk 0.068598539 
        µSv/wk 68.6 
       
Transmitted Leakage 
     Parameters Unit Value 
    Area   Controlled 
    W (18 MV) mGy/wk 1170000 
    W (6 MV) mGy/wk 945000 
    U   0.5 
    L(f) fraction 0.001 
    B (18 MV)   0.000241186 t(s)=125 cm, TVLs from Table B.7 
B (6 MV)   7.27895E-05 t(s)=125 cm, TVLs from Table B.7 
d(L) m 7.1 
    H(LT) mSv/wk 0.003481197 
      µSv/wk 3.5 
     
When gantry points at wall D… 
      Wall-Scattered 
       Parameters Unit Value 
      Area   Controlled 
      W (18 MV) mGy/wk 450000 
      W (6 MV) mGy/wk 225000 
      U   0.5 
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α(0)   3.13E-03 Table B.8a, normal incidence, 40˚ reflection for 18 MV 
α(0)   4.87E-03 Table B.8a, normal incidence, 40˚ reflection for 6 MV 
A(0) m^2 2.82 
      α(z)   2.20E-02 Table B.8b, 45° incidence, 45˚ reflection for 0.5 MeV 
A(z) m^2 5.9 Assume half of A(1) (given) 
   d(h) m 4.2 
      d(_r) m 8.9 Calculated 
    d(z) m 9.6 Approximation 
    H(s) mSv/wk 0.003559184 
        µSv/wk 3.6 
       
Head Leakage Scatter 
        Parameters Unit Value 
        Area   Controlled 
        W (18 MV) mGy/wk 1170000 
        W (6 MV) mGy/wk 945000 
        L(f) fraction 0.001 
        U   0.5 
        α(1)   4.50E-03 Table B.8b, 45˚ incidence, 0⁰ reflection for 18 MV, interpolated 
α(1)   6.40E-03 Table B.8b, 45˚ incidence, 0⁰ reflection for 6 MV, interpolated 
 A(1) m^2 11.8 Same as NCRP 
      d(LS) m 6.6 Calculated 
      d(zz) m 9.9 Same as NCRP 
      H(LS) mSv/wk 0.015634052 
          µSv/wk 15.6 
         
Patient Scatter 
       Parameters Unit Value 
      Area   Controlled 
      W (18 MV) mGy/wk 450000 
      W (6 MV) mGy/wk 225000 
      U   0.5 
      α(θ)   1.31E-04 Table B.4, 130˚ scatter for 18 MV 
  α(θ)   3.14E-04 Table B.4, 130˚ scatter for 6 MV 
  A(1) m^2 11.8 Same as NCRP 
    α(1)   2.20E-02 Table B.8b, 45˚ incidence, 0˚ reflection for 0.5 MeV 
 F m^2 1600 
      d(sca) m 1 
      d(sec) m 7.3 Same as NCRP 
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d(zz) m 9.9 Same as NCRP 
    H(s) mSv/wk 0.012883195 
        µSv/wk 12.9 
       
Transmitted Leakage 
     Parameters Unit Value 
    Area   Controlled 
    W (18 MV) mGy/wk 1170000 
    W (6 MV) mGy/wk 945000 
    U   0.5 
    L(f) fraction 0.001 
    B (18 MV)   0.000241186 t(s)=125 cm, TVLs from Table B.7 
B (6 MV)   7.27895E-05 t(s)=125 cm, TVLs from Table B.7 
d(hd) m 8.1 Calculated 
  H(LT) mSv/wk 0.002674701 
      µSv/wk 2.7 
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Appendix B Pseudo codes for collision software 
Program Calibration 
OPEN file search window 
SELECT all calibration images 
nfiles = number of images 
FOR i = 1 to nfiles 
 DISPLAY one image at a time 
 SHOW the file name of each image 
 INPUT a point at the reference point on the image 
 [x(i) y(i)] = pixel location of the point 
 ENTER the vertical and longitudinal couch positions 
 longitudinal(i) = longitudinal position 
 long(i) = longitudinal 
 IF vertical position > 900, 
  vert(i) = vertical position-1000 
 ELSE 
  vert(i) = vertical position 
 END IF 
 vertical(i)=vert(i) 
END FOR 
 
%Pixel location of the isocenter 
Isox=x(1) 
Isoy=y(1) 
 
%Position of each calibration position relative to the isocenter 
FOR i = 2 to nfiles 
 long(i) = long(i)-long(1) 
 vert(i) = vert(i)-vert(1) 
END FOR 
 
%Making the isocenter as the origin 
long(1)=0 
vert(1)=0 
 
SAVE variables ‘x’ and ‘y’ 
SAVE variables ‘longitudinal’, ‘vertical’, ‘long’, and ‘vert’ 
 
Program Patient outline 
IF there exists calibration file 
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 LOAD the variables 
ELSE run program calibration 
END IF 
 
%Location of the isocenter 
Isox=x(1) 
Isoy=y(1) 
 
READ patient setup image 
OUTLINE the patient contour and the treatment couch 
ENTER the couch positions for patient setup 
SetupLong=longitudinal position 
SetupVert=vertical position 
PROMT the user to enter the on-board imager detector position 
 
%Interpolation between the calibration points 
Fx = interpolant for finding the x pixel location 
Fy = interpolant for finding the y pixel location 
Fvert = interpolant for finding the vertical couch position 
Flong= interpolant for finding the longitudinal couch position 
FPixX= interpolant for finding the x pixel location relative to the isocenter 
FPixY= interpolant for finding the y pixel location relative to the isocenter 
 
%Reference point location in the patient setup image 
Refx=Fx(SetupLong, SetupVert) 
Refy=Fy(SetupLong, SetupVert) 
 
Program CBCT90 
%When the treatment couch is at 90⁰ 
QUERY the x pixel location of the on-board imager detector 
QUERY the y pixel location of the on-board imager detector 
QUERY the x pixel location of the tube 
QUERY the y pixel location of the gantry 
 
CREATE a binary ROI from the patient outline 
CREATE a binary ROI for the gantry 
CREATE a binary ROI for the on-board imager detector 
CREATE a binary ROI for the tube 
 
integerImage = sum of the patient and the detector 
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WHILE integerImage = 1 
 DISPLACE the patient by 1 pixel to the right 
CREATE a binary ROI for the patient outline 
 COMPUTE integerImage 
END WHILE 
Displacement = new location – original location 
QUERY the longitudinal position of the new location 
Long90KV = longitudinal collision position 
FIND the collision pixel location on the right 
 
integerImage = sum of the patient and the tube 
WHILE integerImage = 1 
 DISPLACE the patient by 1 pixel to the left 
CREATE a binary ROI for the patient outline 
 COMPUTE integerImage 
END WHILE 
Displacement = new location – original location 
QUERY the longitudinal position of the new location 
Long90Tube = longitudinal collision position 
FIND the collision pixel location on the left 
 
integerImage = sum of the patient and the gantry 
WHILE integerImage = 1 
 DISPLACE the patient by 1 pixel to the top 
CREATE a binary ROI for the patient outline 
 COMPUTE integerImage 
END WHILE 
Displacement = new location – original location 
QUERY the vertical position of the new location 
VertGantry = vertical collision position 
FIND the collision pixel location on the top 
 
Program CBCT270 
%when the treatment couch is at 270⁰ 
QUERY the x pixel location of the on-board imager detector 
QUERY the y pixel location of the on-board imager detector 
QUERY the x pixel location of the tube 
 
CREATE a binary ROI for the on-board detector 
CREATE a binary ROI for the tube 
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integerImage = sum of the patient and the detector 
WHILE integerImage = 1 
 DISPLACE the patient outline by 1 pixel to the left 
 CREATE a binary ROI for the patient outline 
 COMPUTE integerImage 
END WHILE 
COMPUTE the new location of the reference point 
QUERY the longitudinal position of the new location 
Long270KV = longitudinal collision position 
 
integerImage = sum of the patient and the tube 
WHILE integerImage = 1 
 DISPLACE the patient outline by 1 pixel to the right 
 CREATE a binary ROI for the patient outline 
 COMPUTE integerImage 
END WHILE 
COMPUTE the new location of the reference point 
QUERY the longitudinal position of the new location 
Long270Tube = longitudinal collision position 
 
integerImage = sum of the patient and the detector 
WHILE integerImage = 1 
 DISPLACE the patient by 1 pixel to the top 
CREATE a binary ROI for the patient outline 
 COMPUTE integerImage 
END WHILE 
COMPUTE the new location of the reference point 
QUERY the vertical position of the new location 
VertKV = vertical collision position 
 
Program CBCTCollision 
IF VertGantry > VertKV 
 ImageColl = VertGantry 
ELSE 
 ImageColl = VertKV 
END IF 
 
%Uncertainties 
COMPUTE the lateral distance between the right collision point and the isocenter 
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RtUncert = right lateral distance*26.5/distance between camera and isocenter 
 
COMPUTE the lateral distance between the left collision point and the isocenter 
LtUncert = left lateral distance*26.5/distance between camera and isocenter 
 
COMPUTE the vertical distance between the top collision point and the isocenter 
UpUncert = vertical distance*26.5/distance between the camera and isocenter 
 
%Collision map for CBCT90 
xmin = 15 
xmax = 160 
ymin = ImageColl-5 
ymax = 66 
figure 
SET figure axis to [xmin xmax ymin ymax] 
REVERSE the y-axis direction 
 
FILL area between Long90KV-RtUncert and Long90Tube+LtUncert with green 
FILL area between Long90KV-RtUncert and Long90KV with yellow 
FILL area between Long90Tube+LtUncert and Long90Tube with yellow 
FILL area between ymin and ImageColl with red 
FILL area between xmin and Long90Tube with red 
FILL area between Long90KV and xmax with red 
 
%Collision map for CBCT270 
figure 
SET figure axis to [xmin xmax ymin ymax] 
REVERSE the y-axis direction 
 
FILL area between Long270Tube-RtUncert and Long270KV+LtUncert with green 
FILL area between Long270Tube-RtUncert and Long270Tube with yellow 
FILL area between Long270KV+LtUncert and Long270KV with yellow 
FILL area between ymin and ImageColl with red 
FILL area between xmin and Long270KV with red 
FILL area between Long270Tube and xmax with red 
 
%Collision map for CBCT90+CBCT270 
figure 
SET figure axis to [xmin xmax ymin ymax] 
REVERSE the y-axis direction 
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FILL area between Long90KV-RtUncert and Long90Tube+LtUncert with green 
FILL area between Long90KV-RtUncert and Long90KV with yellow 
FILL area between Long90Tube+LtUncert and Long90Tube with yellow 
FILL area between ymin and ImageColl with red 
FILL area between xmin and Long90Tube with red 
FILL area between Long90KV and xmax with red 
 
FILL area between Long270Tube-RtUncert and Long270KV+LtUncert with green 
FILL area between Long270Tube-RtUncert and Long270Tube with yellow 
FILL area between Long270KV+LtUncert and Long270KV with yellow 
FILL area between ymin and ImageColl with red 
FILL area between xmin and Long270KV with red 
FILL area between Long270Tube and xmax with red 
 
Program Treat90 
%When the patient is facing the gantry 
PROMT the user to enter the portal imager position 
QUERY the x pixel location of the gantry 
QUERY the y pixel location of the gantry 
QUERY the x pixel location of the portal imager 
QUERY the y pixel location of the portal imager 
 
CREATE a binary ROI of the gantry 
CREATE a binary ROI of the portal imager 
 
integerImage = sum of the patient and the gantry 
IF integerImage = 1 
 WHILE integerImage = 1 
  DISPLACE the patient outline by 1 pixel to the right 
  CREATE a new binary ROI of the patient outline 
  COMPUTE integerImage 
 END WHILE 
ELSE IF integerImage = 2 
 WHILE integerImage =2 
  DISPLACE the patient outline by 1 pixel to the left 
  CREATE a new binary ROI of the patient outline 
  COMPUTE integerImage 
 END WHILE 
END IF 
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Displacement = new location – original location 
QUERY the longitudinal position of the new location 
Long90Gantry = longitudinal collision position 
 
integerImage = sum of the patient and the portal imager 
IF integerImage = 1 
 WHILE integerImage = 1 
  DISPLACE the patient outline by 1 pixel to the left 
  CREATE a new binary ROI of the patient outline 
  COMPUTE integerImage 
 END WHILE 
ELSE IF integerImage = 2 
 WHILE integerImage =2 
  DISPLACE the patient outline by 1 pixel to the right 
  CREATE a new binary ROI of the patient outline 
  COMPUTE integerImage 
 END WHILE 
END IF 
Displacement = new location – original location 
QUERY the longitudinal position of the new location 
Long90MV = longitudinal collision position 
 
integerImage = sum of the patient and the portal imager 
IF integerImage = 1 
 WHILE integerImage = 1 
  DISPLACE the patient outline by 1 pixel towards the top 
  CREATE a new binary ROI of the patient outline 
  COMPUTE integerImage 
 END WHILE 
ELSE IF integerImage = 2 
 WHILE integerImage =2 
  DISPLACE the patient outline by 1 pixel towards the bottom 
  CREATE a new binary ROI of the patient outline 
  COMPUTE integerImage 
 END WHILE 
END IF 
Displacement = new location – original location 
QUERY the vertical position of the new location 
Vert90MV = vertical collision position 
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Program Treat270 
%When the patient is facing away from the gantry 
QUERY the x pixel location of the gantry 
QUERY the y pixel location of the gantry 
QUERY the x pixel location of the portal imager 
QUERY the y pixel location of the portal imager 
 
CREATE a binary ROI of the gantry 
CREATE a binary ROI of the portal imager 
 
integerImage = sum of the patient and the gantry 
IF integerImage = 1 
 WHILE integerImage = 1 
  DISPLACE the patient outline by 1 pixel to the left 
  CREATE a new binary ROI of the patient outline 
  COMPUTE integerImage 
 END WHILE 
ELSE IF integerImage = 2 
 WHILE integerImage =2 
  DISPLACE the patient outline by 1 pixel to the right 
  CREATE a new binary ROI of the patient outline 
  COMPUTE integerImage 
 END WHILE 
END IF 
Displacement = new location – original location 
QUERY the longitudinal position of the new location 
Long270Gantry = longitudinal collision position 
 
integerImage = sum of the patient and the portal imager 
IF integerImage = 1 
 WHILE integerImage = 1 
  DISPLACE the patient outline by 1 pixel to the right 
  CREATE a new binary ROI of the patient outline 
  COMPUTE integerImage 
 END WHILE 
ELSE IF integerImage = 2 
 WHILE integerImage =2 
  DISPLACE the patient outline by 1 pixel to the left 
  CREATE a new binary ROI of the patient outline 
  COMPUTE integerImage 
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 END WHILE 
END IF 
Displacement = new location – original location 
QUERY the longitudinal position of the new location 
Long270MV = longitudinal collision position 
 
integerImage = sum of the patient and the gantry 
IF integerImage = 1 
 WHILE integerImage = 1 
  DISPLACE the patient outline by 1 pixel towards the top 
  CREATE a new binary ROI of the patient outline 
  COMPUTE integerImage 
 END WHILE 
ELSE IF integerImage = 2 
 WHILE integerImage =2 
  DISPLACE the patient outline by 1 pixel towards the bottom 
  CREATE a new binary ROI of the patient outline 
  COMPUTE integerImage 
 END WHILE 
END IF 
Displacement = new location – original location 
QUERY the vertical position of the new location 
VertGantry = vertical collision position 
 
 
Program TreatCollision 
IF Vert90MV>VertGantry 
 TreatColl = Vert90MV 
ELSE 
 TreatColl = VertGantry 
END IF 
 
%Collision map for Treat90 
xmin = 15 
xmax = 160 
ymin = TreatColl–5 
ymax = 66 
figure 
SET axis to [xmin xmax ymin ymax] 
REVERSE y-axis direction 
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FILL area between Long90Gantry-RtUncert and Long90MV+LtUncert with green 
FILL area between Long90Gantry-RtUncert and Long90Gantry with yellow 
FILL area between Long90MV+LtUncert and Long90MV with yellow 
FILL area between xmin and Long90MV with red 
FILL area between Long90Gantry and xmax with red 
FILL area between ymin and TreatColl with red 
 
%Collision map for Treat270 
figure 
SET axis to [xmin xmax ymin ymax] 
REVERSE y-axis direction 
 
FILL area between Long270MV-RtUncert and Long270Gantry+LtUncert with green 
FILL area between Long270MV-RtUncert and Long270MV with yellow 
FILL area between Long270Gantry+LtUncert and Long270Gantry with yellow 
FILL area between xmin and Long270Gantry with red 
FILL area between Long270MV and xmax with red 
FILL area between ymin and TreatColl with red 
 
%Collision map for Treat90+Treat270 
figure 
SET axis to [xmin xmax ymin ymax] 
REVERSE y-axis direction 
 
FILL area between Long90Gantry-RtUncert and Long90MV+LtUncert with green 
FILL area between Long90Gantry-RtUncert and Long90Gantry with yellow 
FILL area between Long90MV+LtUncert and Long90MV with yellow 
FILL area between xmin and Long90MV with red 
FILL area between Long90Gantry and xmax with red 
FILL area between ymin and TreatColl with red 
 
FILL area between Long270MV-RtUncert and Long270Gantry+LtUncert with green 
FILL area between Long270MV-RtUncert and Long270MV with yellow 
FILL area between Long270Gantry+LtUncert and Long270Gantry with yellow 
FILL area between xmin and Long270Gantry with red 
FILL area between Long270MV and xmax with red 
FILL area between ymin and TreatColl with red 
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Appendix C Treatment planning data 
 
THOR1 original treatment plan: 
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THOR1 upright treatment plan: 
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THOR2 original treatment plan: 
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THOR2 upright treatment plan: 
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THOR3 original treatment plan: 
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THOR3 upright treatment plan: 
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THOR4 original treatment plan: 
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THOR4 upright treatment plan: 
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THOR5 original treatment plan: 
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THOR5 upright treatment plan: 
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HN1 original treatment plan: 
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HN1 upright treatment plan: 
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HN2 original treatment plan: 
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HN2 upright treatment plan: 
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HN3 original treatment plan: 
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HN3 upright treatment plan: 
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HN4 original treatment plan: 
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HN4 upright treatment plan: 
 
 
 
  
 234 
 
HN5 original treatment plan: 
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HN5 upright treatment plan: 
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Lung plan target doses (cGy): 
THOR1 Dmin,up Dmin,org % Dmax,up Dmax,org % Dmean,up Dmean,org % 
PTV 4890 4853 0.8 6272 6236 0.6 5492.7 5553.1 -1.1 
CTV 5198 5122 1.5 6291 6250 0.7 5646.2 5688.9 -0.8 
GTV 5642 5529 2.0 6339 6275 1.0 6004.8 5972.4 0.5 
 
THOR2 Dmin,up Dmin,org % Dmax,up Dmax,org % Dmean,up Dmean,org % 
PTV 6052 6182 -2.1 7153 7399 -3.3 6806 6946.4 -2.0 
CTV 6663 6745 -1.2 7157 7398 -3.3 6869.4 7018.4 -2.1 
GTV 6683 6778 -1.4 7139 7382 -3.3 6875.9 7017.7 -2.0 
 
THOR3 Dmin,up Dmin,org % Dmax,up Dmax,org % Dmean,up Dmean,org % 
PTV 6437 6792 -5.2 7929 8230 -3.7 7560.5 7790.5 -3.0 
CTV 7413 7521 -1.4 7939 8245 -3.7 7678.1 7916.3 -3.0 
GTV 7522 7638 -1.5 7945 8240 -3.6 7713.8 7962.1 -3.1 
 
THOR4 Dmin,up Dmin,org % Dmax,up Dmax,org % Dmean,up Dmean,org % 
PTV 7112 6875 3.4 8072 8192 -1.5 7791.6 7765.5 0.3 
CTV 7666 7535 1.7 8079 8216 -1.7 7863.2 7880.7 -0.2 
GTV 7714 7619 1.2 8000 8177 -2.2 7894.8 7910.3 -0.2 
 
THOR5 Dmin,up Dmin,org % Dmax,up Dmax,org % Dmean,up Dmean,org % 
PTV 6138 5912 3.8 7097 7372 -3.7 6798.9 6946.7 -2.1 
CTV 6687 6471 3.3 7120 7385 -3.6 6855.1 7083 -3.2 
GTV 6682 6944 -3.8 7009 7292 -3.9 6860 7148.1 -4.0 
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H&N plan target doses (cGy): 
HN1 Dmin,up Dmin,org % Dmax,up Dmax,org % Dmean,up Dmean,org % 
PTV1 4522 5054 -10.5 5980 5838 2.4 5476.7 5530.6 -1.0 
PTV2 5179 5364 -3.4 6109 6091 0.3 5787.7 5829.5 -0.7 
PTV3 5817 5862 -0.8 6274 6338 -1.0 6113.2 6138.5 -0.4 
CTV1 5311 5352 -0.8 6122 5900 3.8 5571.3 5586 -0.3 
CTV2 5605 5674 -1.2 6254 6302 -0.8 5936.3 5967 -0.5 
CTV3 5934 5972 -0.6 6279 6339 -0.9 6140.1 6161 -0.3 
GTV 5976 6025 -0.8 6290 6295 -0.1 6140.2 6157.1 -0.3 
 
HN2 Dmin,up Dmin,org % Dmax,up Dmax,org % Dmean,up Dmean,org % 
PTV1 3220 5187 -37.9 6183 6106 1.3 5760.6 5773 -0.2 
PTV2 5178 5593 -7.4 7047 7100 -0.7 6336.7 6348.7 -0.2 
PTV3 6231 6448 -3.4 7058 7060 0 6852.9 6807.9 0.7 
PTV4 6536 6742 -3.1 7701 7446 3.4 7227.6 7203.3 0.3 
CTV1 5172 5191 -0.4 6228 6121 1.7 5849.3 5806.6 0.7 
CTV2 5454 6021 -9.4 7670 7430 3.2 7031.5 7015.8 0.2 
CTV3 6097 6276 -2.9 7234 7225 0.1 6904.5 6836.3 1.0 
CTV4 6949 7021 -1.0 7725 7454 3.6 7313.4 7242.4 1.0 
GTV 7171 7045 1.8 7750 7423 4.4 7352.7 7231.5 1.7 
 
HN3 Dmin,up Dmin,org % Dmax,up Dmax,org % Dmean,up Dmean,org % 
PTV1 5240 5315 -1.4 5726 5743 -0.3 5535.2 5558 -0.4 
PTV2 5344 5513 -3.1 6238 6103 2.2 5827.5 5846.1 -0.3 
PTV3 5776 5907 -2.2 6345 6344 0 6119.2 6156.9 -0.6 
CTV1 5440 5452 -0.2 5871 5733 2.4 5614 5609.6 0.1 
CTV2 5678 5723 -0.8 6335 6329 0.1 6037.2 6064 -0.4 
CTV3 5974 6056 -1.4 6345 6349 -0.1 6153.8 6178.6 -0.4 
GTV 6028 6052 -0.4 6274 6256 0.3 6155 6168.2 -0.2 
 
HN4 Dmin,up Dmin,org % Dmax,up Dmax,org % Dmean,up Dmean,org % 
PTV1 5249 5287 -0.7 5755 5759 -0.1 5539.6 5546.8 -0.1 
PTV2 5391 5492.5 -1.8 6140 6127.5 0.2 5848.8 5857 -0.1 
PTV3 5760 5916 -2.6 6675 6335 5.4 6149.7 6143.1 0.1 
CTV1 5420 5393 0.5 5865 5907 -0.7 5593.5 5596 0 
CTV2 5738 5767 -0.5 6650 6327 5.1 6115.2 6105 0.2 
CTV3 5959 6001 -0.7 6695 6335 5.7 6184.4 6158.4 0.4 
GTV 6017 5995 0.4 6679 6322 5.6 6193.7 6142.8 0.8 
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HN5 Dmin,up Dmin,org % Dmax,up Dmax,org % Dmean,up Dmean,org % 
PTV1 4097 5143 -20.3 5831 5705 2.2 5526.5 5496.7 0.5 
PTV2 5146 5357 -3.9 6219 6112 1.8 5825.4 5813.3 0.2 
PTV3 5716 5776 -1.0 6378 6303 1.2 6131 6144.1 -0.2 
CTV1 5297 5377 -1.5 5841 5834 0.1 5604.1 5540.6 1.1 
CTV2 5392 5586 -3.5 6348 6280 1.1 5982.1 5969.2 0.2 
CTV3 5890 5963 -1.2 6391 6308 1.3 6163 6117.6 0.7 
GTV 6025 6009 0.3 6410 6278 2.1 6190.2 6130.5 1.0 
 
 
Normal tissue parameters for lung treatment plans: 
 
Total Lung 
 V20,up V20,org % MLDup MLDorg % 
THOR1 8.23 9.41 -12.5 4.97 5.51 -9.8 
THOR2 35.68 32.29 10.5 21.58 21.41 0.8 
THOR3 34.29 30.23 13.4 20.46 20.32 0.7 
THOR4 25.68 22.44 14.4 15.91 14.97 6.3 
THOR5 34.04 34.92 -2.5 19.88 20.02 -0.7 
 
Spinal cord 
 Dmax,up Dmax,org % 
THOR1 6.36 6.63 -4.1 
THOR2 41.37 42.05 -1.6 
THOR3 40.65 44.07 -7.8 
THOR4 40.68 43.3 -6.1 
THOR5 39.88 39.55 0.8 
 
Contralateral lung and brachial plexus 
 Contralateral lung Brachial plexus 
 Dmean,up Dmean,org % Dmax,up Dmax,org % 
THOR1 1.24 1.36 -8.8    
THOR2 4.62 6.97 -33.7    
THOR3 4.63 3.28 41.2 69.63 68.49 1.7 
THOR4 5.41 5.41 0 59.59 59.97 -0.6 
THOR5 4.08 4.64 -12.1 69.89 69.55 0.5 
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Heart 
 Dmean,up Dmean,org % V20,up V20,org % 
THOR1 5.17 5.33 -3.0 1.92 4.82 -60.2 
THOR2 18.17 25.68 -29.2 29.88 51.09 -41.5 
THOR3 14.8 22.06 -32.9 20.76 33.38 -37.8 
THOR4 2.15 3.2 -32.8 1.83 1.85 -1.1 
THOR5 14.99 24.71 -47.4 20.1 47.07 -57.3 
 
Esophagus 
 V40,up V40,org % V70,up V70,org % 
THOR1 0 0 0 0 0 0 
THOR2 29.05 28.82 0.8 0 0.67 -100 
THOR3 29.08 30 -3.1 10.48 11.89 -11.9 
THOR4 42.43 41.01 3.5 3.17 7.9 -59.9 
THOR5 36.06 48.2 -25.2 2.05 2.12 -3.3 
 
 Dmean,up Dmean,org % Dmax,up Dmax,org % 
THOR1 1.09 1.8 -39.4 6.03 6.07 -0.7 
THOR2 25.84 25.07 3.1 70.28 76.22 -7.8 
THOR3 25.95 24.84 4.5 75.81 78.12 -3.0 
THOR4 29.15 29.7 -1.9 75.54 76.94 -1.8 
THOR5 28.58 32.58 -12.3 72.11 76.44 -5.7 
 
Normal tissue parameters for H&N treatment plans: 
Spinal cord and brainstem 
 Spinal cord Brainstem 
 Dmax,up Dmax,org % Dmax,up Dmax,org % 
HN1 34.36 37.45 -8.3 30.47 33.28 -8.4 
HN2 41.64 36.67 13.5 43.37 38.25 13.4 
HN3 40.44 37.45 8.0 29.28 11.16 162.4 
HN4 40.32 38.92 3.6 32.7 25.47 28.4 
HN5 37.34 39.24 -4.8 21.6 20.53 5.2 
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Cochleae 
 Left Right 
 Dmax,up Dmax,org % Dmax,up Dmax,org % 
HN1 5.42 7.95 -31.8 27.04 17.92 50.9 
HN2 23.83 23.57 1.1 36 27.16 32.5 
HN3 4.73 1.3 264 2.49 1.29 93.0 
HN4 1.97 1.45 35.9 3.76 2.81 33.8 
HN5 5.52 2.42 128 7.58 1.71 343 
 
Parotids 
 Left Right 
 Dmean,up Dmean,org % Dmean,up Dmean,org % 
HN1 20.47 18.93 8.1 44.18 37.74 17.1 
HN2 40.52 24.63 64.5 61.69 65.61 -6.0 
HN3 25.98 21.54 20.6 31.96 28.4 12.5 
HN4 18.36 6.74 172 45.54 45.46 0.18 
HN5 34.19 33.32 2.6 25.04 23.3 7.5 
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Appendix D Upright imaging scripts 
Courtesy of Xenia Favè 
Upright CBCT imaging script for detector offset of positive 14.5 cm: 
<VarianResearchBeam SchemaVersion="1.0"> 
<!--******************************************************* 
Rotate couch 180 degree and take KV images to be used  
for Cone Beam Reconstruction of the left half of the Thorax.  
Done via two steps of 190 degrees each. 
********************************************************--> 
  <SetBeam> 
    <Id>1</Id> 
    <MLCModel>NDS120</MLCModel> 
    <Accs/> 
    <ControlPoints> 
      <Cp> <!--Cp0--> 
        
<SubBeam><Seq>0</Seq><Name>ThoraxP_CouchRot_LeftHalf</Name></SubBeam
> 
        <Energy>0k</Energy> 
        <!--******************************************************* 
        MU and dose rate are 0 since we will be taking KV images only 
        and we are using the outside treatment mode 
        ********************************************************--> 
        <Mu>0</Mu><DRate>0</DRate> 
        <!--Move the gantry to 180 and couch to starting position on left--> 
        <GantryRtn>180.0</GantryRtn> 
  <CouchRtn>275.0</CouchRtn> 
      </Cp> 
 
      <Cp><!--Cp1--> 
        <!--Couch rotates 180 degrees  --> 
        <CouchRtn>85</CouchRtn> 
      </Cp> 
    
    </ControlPoints> 
 
    <!--Defines the imaging parameter for the beam and each control point --> 
    <ImagingParameters> 
      <OutsideTreatment> 
        <!--
******************************************************************* 
        No need to set a max MU because we're taking KV images only 
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********************************************************************--> 
        <MaxMu>0</MaxMu> 
      <!--
******************************************************************* 
     Here is where we specify that outside treatment mode 
    
 ****************************************************************
****--> 
      </OutsideTreatment> 
    
      <ImagingPoints> 
        <!--************************************************ 
        Start continuous acquisition in DynamicGainFluoro 
        mode (a good choice for CBCT) 
        *************************************************--> 
        <ImagingPoint> 
          <Cp>0</Cp> 
          <AcquisitionStart> 
            <AcquisitionId>1</AcquisitionId> 
            <AcquisitionSpecs> 
              <Handshake>true</Handshake> 
              <KV>true</KV> 
            </AcquisitionSpecs> 
            <AcquisitionParameters> 
              <ImageMode id="DynamicGainFluoro"/> 
              <CalibrationSet>IMG-CBCT</CalibrationSet> 
              <ImageDestination>ImageDestination</ImageDestination> 
                <KV> 
                <KiloVolts>125</KiloVolts><MilliAmperes>60</MilliAmperes> 
                 <MilliSeconds>20</MilliSeconds><eFocalSpot>Large</eFocalSpot> 
                 <eFluoroLevelControl>None</eFluoroLevelControl> 
               </KV> 
             </AcquisitionParameters> 
          </AcquisitionStart> 
          <KvFilters><Foil>1</Foil><Shape>0</Shape></KvFilters> 
       <!-- Shape values: 0=no bowtie, 1= full fan, 2= half fan 
      Foil value: 0=no Ti filter present, 1= Ti filter present--> 
 <KvBlades> 
  <Positions> 
  <KVX1>13</KVX1> 
  <KVX2>13</KVX2> 
  <KVY1>20</KVY1> 
  <KVY2>1</KVY2> 
  </Positions> 
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 </KvBlades> 
 
          <Kvd> 
            <Positions> 
              <Lat>0</Lat><Lng>-14.5</Lng><Vrt>-50</Vrt><Pitch>0</Pitch> 
            </Positions> 
          </Kvd> 
          <Kvs> 
            <Positions> 
              <Lat>0</Lat><Lng>0</Lng><Vrt>100</Vrt><Pitch>0</Pitch> 
            </Positions> 
          </Kvs> 
        </ImagingPoint> 
 
        <!--*************************************************************** 
        Stop the continuous image acquisition...when couch reaches 90 
        ****************************************************************--> 
        <ImagingPoint> 
          <Cp>1</Cp> 
          <AcquisitionStop> 
            <AcquisitionId>1</AcquisitionId> 
            <AcquisitionSpecs /> 
          </AcquisitionStop> 
        </ImagingPoint> 
   
      </ImagingPoints> 
      <ImagingTolerances/> 
    </ImagingParameters> 
  </SetBeam> 
</VarianResearchBeam> 
 
 
Upright CBCT imaging script for detector offset of negative 14.5 cm: 
<VarianResearchBeam SchemaVersion="1.0"> 
<!--******************************************************* 
Rotate couch 180 degree and take KV images to be used  
for Cone Beam Reconstruction of the left half of the Thorax.  
Done via two steps of 190 degrees each. 
********************************************************--> 
  <SetBeam> 
    <Id>1</Id> 
    <MLCModel>NDS120</MLCModel> 
    <Accs/> 
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    <ControlPoints> 
      <Cp> <!--Cp0--> 
        
<SubBeam><Seq>0</Seq><Name>ThoraxP_CouchRot_LeftHalf</Name></SubBeam
> 
        <Energy>0k</Energy> 
        <!--******************************************************* 
        MU and dose rate are 0 since we will be taking KV images only 
        and we are using the outside treatment mode 
        ********************************************************--> 
        <Mu>0</Mu><DRate>0</DRate> 
        <!--Move the gantry to 180 and couch to starting position on left--> 
        <GantryRtn>180.0</GantryRtn> 
  <CouchRtn>275.0</CouchRtn> 
      </Cp> 
 
      <Cp><!--Cp1--> 
        <!--Couch rotates 180 degrees  --> 
        <CouchRtn>85</CouchRtn> 
      </Cp> 
    
    </ControlPoints> 
 
    <!--Defines the imaging parameter for the beam and each control point --> 
    <ImagingParameters> 
      <OutsideTreatment> 
        <!--
******************************************************************* 
        No need to set a max MU because we're taking KV images only 
        
********************************************************************--> 
        <MaxMu>0</MaxMu> 
      <!--
******************************************************************* 
     Here is where we specify that outside treatment mode 
    
 ****************************************************************
****--> 
      </OutsideTreatment> 
    
      <ImagingPoints> 
        <!--************************************************ 
        Start continuous acquisition in DynamicGainFluoro 
        mode (a good choice for CBCT) 
        *************************************************--> 
        <ImagingPoint> 
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          <Cp>0</Cp> 
          <AcquisitionStart> 
            <AcquisitionId>1</AcquisitionId> 
            <AcquisitionSpecs> 
              <Handshake>true</Handshake> 
              <KV>true</KV> 
            </AcquisitionSpecs> 
            <AcquisitionParameters> 
              <ImageMode id="DynamicGainFluoro"/> 
              <CalibrationSet>IMG-CBCT</CalibrationSet> 
              <ImageDestination>ImageDestination</ImageDestination> 
                <KV> 
                <KiloVolts>125</KiloVolts><MilliAmperes>60</MilliAmperes> 
                 <MilliSeconds>20</MilliSeconds><eFocalSpot>Large</eFocalSpot> 
                 <eFluoroLevelControl>None</eFluoroLevelControl> 
               </KV> 
             </AcquisitionParameters> 
          </AcquisitionStart> 
          <KvFilters><Foil>1</Foil><Shape>0</Shape></KvFilters> 
       <!-- Shape values: 0=no bowtie, 1= full fan, 2= half fan 
      Foil value: 0=no Ti filter present, 1= Ti filter present--> 
 <KvBlades> 
  <Positions> 
  <KVX1>13</KVX1> 
  <KVX2>13</KVX2> 
  <KVY1>1</KVY1> 
  <KVY2>20</KVY2> 
  </Positions> 
 
 </KvBlades> 
 
          <Kvd> 
            <Positions> 
              <Lat>0</Lat><Lng>14.5</Lng><Vrt>-50</Vrt><Pitch>0</Pitch> 
            </Positions> 
          </Kvd> 
          <Kvs> 
            <Positions> 
              <Lat>0</Lat><Lng>0</Lng><Vrt>100</Vrt><Pitch>0</Pitch> 
            </Positions> 
          </Kvs> 
        </ImagingPoint> 
 
        <!--*************************************************************** 
        Stop the continuous image acquisition...when couch reaches 90 
        ****************************************************************--> 
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        <ImagingPoint> 
          <Cp>1</Cp> 
          <AcquisitionStop> 
            <AcquisitionId>1</AcquisitionId> 
            <AcquisitionSpecs /> 
          </AcquisitionStop> 
        </ImagingPoint> 
   
      </ImagingPoints> 
      <ImagingTolerances/> 
    </ImagingParameters> 
  </SetBeam> 
</VarianResearchBeam> 
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